var title_f42_44_43712="Nitrofurantoin lung injury";
var content_f42_44_43712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Nitrofurantoin-induced pulmonary injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior and lateral chest radiographs show bilateral pleural effusions and parenchymal changes, predominantly located in the lower zones, in a 69-year-old woman who received nitrofurantoin for ten years because of recurrent urinary tract infections. Her symptoms consisted of dyspnea and a dry cough.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Justus de Zeeuw, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43712=[""].join("\n");
var outline_f42_44_43712=null;
var title_f42_44_43713="AEN GE junction Endosc";
var content_f42_44_43713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Acute esophageal necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sharp demarcation at the gastroesophageal junction is visible in these endoscopic images of acute esophageal necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Gelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43713=[""].join("\n");
var outline_f42_44_43713=null;
var title_f42_44_43714="Thoracic aortic dissection on computed tomography";
var content_f42_44_43714=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81919%7ECARD%2F58395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81919%7ECARD%2F58395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thoracic aortic dissection on computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse plane through ascending (AA) and descending (DA) thoracic aorta showing the intimal flap (arrows) and both lumens of a type A aortic dissection. One cannot distinguish between the true and false lumens based on this view alone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vassilios Raptopoulos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thoracic aortic dissection on reconstructed computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal plane reconstruction of transverse and descending thoracic aorta showing the true (TL) and false (FL) lumens of the same patient as the previous CT.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vassilios Raptopoulos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43714=[""].join("\n");
var outline_f42_44_43714=null;
var title_f42_44_43715="Phenylephrine, pyrilamine, and dextromethorphan: Drug information";
var content_f42_44_43715=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenylephrine, pyrilamine, and dextromethorphan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/16/15621?source=see_link\">",
"    see \"Phenylephrine, pyrilamine, and dextromethorphan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Codituss DM [OTC];",
"     </li>",
"     <li>",
"      Pyril DM [OTC];",
"     </li>",
"     <li>",
"      Ru-Hist Plus [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F209536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-Adrenergic Agonist;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Ethylenediamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F209527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Relief of cough, congestion:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     All dosing is presented in terms of  phenylephrine hydrochloride,  pyrilamine maleate, and dextromethorphan hydrobromide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenylephrine 5 mg, pyrilamine 8.33 mg, and dextromethorphan 10 mg per 5 mL: 10 mL every 4 hours (maximum: 60 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenylephrine 5 mg, pyrilamine 16 mg, and dextromethorphan 15 mg per 5 mL: 5-10 mL every 6-8 hours (maximum: 40 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenylephrine 10 mg, pyrilamine 30 mg, and dextromethorphan 20 mg per 5 mL: 5 mL every 4-6 hours (maximum: 30 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Phenylephrine 10 mg, pyrilamine 30 mg, and dextromethorphan 20 mg: One tablet every 4-6 hours (maximum: 6 tablets/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F209532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Relief of cough, congestion:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     All dosing is presented in terms of  phenylephrine hydrochloride,  pyrilamine maleate, and dextromethorphan hydrobromide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years: Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenylephrine 5 mg, pyrilamine 8.33 mg, and dextromethorphan 10 mg per 5 mL: 5 mL every 4 hours (maximum: 30 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenylephrine 5 mg, pyrilamine 16 mg, and dextromethorphan 15 mg per 5 mL: 5 mL every 6-8 hours (maximum: 20 mL /24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adults: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ru-Hist Plus: Phenylephrine hydrochloride 10 mg, pyrilamine maleate 30 mg, and dextromethorphan hydrobromide 20 mg per 5 mL (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pyril DM: Phenylephrine hydrochloride 5 mg, pyrilamine maleate 16 mg, and dextromethorphan hydrobromide 15 mg per 5 mL (473 mL) [contains sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Codituss DM: Phenylephrine hydrochloride 5 mg, pyrilamine maleate 8.33 mg, and dextromethorphan hydrobromide 10 mg per 5 mL (118 mL) [dye free, ethanol free, sugar free; contains menthol, propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ru-Hist Plus: Phenylephrine hydrochloride 10 mg, pyrilamine maleate 30 mg, and dextromethorphan hydrobromide 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F209514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of cough, nasal congestion, and discharge associated with the common cold, sinusitis, allergic rhinitis, and other respiratory tract conditions",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F209534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F209516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenylephrine, pyrilamine, dextromethorphan, or any component of the formulation; use with or within 14 days of MAO inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F209504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; contraindicated in patients with hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with asthma or other chronic breathing disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in patients who are sedated, debilitated or confined to a supine position.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in atopic children. Antihistamines may cause excitation in young children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever, rash, or persistent headache. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F209533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F209522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Theraflu Cold &amp; Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-20-20 mg (6): $4.39",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F209503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Phenylephrine hydrochloride is a sympathomimetic agent (primarily alpha), decongestant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pyrilamine is an H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dextromethorphan, a non-narcotic antitussive, increases cough threshold by its activity on the medulla oblongata.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10152 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43715=[""].join("\n");
var outline_f42_44_43715=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209525\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209536\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209527\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209532\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062260\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209512\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209502\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209514\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209534\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209516\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209504\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209533\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209508\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209522\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323681\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209503\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10152\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10152|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/16/15621?source=related_link\">",
"      Phenylephrine, pyrilamine, and dextromethorphan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_44_43716="Causes of nonulcer dyspepsia";
var content_f42_44_43716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Causes of nonulcer dyspepsia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A number of motor and sensory disorders may contribute to nonulcer dyspepsia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Camilleri M, Prather CM. Gastric motor physiology and motor disorders. In: Sleisenger and Fordtran's Gastrointestinal Disease, 6th ed, Feldman M, Scharschmidt BF, Sleisenger MH (Eds), WB Saunders, Philadelphia, PA 1998.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43716=[""].join("\n");
var outline_f42_44_43716=null;
var title_f42_44_43717="Glossary of genetic terms";
var content_f42_44_43717=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Glossary of genetic terms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/44/43717/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43717/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43717/contributors\">",
"     Robert D Blank, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/44/43717/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43717/contributors\">",
"     Anne Slavotinek, MBBS, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/44/43717/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43717/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/44/43717/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the greatest obstacles clinicians experience in reading about and understanding genetics is the extensive use of technical language and jargon. It should be noted that genetic terms are frequently used imprecisely in published clinical literature. The following is a compilation of some of the most important technical terms.",
"   </p>",
"   <p>",
"    A more extensive discussion of terms can be accessed in standard genetics reference texts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43717/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, a guide for the conventions regarding the proper names of genes and alleles in humans can be found at",
"    <a class=\"external\" href=\"file://www.genenames.org/guidelines.html\">",
"     www.genenames.org/guidelines.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLOSSARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allele &mdash; One member of a pair (or of a series of alternative forms) of a gene. At the DNA level, different alleles have different base sequences.",
"     </li>",
"     <li>",
"      Allele frequency &mdash; The proportion of chromosomes in a population harboring a specific genetic variant. \"Minor allele frequency\" typically refers to the less common variant at a biallelic single nucleotide polymorphism.",
"     </li>",
"     <li>",
"      Allelic heterogeneity &mdash; Common occurrence of multiple mutations in one gene that all result in the same phenotype. As an example, more than 1500 mutations in CFTR cause cystic fibrosis. Note that this term differs from genetic heterogeneity.",
"     </li>",
"     <li>",
"      Aneuploidy &mdash; The state of having an abnormal number of chromosomes. A euploid human karyotype has 46 chromosomes (",
"      <a class=\"graphic graphic_figure graphicRef72134 \" href=\"mobipreview.htm?21/35/22064\">",
"       figure 1",
"      </a>",
"      ). Aneuploidy can affect the entire somatic cell population, as in trisomy 21 in which an extra chromosome results in Down Syndrome. Aneuploidy may also affect only certain cells.",
"     </li>",
"     <li>",
"      Anticipation &mdash; A phenomenon whereby the symptoms of a genetically-based condition appear at an earlier age, or with greater severity, with successive generations. Expansion of short tandem repeats is a known molecular cause for specific diseases (such as myotonic dystrophy) that manifest anticipation.",
"     </li>",
"     <li>",
"      Association &mdash; The non-random relationship between an allele and a phenotype in a population. Genetic association between a marker allele and a phenotype can result either because the allele is a direct causal variant, or because the allele is in linkage disequilibrium with a causal variant in close proximity. Genetic association is a property of alleles.",
"     </li>",
"     <li>",
"      Autosome &mdash; A chromosome other than X or Y. The human genome has 44 autosomes (22 pairs) (",
"      <a class=\"graphic graphic_figure graphicRef72134 \" href=\"mobipreview.htm?21/35/22064\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Autosomal &mdash; A gene is autosomal if it is located on an autosome. A gene's inheritance pattern is also referred to as autosomal if the pattern corresponds to that of known autosomal genes.",
"     </li>",
"     <li>",
"      Carrier &mdash; An individual who is heterozygous for a risk allele. The term is typically used to describe heterozygotes for mutations that cause recessive disease, but it is also used to describe heterozygotes for risk alleles of complex traits with variable penetrance, regardless of inheritance type.",
"     </li>",
"     <li>",
"      Carrier rate &mdash; The frequency of carriers in a population.",
"     </li>",
"     <li>",
"      Carrier testing &mdash; Clinical method of genotyping at risk populations or family members to identify individuals, usually asymptomatic, who have a gene mutation for an autosomal recessive or X-linked disorder. One example is prenatal screening for Tay-Sachs mutations in people of Ashkenazi Jewish ancestry.",
"     </li>",
"     <li>",
"      Centromere &mdash; A condensed chromosome region that mediates attachment of chromosomes to the mitotic or meiotic spindle. The centromere also contains the information that preserves the normal chromosome complement (eg, number of chromosomes).",
"     </li>",
"     <li>",
"      Chromatid &mdash; One of two replications of a chromosome formed prior to cell division and joined together at their centromeres. The centromere is the last portion of a chromosome to replicate during cell division. Sister chromatids are a pair of chromatids attached at the centromere.",
"     </li>",
"     <li>",
"      Coding mutation or polymorphism &mdash; A genetic variation in the open reading frame of a gene. Coding variants that alter amino acid composition of a protein are called non-synonymous or missense variants (",
"      <a class=\"graphic graphic_figure graphicRef55798 \" href=\"mobipreview.htm?4/50/4899\">",
"       figure 2",
"      </a>",
"      ). Variants that do not alter amino acid composition are called synonymous variants. Nonsense variants are coding variants that result in the introduction of a stop codon (",
"      <a class=\"graphic graphic_figure graphicRef78399 \" href=\"mobipreview.htm?36/37/37458\">",
"       figure 3",
"      </a>",
"      ). A frame-shift mutation results from an insertion or deletion of a number of bases not divisible by 3, resulting in shifting of the reading frame (",
"      <a class=\"graphic graphic_figure graphicRef78767 \" href=\"mobipreview.htm?12/14/12515\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Codon &mdash; A three-nucleotide sequence that codes either for a specific amino acid or for chain termination during protein synthesis.",
"     </li>",
"     <li>",
"      Complementation &mdash; The restoration of normal phenotype by gene replacement. The replaced gene can either be an intact copy of a defective gene (direct replacement), or a gene with function that can compensate for the defective gene's aberrant function.",
"     </li>",
"     <li>",
"      Compound heterozygote &mdash; An individual bearing two different pathogenic mutations in the same gene that together are sufficient to manifest a recessive phenotype. This differs from double heterozygote, which refers to an individual who is heterozygous for mutations at two separate genetic loci, which together manifest disease.",
"     </li>",
"     <li>",
"      Consanguinity &mdash; The state of genetic relatedness between two individuals who mate. The probability of a rare recessive disease is increased within pedigrees of consanguineous matings known to carry recessive disease alleles.",
"     </li>",
"     <li>",
"      Copy number variation &mdash; The most prevalent type of chromosomal structural variation, in which the number of copies of a large DNA segment (measuring thousands to millions of bases) varies between individuals.",
"     </li>",
"     <li>",
"      Crossing-over &mdash; The exchange of chromosome segments that occurs during meiosis. Crossing over is the most common mechanism of recombination. The site on the chromosome where the exchange occurs is called a crossover.",
"     </li>",
"     <li>",
"      Coupling &mdash; The presence of alleles at two linked loci on the same chromosome. The presence of alleles at two linked loci on different chromosomes is repulsion (",
"      <a class=\"graphic graphic_figure graphicRef58385 \" href=\"mobipreview.htm?0/32/525\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      De novo mutation &mdash; A novel genetic variant introduced by germline mutation. Often used to distinguish familial from sporadic cases of genetic disease.",
"     </li>",
"     <li>",
"      Digenic inheritance &mdash; Diseases caused by co-inheritance of mutations at two distinct genetic loci (ie, in two different genes).",
"     </li>",
"     <li>",
"      Diploid &mdash; Possessing two copies of each autosomal chromosome, and therefore of each (autosomal) gene. Most human cells are diploid. Gametes are haploid (one copy of each autosome) (",
"      <a class=\"graphic graphic_figure graphicRef72134 \" href=\"mobipreview.htm?21/35/22064\">",
"       figure 1",
"      </a>",
"      ). Normal hepatocytes are tetraploid.",
"     </li>",
"     <li>",
"      Dominant negative &mdash; Alleles that cause an abnormal phenotype or disease by a mechanism that depends on the presence of an abnormal gene product interfering with the function of products from a normal gene.",
"     </li>",
"     <li>",
"      Double heterozygote &mdash; An individual who is heterozygous for mutations at two separate genetic loci that together are sufficient to manifest a phenotype. Differs from compound heterozygote.",
"     </li>",
"     <li>",
"      Epigenetic change &mdash; A modification of a chromosome that does not alter the base sequence, but alters the expression of a gene. Epigenetic changes may be stable in an individual, but may be reversed during gametogenesis or early development. DNA methylation and histone acetylation are common epigenetic changes. Epigenetic changes are the mechanistic basis of imprinting.",
"     </li>",
"     <li>",
"      Epistasis &mdash; The process by which variation at two or more genetic loci interact to produce phenotypes different from the individual effects of each variant. This process is often referred to as either a gene-gene interaction or a genetic modifier effect.",
"     </li>",
"     <li>",
"      Exon &mdash; A segment of DNA that is transcribed and present in mature messenger RNA (mRNA). This is in contrast to an intron, referring to the DNA sequence between exons that does not become part of mature mRNA.",
"     </li>",
"     <li>",
"      Expressivity &mdash; A parameter used in genetic models that quantifies the degree to which an inherited characteristic is expressed in an organism.",
"     </li>",
"     <li>",
"      Frame-shift mutation &mdash; A mutation that results from an insertion or deletion of a number of bases (not divisible by 3), resulting in shifting the reading frame (",
"      <a class=\"graphic graphic_figure graphicRef78767 \" href=\"mobipreview.htm?12/14/12515\">",
"       figure 4",
"      </a>",
"      ) and thus altering the protein.",
"     </li>",
"     <li>",
"      Fusion gene &mdash; a functional gene product that results from the juxtaposition of DNA segments from two physically distinct genes. The juxtaposition occurs as a consequence of chromosomal rearrangements such as translocations, inversions, segmental deletions or duplications. Examples include the BCR-ABL and the FIP1L1-PDGFRA fusion genes.",
"     </li>",
"     <li>",
"      Gene &mdash; A unit of DNA sequence that encodes specific function. Classical definitions limit genes to those elements that code for protein. However, non-protein coding genes (such as non-coding RNAs) are also genes.",
"     </li>",
"     <li>",
"      Genetic heterogeneity &mdash; Mutations in different genes resulting in the same phenotype. Examples include the multiple genetic causes of sensorineural deafness. This differs from allelic heterogeneity.",
"     </li>",
"     <li>",
"      Genotype &mdash; The combination of alleles in diploid organisms at one genomic location in an individual.",
"     </li>",
"     <li>",
"      Genome-wide association study &mdash; A genetic mapping study design that assesses across the genome for evidence of association between genetic variants and heritable traits. Typical studies consist of genotyping hundreds of thousands of common SNPs, using DNA microarrays in large case-control populations, with the goal of identifying specific risk alleles that are more prevalent in cases than in controls.",
"     </li>",
"     <li>",
"      Germline &mdash; Referring to the gametic cell lines (ova and spermatozoa and their precursors).",
"     </li>",
"     <li>",
"      Haploid &mdash; Possessing one copy of each chromosome, and therefore of each gene. Gametes (ova and sperm) are haploid. Fertilization of a haploid ovum by a haploid sperm results in formation of a diploid embryo. Many microorganisms are haploid.",
"     </li>",
"     <li>",
"      Haploinsufficiency &mdash; Refer to definition of &lsquo;Hemizygous&rsquo; below.",
"     </li>",
"     <li>",
"      Haplotype &mdash; The physical combination of alleles present on a single chromosome. By definition, alleles on one haplotype are in coupling (",
"      <a class=\"graphic graphic_figure graphicRef58385 \" href=\"mobipreview.htm?0/32/525\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hemizygous &mdash; The state of carrying only one copy of a genomic region due to deletion of the corresponding region on the other chromosome. Carriers of large-scale deletions are hemizygotes. Hemizygosity can confer disease if having one normally functioning copy is insufficient for normal cellular function (haploinsufficiency).",
"     </li>",
"     <li>",
"      Heritability &mdash; The proportion of phenotypic variation that is explained by genetic factors.",
"     </li>",
"     <li>",
"      Heteroplasmy &mdash; The occurrence in a single cell of more than one population of mitochondrial DNA sequence.",
"     </li>",
"     <li>",
"      Identity by descent &mdash; Alleles are identical by descent if they can be traced to a common ancestor. Identity by descent is a more stringent classification than identity by state. Identify by descent is the basis for establishing linkage.",
"     </li>",
"     <li>",
"      Identity by state &mdash; Alleles are identical by state if the assay being used to distinguish alleles determines that they are identical. Identity by state is the basis for establishing association.",
"     </li>",
"     <li>",
"      Imprinting &mdash; Gamete-specific gene silencing, in which only the allele from the mother or only the allele from the father is expressed, leading to observed parent-of-origin effects in offspring. Examples include the Prader-Willi and Angelman Syndrome locus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/8/16516?source=see_link\">",
"       \"Epidemiology and genetics of Prader-Willi syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=see_link\">",
"       \"Congenital cytogenetic abnormalities\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Indel &mdash; A class of common polymorphisms defined by the presence or absence of a short, usually silent, genetic sequence. These are useful as markers.",
"     </li>",
"     <li>",
"      Intron &mdash; A segment of DNA between two exons that is transcribed to pre-mRNA but is removed through the process of splicing and is therefore not part of mature mRNA.",
"     </li>",
"     <li>",
"      Inversion &mdash; A chromosomal rearrangement characterized by rotation and reintegration of a DNA segment, resulting in an inverted orientation of the segment relative to its natural state.",
"     </li>",
"     <li>",
"      Linkage &mdash; The relationship that exists between two loci that violate the Mendelian law of independent assortment and therefore segregate in families in a non-random fashion. Non-independent assortment results because linked loci reside together on the same chromosome (ie, they are syntenic). However, most syntenic loci are not linked due to mandatory recombination during meiosis. Linkage therefore implies the linked loci are in close physical proximity to each other.",
"     </li>",
"     <li>",
"      Linkage analysis &mdash; Gene mapping study design methods that test for the non-random segregation of disease phenotypes with discrete chromosomal segments. Identification of linked regions implies the existence of disease-causing mutations within or proximal to the linked region. The process of disease-gene identification within this region is termed positional cloning.",
"     </li>",
"     <li>",
"      Linkage disequilibrium &mdash; The non-random association of alleles at two or more loci in a population. Linkage disequilibrium is present when the observed haplotype distribution of two or more markers in a population is significantly different from the expected haplotype distribution (which can be derived from the cross-product of observed allele frequencies) (",
"      <a class=\"graphic graphic_figure graphicRef76528 \" href=\"mobipreview.htm?22/19/22845\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Locus &mdash; A specific chromosomal or genomic location.",
"     </li>",
"     <li>",
"      Lyonization &mdash; See &ldquo;X-inactivation.&rdquo;",
"     </li>",
"     <li>",
"      Marker &mdash; A locus with alternative alleles that can be used in genetic mapping experiments.",
"     </li>",
"     <li>",
"      Meiosis &mdash; The cell division process in germline cells by which the chromosomal complement is reduced from the diploid to the haploid number (",
"      <a class=\"graphic graphic_figure graphicRef79125 \" href=\"mobipreview.htm?5/0/5120\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Mendelian inheritance &mdash; A trait is said to have Mendelian inheritance if its genetic transmission can be explained by a single gene model. This is in contrast to digenic and quantitative traits.",
"     </li>",
"     <li>",
"      Mendelian randomization &mdash; An epidemiologic analytical method in which the random assignment of genotype at meiosis is used to test whether there is an association between an exposure or intermediate phenotype (a biomarker) and a specified outcome.",
"     </li>",
"     <li>",
"      Methylation &mdash; The addition of methyl groups to cytosine in DNA. Methylation, when followed by deamination, is a major pathway for mutation to thymine. Methylation also correlates with reduced gene transcription, and is an important mechanism for gene imprinting and X-inactivation.",
"     </li>",
"     <li>",
"      Microsatellite &mdash; A tandem array of a short sequence of DNA (typically two to four bases). Microsatellites are numerous and widely distributed in the genome. There is often polymorphism in their length, making them useful markers in genetic studies, including genome mapping and family-based linkage analysis. Microsatellites are also known as short tandem repeat markers (STRs).",
"     </li>",
"     <li>",
"      Mitosis &mdash; The process of cell division occurring in most cells, in which each daughter cell receives a full chromosome complement.",
"     </li>",
"     <li>",
"      Mutation, mutant &mdash; An altered version of a gene. These terms are used in several different senses, depending on context:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      a genetic variant of low population frequency (less than 1 percent), in contrast to a polymorphism (often a single nuclear polymorphism, or SNP) with an allele frequency of 1 percent or greater",
"     </li>",
"     <li>",
"      implication of abnormal function (eg, sickle cell mutation of the hemoglobin b chain)",
"     </li>",
"     <li>",
"      implication of recent sequence change (either germline or somatic), in contrast to inheritance from a carrier parent",
"     </li>",
"     <li>",
"      an organism or population harboring a specific mutation (eg, antibiotic-resistant mutants)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Next generation sequencing &mdash; Any of several high-throughput DNA sequencing methods that rely on parallel analysis of multiple DNA fragments. These methods have resulted in dramatic decreases in the cost and time needed for sequencing projects, allowing some to be applied in clinical settings.",
"     </li>",
"     <li>",
"      Non-coding variant &mdash; Genetic variation that does not map to gene regions that code for protein. These variants can be functional if they reside in and disrupt functional elements, such as non-coding RNA sequences or regulatory sites (eg, promoters, enhancers, suppressors, or splice-sites).",
"     </li>",
"     <li>",
"      Penetrance &mdash; A parameter of genetic models that quantifies the probability that an individual harboring a disease-causing genotype will develop the associated disease or condition. Incomplete penetrance occurs when an individual with a disease-causing genotype does not manifest features of the disorder. There are multiple causes of incomplete penetrance, including absence of environmental or genetic co-factors, epigenetic effects such as imprinting, sex-specific effects, or age-related expression differences.",
"     </li>",
"     <li>",
"      Phenotype &mdash; A characteristic of an organism that is related to its genetic constitution. Phenotypes are sensitive to the assays used to assign or measure them. They may be categorical, such as presence or absence of a disease; or quantitative, such as systolic blood pressure. Further complexities in phenotypic description involve the physiological state of the organism at the time of measurement, age, or use of provocative stimuli. Most phenotypes are variable, and this variability leads to the concepts of penetrance and expressivity.",
"     </li>",
"     <li>",
"      Ploidy &mdash; The number of sets of chromosomes present in an organism or cell. Ploidy varies among different organisms, including those that are always haploid (eg, bacteria), either haploid or diploid (eg, Saccharomyces species), consistently diploid (eg, mammals), or polyploid (eg, hexaploid wheat). Different tissues in multicellular organisms may have different ploidies (eg, mammalian hepatocytes may be tetraploid). The designation of ploidy is based on the predominant ploidy of cells in the organism.",
"     </li>",
"     <li>",
"      Polymorphism &mdash; A genetic sequence with two or more alleles in at least one population. Most typically refers to a common single base-pair change or single nucleotide polymorphism (SNP). By definition, a SNP has a population frequency of at least 1 percent, in contrast to a mutation, which has a frequency of less than 1 percent.",
"      <br/>",
"      <br/>",
"      A polymorphism also refers to any biologic marker (DNA, RNA or protein) with two or more states. Protein polymorphisms (varying amino acid sequence) can result from differences in DNA sequence (ie, DNA polymorphisms) or from differential RNA splicing (ie, isoforms) which in turn can result from sequence variation, epigenetic phenomenon, or",
"      <span class=\"nowrap\">",
"       temporal/spatial/environmental",
"      </span>",
"      differences.",
"     </li>",
"     <li>",
"      Quantitative traits and quantitative trait loci (QTL) &mdash; \"Quantitative\" traits are distinguished from discrete traits. The population varies continuously for quantitative traits and falls into obvious phenotypic classes for discrete traits. Quantitative traits are sometimes referred to as \"complex\" traits, reflecting the fact that multiple genes, the environment, and gene-environment interactions all contribute to an individual's trait value. Many traits are quantitative and their inheritance is much more challenging to unravel than discrete traits. A quantitative trait locus (QTL) is a genomic region linked or associated with a quantitative trait.",
"     </li>",
"     <li>",
"      Read depth &mdash; The number of independent times each base in a targeted region has been sequenced. Typically expressed as an average X coverage (for example 20X = an average of 20 sequence reads per base). A minimum read depth of 30X is often required for clinical-grade sequencing.",
"     </li>",
"     <li>",
"      Reading frame &mdash; The starting point in translating the DNA sequence to protein. Since each codon includes three nucleotides, the reading frame can be initiated at one of three nucleotides. Offsetting the reading frame changes the encoded protein.",
"     </li>",
"     <li>",
"      Recombinant &mdash; Refers to offspring whose genotype and phenotype combinations differ from their parents, implying genetic recombination between the loci under study. Recombinant technologies, or genetic engineering, are molecular genetic approaches that leverage the process of homologous recombination to manipulate genetic information for experimental purposes.",
"      <br/>",
"      <br/>",
"      Examples include transgenic models where specific genetic loci are either knocked-out (removed) or knocked-in (introduced) to enable study of the locus; recombinant inbred mouse strains; recombinant viral transfection for synthesis of clonal protein.",
"     </li>",
"     <li>",
"      Recombination &mdash; The process of exchanging DNA sequence between two chromosomal structures. Mandatory recombination occurs at least once per aligned chromosome pair during meiosis. The exchange results in the creation of novel haplotypes that are combinations of the grandparental haplotypes present in a diploid cell. Exchange of unequal sequence content (ie, non-homologous recombination) introduces DNA gains and losses of thousands or millions of bases. These gains and losses result in structural genetic variants and copy number variation (CNVs).",
"     </li>",
"     <li>",
"      Repulsion &mdash; The state in which alleles at two distinct loci are on physically opposing chromosomal strands. By definition, these variants are not on the same haplotype (",
"      <a class=\"graphic graphic_figure graphicRef58385 \" href=\"mobipreview.htm?0/32/525\">",
"       figure 5",
"      </a>",
"      ). The opposite relationship is coupling,",
"     </li>",
"     <li>",
"      Risk allele &mdash; The allele associated with a disease phenotype. Though the risk allele is often that which is least common (ie, the minor allele), risk alleles associated with some complex traits may be the more common allele.",
"     </li>",
"     <li>",
"      RNA interference: A ubiquitous intracellular process mediated by small RNA species, whereby specific RNAs are targeted for editing, degradation or clearance. RNA interference has important roles in the regulation of gene expression, developmental processes, cellular defense, and epigenetic effects.",
"     </li>",
"     <li>",
"      Single nucleotide polymorphism (SNP) &mdash; A polymorphism that affects a single base pair with a population frequency of at least one percent. Single base pair changes that occur at a lower population frequency are, by convention, called mutations. Refer to definition of Polymorphism above.",
"     </li>",
"     <li>",
"      Somatic &mdash; Refers to tissues that are not within the germline. Somatic mutations arise in the somatic tissues and are therefore not passed from parent to offspring. Somatic mutations are common features in neoplasms.",
"     </li>",
"     <li>",
"      Structural genetic variation &mdash; A term that encompasses variety of large-scale genomic aberrations, including segmental rearrangements, translocations or inversions, and DNA copy-number variants (CNVs). Large rearrangements or deletions can be visualized through karyotyping. Smaller variants, particularly CNVs, segmental duplications, and interchromosomal interstitial rearrangements, are assessed by fluorescence in situ hybridization (FISH) or competitive genomic hybridization arrays (aCGH).",
"     </li>",
"     <li>",
"      Syntenic &mdash; Describing genetic loci that reside on the same chromosome. As an example, the genes causing Brit-Hogg-Dube syndrome (Folliculin - FLCN) on chromosome 17p11 and early-onset breast cancer (BRCA1) on 17q21 are syntenic to each other on chromosome 17. However, because they sit far apart from each other, they are not linked.",
"     </li>",
"     <li>",
"      Translocation &mdash; A structural chromosomal abnormality whereby chromosome segments are swapped between non-homologous chromosomes. This form of rearrangement can be either (i) balanced, when the translocation does not result in any loss or gain of genetic material in the resultant gamete; or (ii) unbalanced, when there is a gain or loss of genetic material in the resultant gamete.",
"     </li>",
"     <li>",
"      Uniparental disomy &mdash; The inheritance of two copies of a chromosome (or part of a chromosome) from one parent, and no copy from the other parent, due either to non-dysjunction errors during either the first or second phases of meiosis, or to chromosomal alterations in early fetal development. Non-dysjunction during the first phase of meiosis (meiosis I) will result in inheritance of each of the grandparental chromosomes from one parent, termed &ldquo;heterodisomy.&rdquo; In contrast, non-dysjunction during meiosis II results in inheritance of two identical copies of one grandparental chromosome, termed &ldquo;isodisomy.&rdquo;",
"     </li>",
"     <li>",
"      X-inactivation &mdash; An epigenetic process that occurs in all female mammalian cells whereby one of the two X chromosomes are randomly rendered inactive, such that all subsequent gene expression is derived from the other (active) X chromosome. This is sometimes called Lyonization, after Mary Lyon, who did important early work on this phenomenon.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Encyclopedia of Genetics, Brenner S, Miller J (Eds), Academic Press, San Diego 2001.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2898 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43717=[""].join("\n");
var outline_f42_44_43717=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLOSSARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2898\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2898|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/35/22064\" title=\"figure 1\">",
"      Human karyotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/50/4899\" title=\"figure 2\">",
"      Missense mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/37/37458\" title=\"figure 3\">",
"      Nonsense mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/14/12515\" title=\"figure 4\">",
"      Frameshift mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/32/525\" title=\"figure 5\">",
"      Haplotypes coupling repulsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/19/22845\" title=\"figure 6\">",
"      Linkage disequilibrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/0/5120\" title=\"figure 7\">",
"      Essential features meiosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/8/16516?source=related_link\">",
"      Epidemiology and genetics of Prader-Willi syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_44_43718="Rabeprazole: Pediatric drug information";
var content_f42_44_43718=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rabeprazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?43/18/44327?source=see_link\">",
"    see \"Rabeprazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/44/41668?source=see_link\">",
"    see \"Rabeprazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16572477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Bone Fracture Risk with Proton Pump Inhibitors: Health Canada Issues Alert",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has informed healthcare professionals that proton pump inhibitors (PPIs) may increase the risk of bone fractures. The risk of fracture was observed to be higher in patients receiving multiple daily doses for &ge;1 year; age, gender, and concomitant health conditions may also be a factor. Patients with risk factors for osteoporosis should be closely monitored and should receive a PPI at the lowest effective dose and for the shortest duration of therapy appropriate for the condition.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10539946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AcipHex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Rabeprazole&reg;;",
"     </li>",
"     <li>",
"      Pariet&reg;;",
"     </li>",
"     <li>",
"      Pat-Rabeprazole;",
"     </li>",
"     <li>",
"      PMS-Rabeprazole EC;",
"     </li>",
"     <li>",
"      PRO-Rabeprazole;",
"     </li>",
"     <li>",
"      Rabeprazole EC;",
"     </li>",
"     <li>",
"      RAN&trade;-Rabeprazole;",
"     </li>",
"     <li>",
"      Riva-Rabeprazole EC;",
"     </li>",
"     <li>",
"      Sandoz-Rabeprazole;",
"     </li>",
"     <li>",
"      Teva-Rabeprazole EC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastric Acid Secretion Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Proton Pump Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/18/44327?source=see_link\">",
"      see \"Rabeprazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;12 years: GERD: 20 mg/day for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erosive/ulcerative GERD: Treatment: 20 mg once daily for 4-8 weeks; if inadequate response, may repeat up to an additional 8 weeks; maintenance: 20 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symptomatic GERD: Treatment: 20 mg once daily for 4 weeks; if inadequate response, may repeat for an additional 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duodenal ulcer: 20 mg/day before breakfast for 4 weeks; additional therapy may be required for some patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     eradication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer labeling: 20 mg twice daily administered with amoxicillin 1000 mg",
"     <b>",
"      and",
"     </b>",
"     clarithromycin 500 mg twice daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     American College of Gastroenterology guidelines (Chey, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Nonpenicillin allergy: 20 mg twice daily administered with amoxicillin 1000 mg",
"     <b>",
"      and",
"     </b>",
"     clarithromycin 500 mg twice daily for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Penicillin allergy: 20 mg twice daily administered with clarithromycin 500 mg",
"     <b>",
"      and",
"     </b>",
"     metronidazole 500 mg twice daily for 10-14 days",
"     <b>",
"      or",
"     </b>",
"     20 mg once or twice daily administered with bismuth subsalicylate 525 mg",
"     <b>",
"      and",
"     </b>",
"     metronidazole 250 mg",
"     <b>",
"      plus",
"     </b>",
"     tetracycline 500 mg 4 times/day for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypersecretory conditions: 60 mg once daily; dose may need to be adjusted as necessary. Doses as high as 100 mg once daily and 60 mg twice daily have been used and continued as long as necessary (up to 1 year in some patients).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild to moderate: No adjustment is necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: Use cautiously due to lack of clinical data",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment necessary",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, enteric coated, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AcipHex&reg;: 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16562879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aciphex Sprinkle (delayed-release capsule): FDA approved March 2013; anticipated availability currently unknown. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15386957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     AcipHex&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM324059.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM324059.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to food; tablets should be swallowed whole, do not chew, crush, or split. May administer with an antacid.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); protect from moisture",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptomatic gastroesophageal reflux disease (GERD) (FDA approved in ages &ge;12 years and adults); short-term treatment (4-8 weeks) and maintenance of erosive or ulcerative GERD (FDA approved in adults); short-term treatment (4 weeks) of duodenal ulcers (FDA approved in adults); long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome) (FDA approved in adults); in combination with clarithromycin and amoxicillin, adjunctive treatment of duodenal ulcers associated with",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       AcipHex&reg; may be confused with Acephen&trade;, Accupril&reg;, Aricept&reg;, pHisoHex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       RABEprazole may be confused with ARIPiprazole, donepezil, lansoprazole, omeprazole, raloxifene",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F216748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, flatulence, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic encephalopathy, hepatic enzymes increased, hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agitation, agranulocytosis, albuminuria, allergic reaction, alopecia, amblyopia, anaphylaxis, anemia, angioedema, bullous skin eruption, chest pain, cholecystitis, cholelithiasis,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD), colitis, coma, delirium, disorientation, erythema multiforme, fever, fracture, gynecomastia, hematuria, hemolytic anemia, hyperammonemia, hypertension, hypokalemia, hypomagnesemia, hyponatremia, interstitial nephritis, jaundice, leukocytosis, leukopenia, melena, migraine, osteoporosis-related fracture, palpitation, pancreatitis, pancytopenia, pneumonia, pruritus, rhabdomyolysis, sinus bradycardia, somnolence, Stevens-Johnson syndrome, sudden death, taste abnormal, thrombocytopenia, toxic epidermal necrolysis, TSH increased, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rabeprazole, substituted benzimidazole proton pump inhibitors (eg, lansoprazole, omeprazole), or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic response to therapy with rabeprazole does not preclude the presence of gastric malignancy. Use of gastric acid inhibitors including proton pump inhibitors and H",
"     <sub>",
"      2",
"     </sub>",
"     blockers has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia (Canani, 2006). An increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy; patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk. Hypomagnesemia has been reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy), and may be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of rabeprazole may be necessary; magnesium concentrations typically return to normal within 1 week of stopping.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F216736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C8 (moderate), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: RABEprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.  Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1061740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered with a high fat meal, absorption may be delayed; however, the extent of absorption (AUC) is not significantly altered.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not shown to be teratogenic in animal studies, however, adequate and well-controlled studies have not been done in humans; use during pregnancy only if clearly needed",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppresses gastric acid secretion by inhibiting the parietal cell membrane enzyme (H",
"     <sup>",
"      +",
"     </sup>",
"     /K",
"     <sup>",
"      +",
"     </sup>",
"     )-ATPase or proton pump; demonstrates antimicrobial activity against",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: 1 hour",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 96.3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive metabolism in the liver by cytochrome isoenzymes CYP3A and CYP2C19 to inactive metabolites; [CYP2C19 exhibits a known genetic polymorphism due to its deficiency in some subpopulations (3% to 5% of Caucasians and 17% to 20% of Asians) which results in slower metabolism]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 52%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: ~0.55-1 hour (James, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: 3.3-4.1 hours (James, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: 90% in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/44/41668?source=see_link\">",
"      see \"Rabeprazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not chew or crush tablets; may cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Canani RB, Cirillo P, Roggero P, et al, \"Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(5):e817-20.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD, Wong BC, and Practice Parameters Committee of the American College of Gastroenterology, \"American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,\"",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007, 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/44/43718/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibbons TE and Gold BD, &ldquo;The Use of Proton Pump Inhibitors in Children: A Comprehensive Review,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2003, 5(1):25-40.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James L, Walson P, Lomax K, et al, \"Pharmacokinetics and Tolerability of Rabeprazole Sodium in Subjects Aged 12 to 16 Years With Gastroesophageal Reflux Disease: An Open-Label, Single- and Multiple-Dose Study,\"",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2007, 29(9):2082-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/44/43718/abstract-text/18035206/pubmed\" id=\"18035206\" target=\"_blank\">",
"        18035206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13098 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43718=[""].join("\n");
var outline_f42_44_43718=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16572477\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10539946\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216709\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061731\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061725\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216683\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216669\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16562879\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15386957\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061734\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061728\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061733\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216750\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216748\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061738\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061724\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061723\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216736\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216678\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061740\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216680\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216691\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061722\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061736\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061737\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061730\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13098\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13098|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/18/44327?source=related_link\">",
"      Rabeprazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/44/41668?source=related_link\">",
"      Rabeprazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_44_43719="Functional problems in the patient with cancer";
var content_f42_44_43719=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Functional problems in the patient with cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/44/43719/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43719/contributors\">",
"     Vikas Malhotra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/44/43719/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43719/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/44/43719/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43719/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/44/43719/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in early detection, diagnosis, and treatment have led to prolonged survival for many individuals with cancer. More than 50 percent of all newly diagnosed cancer patients will survive for more than five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/1\">",
"     1",
"    </a>",
"    ], and many with early stage cancer can anticipate a normal life expectancy. Functional impairment of patients with cancer can occur at any point in the diagnostic and therapeutic continuum:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients who are cured or have a long disease-free interval experience long-term treatment-related sequelae that impair their functional status.",
"     </li>",
"     <li>",
"      For patients who are living with cancer over many years, symptoms may be controlled by surgery, hormones, chemotherapy, or radiation therapy; for these individuals, cancer is truly a chronic disease.",
"     </li>",
"     <li>",
"      Patients with advanced cancer at the time of diagnosis may present with functional impairment that is a direct result of the disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of cancer has increased in complexity, leading to new kinds of functional problems. Surgical procedures are often less extensive than in preceding decades in an attempt to preserve organ function. However, to limit the extent of surgery, patients must receive complex multimodality therapy (combining two or three treatment approaches such as surgery, radiation, and chemotherapy) that increases the length and potential toxic effects of treatment as well as the rehabilitation and recovery process. Primary treatment frequently extends from 6 to 12 months, and the combined side effects can affect all areas of functioning (ie, physical, psychosocial, vocational, and economic). Furthermore, functional impairment from cancer and its treatment is particularly important in the elderly population, a group in which cancer is being diagnosed and treated more aggressively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of functional impairment on quality of life and the assessment of functional impairment in patients with cancer is discussed here. Specific rehabilitation issues in these patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3690?source=see_link\">",
"     \"Various rehabilitation issues in patients treated for cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     QUALITY OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional status and quality of life have been fundamental concerns of oncologic practice since 1949, when Karnofsky and Burchenal developed a clinical scale to quantify the functional performance of cancer patients (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, quality of life is a far greater issue than is reflected in the performance status scales. Increasing interest in the systematic assessment of health-related quality of life (a multidimensional construct that includes the subjective appraisal of the patient's physical, mental, and social well-being) in cancer patients using standardized, self-administered measures has emerged in the past two decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4120?source=see_link\">",
"     \"Evaluation of health-related quality of life\"",
"    </a>",
"    .) QOL assessments are commonly used in clinical trials and in research settings to assess the impact of treatment on functional status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    QOL outcomes are also key goals of contemporary cancer rehabilitation. Rehabilitation interventions can help maximize the functional status of individuals with cancer and reduce the morbidity associated with the disease and its treatments. They also can address the psychosocial and vocational problems associated with cancer and lead to improvements in wellbeing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXTENT OF DISEASE AND IMPACT UPON FUNCTIONAL STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer is a biological process that can potentially affect any tissue in the body. Patients can be affected by different symptoms and functional problems depending upon the primary site of the cancer, and the recommended treatment, which is dictated by the histologic type, location, and disease extent.",
"   </p>",
"   <p>",
"    As an example, treatment of a superficial melanoma that is localized to the trunk will result in a modest cosmetic skin change in that area, with a limited functional impact from the surgical excision. In contrast, the same superficial melanoma involving the eye or the ear may require significant plastic and reconstructive surgery, have an impact upon the function of the organ involved, and may have important psychological effects because of changes in body image.",
"   </p>",
"   <p>",
"    Chronic fatigue and anxiety may be more frequent in patients with cancer compared to those who have never had cancer, and this may result in a poorer quality of life. In a study of 189 women who had survived at least 18 months after treatment for ovarian cancer, these abnormalities were present both in those who had relapsed and those who were disease-free following their initial management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Localized disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have localized or locoregional disease are generally approached with curative intent therapy. Treatment is often multimodal and intensive, aimed at local control of the tumor (surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation), and may be followed by some form of systemic therapy (termed adjuvant therapy) to eradicate occult metastatic disease.",
"   </p>",
"   <p>",
"    Many patients with localized cancers have few symptoms or impairments from the cancer itself, but experience functional changes as a result of the primary treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adjuvant therapy which may be long-lastsing, especially among older individuals. Data from at least one randomized trial suggests that older overweight cancer survivors who participate in a home-based diet and exercise program can reduce the rate of self-reported functional decline over time (albeit modestly) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All patients are psychologically affected by the diagnosis of cancer, but patients receiving curative intent therapy are usually hopeful about the long-term outcome of treatment on their life expectancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant proportion of patients with newly diagnosed cancer have metastatic disease. About two-thirds of patients with non-small cell lung cancer, for example, are not candidates for surgical resection at the time of diagnosis and have either advanced regional or distant metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16282?source=see_link\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients are usually symptomatic from the cancer and have cancer-related functional problems. Their treatment is focused upon symptom relief and prolongation of life. While chemotherapy or radiation therapy may have a reasonable chance of controlling the metastatic disease, it is given with palliative rather than curative intent.",
"   </p>",
"   <p>",
"    Although the majority of metastatic tumors are approached with palliative rather than curative intent, notable exceptions to this general rule include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some of the hematologic malignancies (acute and chronic leukemias, the lymphomas) &mdash; Widespread disease at diagnosis is the rule with these disorders, although chemotherapy may frequently be curative or prolong life substantially. In any case, treatment is more challenging in this patient group because of the high rate of symptoms from the disease as well as toxicities from therapy.",
"     </li>",
"     <li>",
"      Testicular cancer &mdash; Cisplatin-based combination chemotherapy can cure patients with disseminated germ cell cancers, even in the context of widespread visceral metastases, highly elevated serum tumor markers, and other adverse prognostic features. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=see_link\">",
"       \"Overview of the treatment of testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ovarian germ cell tumors, and to a lesser extent, epithelial ovarian cancers &mdash; Prolonged recurrence-free survival can be obtained with combined surgery and chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=see_link\">",
"       \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer can be psychologically and physically devastating when it recurs. The optimism present at diagnosis may be lost, and the patient may have to deal with pain, fatigue, and other problems that impair function. Cancer treatment is usually reinstituted and the toxicities of therapy are added to the symptoms of recurrent disease. Patients may receive substantial functional benefit if the disease responds once again to treatment; progressive symptoms will lead to further functional decline if treatments are ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Advanced metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced metastatic cancer share many of the same problems that other patients face. However, they have some unique concerns that are specific to this phase of the illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They often face progressive deterioration in physical functioning with increasing dependence upon others.",
"     </li>",
"     <li>",
"      A range of symptoms, including in particular pain, are common in this setting; these symptoms can lead to further decline in physical abilities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"       \"Assessment of cancer pain\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=see_link\">",
"       \"Overview of managing common non-pain symptoms in palliative care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psychosocial concerns related to death and dying occupy both the patient and family support network. Financial, legal, and insurance problems present additional burdens for many families. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29769?source=see_link\">",
"       \"Psychosocial issues at the end of life\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rehabilitation efforts should include regular reassessment as patients transition into a new phase of illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FUNCTIONAL ASSESSMENT AND INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective intervention can only be provided when the physician and health care team assess functioning and identify the rehabilitation needs of the patient. A systematic rehabilitation needs assessment should be performed at the time of diagnosis, with periodic reassessment of needs as treatment and the disease progress.",
"   </p>",
"   <p>",
"    Physical problems, such as pain, are more likely to be regularly assessed than are the majority of rehabilitation problems (eg, psychosocial, vocational, and economic) because many physicians have not been trained to address these concerns. Other members of the cancer care team may be more effective in this regard, especially social workers and nurses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with cancer, physical problems are the most common reason for needing formal rehabilitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The intensity of the physical rehabilitation intervention relates to the type of cancer and cancer treatment, the degree to which the cancer is treatable, the reversibility of the problem, and the extent of disability suffered by the patient (which is reflected in the Karnofsky performance status [(",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 1",
"    </a>",
"    )]). As an example, a patient undergoing curative surgery for breast cancer will sometimes require short-term physical therapy to restore arm mobility, while a patient with advanced metastatic breast cancer with a pathologic hip fracture will need intensive physical therapy to restore mobility. In addition, the patient with the hip fracture will also benefit from working with an occupational therapist to assist her in activities of daily living.",
"   </p>",
"   <p>",
"    All patients suffering from physical problems related to their cancer should ideally be evaluated for physical therapy. Unfortunately, physicians do not always recognize these physical problems until they become severe. An early consultation with a physiatrist (a physician with training in rehabilitation medicine) or a physical therapist can facilitate prompt intervention. There are established physical therapy interventions for dealing with various surgical treatments (post-thoracotomy,",
"    <span class=\"nowrap\">",
"     post-mastectomy/axillary",
"    </span>",
"    node dissection, amputation of limbs, radical neck dissection) that should be offered to patients undergoing such treatment. In centers with well developed cancer rehabilitation programs, patients are seen by the rehabilitation service preoperatively to prepare for the postoperative physical limitations and the specific interventions that will be employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with advanced cancer, physical therapy interventions are useful for maintaining mobility, improving stamina, and retaining control over activities of daily living (grooming, bathing, eating, toileting). Assistive devices can be used to improve physical function and QOL. Patients with neurologic deficits (brain metastases, spinal cord compression syndrome, peripheral neuropathies) often benefit from a physical rehabilitation intervention. Consultation with the hospital rehabilitation service prior to the patient's discharge from the hospital is invaluable and will maximize the chance of maintaining physical function and independence while at home.",
"   </p>",
"   <p>",
"    Physical rehabilitation is also important for patients living with cancer as a chronic illness. This was shown in a survey of 500 patients with colorectal, lung, and prostate cancer who on average had been living with the disease for over three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than 80 percent of this sample reported problems related to mobility (eg, difficulty walking, bending, lifting); for more than 50 percent of the sample, this problem was severe.",
"     </li>",
"     <li>",
"      Difficulty with activities of daily living were reported in 41 percent of patients with colorectal cancer, 69 percent with lung cancer, and 40 percent with prostate cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These physical problems occurred in this relatively functional sample whose average Karnofsky performance status scores were greater than 80 percent and over 40 percent of whom had no evidence of active disease (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 1",
"    </a>",
"    ). These data underscore the insensitivity of performance status scales in the assessment of functional status.",
"   </p>",
"   <p>",
"    Thus, physicians should obtain the advice and consultation of a physical therapist when difficulties with mobility or activities of daily living are suspected. Physical therapy assessment and intervention can be provided in the home if the patient is unable to visit an outpatient treatment center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Psychological and emotional problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not surprisingly, psychosocial problems (eg, anxiety, depression, worry,",
"    <span class=\"nowrap\">",
"     marital/partner",
"    </span>",
"    difficulties, sexual problems, interpersonal communication problems) occur with considerable frequency in patients with cancer. In one sample of patients with colorectal, lung, and prostate cancer living for greater than one year after their cancer diagnosis, a wide range of psychosocial problems were found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. These problems are less obvious than physical difficulties and are less likely to be acknowledged by the patient or recognized by the physician. During medical encounters, patients tend to focus on physical problems and may not want to burden the physician with their psychosocial concerns. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=see_link\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychosocial problems tend to fluctuate with the clinical course of the illness. Patients generally experience the most difficulty at the time of diagnosis, at recurrence, and with approaching death. Needs assessment should occur at these times as well as during more stable periods. Psychosocial distress is frequently aggravated by declining physical abilities.",
"   </p>",
"   <p>",
"    While most cancer patients cope successfully with their psychological difficulties, some will need and benefit from professional interventions. Psychological distress should be managed with appropriate psychotropic medications (antidepressants, anxiolytics) and referral to mental health professionals who have experience working with cancer patients or medically ill persons. Short-term professional counseling should be encouraged to address psychological problems before they become severe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=see_link\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients and physicians often have negative stereotypes about mental health interventions. A physician treating patients with cancer can benefit from developing a working relationship with a mental health professional. This can aid the physician in reassuring the patient that psychological assistance is an appropriate component of patient care, rather than an indication of mental illness.",
"   </p>",
"   <p>",
"    Patients often need substantial reassurance and education about the help they can receive. Support groups can be useful; the local units of the American Cancer Society are an excellent resource for obtaining information about ongoing groups in the community. Support groups vary considerably in their structure and format (time limited versus ongoing, disease specific versus heterogeneous, family versus patient only); they may have less associated stigma than individual counseling and are therefore a good first referral for some patients. The individual patient's needs and attitudes will have to be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Social issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cancer diagnosis adds considerable stress to otherwise supportive and stable social networks, and preexisting family and social problems can contribute to the problem. The physician should assess the characteristics and quality of the patient's support network at an early stage since members of the patient's family may play a crucial role in accomplishing the treatment goals. With the patient's permission, it is useful to share information with the family about the patient's disease and the treatment plan. Early identification of conflicts within the family or lack of social support is important as these issues can negatively impact upon the patient's care. As the patient's functional status declines, additional assistance might be required at home; knowledge of the patient's available support will determine when referral to a home care agency might be helpful.",
"   </p>",
"   <p>",
"    A wide variety of services are available to both patients and their families to assist them in dealing with the impact of cancer and treatment. Among the range of available services are: providing information about specific cancers and available treatment options, individual family",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    group psychological counseling, and the provision of concrete services such as transportation, assistance with meals, household chores, or nursing care. A social worker is usually the most appropriate person to evaluate the patient's supportive care needs and determine the most appropriate resources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vocational issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vocational problems are common among cancer survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. In a meta-analysis of 36 studies that compared cancer survivors to a control group, the cancer survivors were significantly more likely to be unemployed (34 versus 15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/19\">",
"     19",
"    </a>",
"    ]. When analyzed according to cancer diagnosis, unemployment was significantly higher among survivors of breast, gastrointestinal, and female reproductive organ cancer, but not blood cancers, prostate, or testicular cancer.",
"   </p>",
"   <p>",
"    The impact of the cancer diagnosis is frequently most serious for those in blue-collar occupations; more flexibility in work schedules is often available for individuals with higher levels of education and employment status.",
"   </p>",
"   <p>",
"    A major impact of job loss in cancer patients is that health insurance benefits in the United States are linked to employment. In addition, cancer is usually considered an excluded preexisting condition that can make it difficult to obtain new health insurance coverage when a new job is begun. Thus, to maintain health insurance, many patients are reluctant to change jobs and experience \"job-lock\". Although many patients successfully negotiate modifications in their work schedules to accommodate their cancer treatment schedules, some may feel threatened by the employer or by the fear of losing their jobs. The physician can play an important role as an advocate for the patient under these circumstances, educating the employer about the patient's abilities and prognosis. This can be done by early contact with the employer (with the express approval of the patient) describing the length of time the patient is likely to be disabled, or what accommodations could be made at work to allow the patient to continue working while receiving chemotherapy or radiation treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Federal Rehabilitation Act of 1973 provides some protection for patients, and a number of states have legislation that protects the employment rights of these individuals, especially in relation to hiring discrimination and reasonable accommodation during needed treatments. The Americans with Disabilities Act of 1991 now gives federal protection to cancer patients. According to these acts, employers must accommodate patients receiving cancer treatment by allowing change in schedule or workload. Vocational counseling should be considered for individuals who lose their jobs or who are unable to continue in their previous type of employment secondary to the effects of cancer or its treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Economic issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer treatment is expensive and has a major impact upon the patient's financial resources. The non-reimbursable out-of-pocket expenses associated with cancer treatment are considerable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In one study, 14 percent of 139 patients receiving outpatient chemotherapy were estimated to be spending more than 50 percent of their weekly incomes on nonmedical expenses associated with their illness and treatment, principally upon transportation and food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physicians should make a brief assessment of the patient's financial status and promptly refer the patient (when appropriate) for social service evaluation to determine if other sources of income are available. It may be appropriate for some patients with advanced cancer to file for Social",
"    <span class=\"nowrap\">",
"     Security/Disability",
"    </span>",
"    Benefits early since this may take many months to process. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32326?source=see_link\">",
"     \"Social Security Disability Insurance and workers' compensation in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sexuality issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual problems are relatively common in the general population of healthy individuals; the cancer experience can exacerbate old problems and create new ones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Fatigue from treatment (particularly radiation or chemotherapy) or from progressive cancer usually leads to a decline in sexual desire and a loss of interest in sexual activity. Body image may be distorted by weight loss, hair loss, and physical scars, leaving patients feeling less sexually attractive.",
"   </p>",
"   <p>",
"    Abdominal and pelvic surgical procedures (prostatectomy, abdominoperineal resection, retroperitoneal lymph node dissection) can damage enervation to pelvic organs causing impotence or physical problems that lead to sexual dysfunction. Other surgical procedures (vaginectomy, penectomy, radical vulvectomy) remove tissues that are important for sexual activity with resultant functional impairment. For women with breast cancer or endometrial cancer, premature menopause and estrogen deficiency may precipitate sexual dysfunction (eg, decreased libido, vaginal dryness) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In one quality of life analysis, sexual functioning was significantly worse for women who received chemotherapy for primary breast cancer than for those who did not, regardless of type of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is considerable interest in management of symptoms with nonestrogen alternatives; the safety of hormone therapy (HT) remains a controversial issue. Although other data are conflicting, a significant increase (relative risk 3.5) in the risk of breast cancer was observed In the HABITS trial, in which 434 women with a prior history of breast cancer were randomly assigned to receive two years of HT (estrogen alone or with progestin depending upon hysterectomy status) or best treatment without hormones (no placebo given) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/29\">",
"     29",
"    </a>",
"    ]. These data are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In spite of the importance of sexual functioning for the patient and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    partner, most physicians do not systematically address the impact of cancer and its treatment upon sexual function prior to therapy. Sexual problems are usually overlooked unless the patient is assertive or presents in a crisis situation. As a first step, physicians should review the patient's present level of sexual activity and discuss the potential impact of therapy. Awareness of these potential problems will help the patient adapt to posttreatment difficulties. Pretreatment discussion of sexuality and intimacy provides a baseline for comparison during subsequent reevaluation after treatment. Once specific problems are identified, physicians and other members of the health care team can successfully implement simple interventions that do not require extensive training in sex therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     REHABILITATION RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only a few centers in the United States with established programs in cancer rehabilitation. These are generally in large cancer hospitals or in centers where there has been an individual with an interest in this field as a specialty. More often, the rehabilitation problems of cancer patients are addressed through the hospital's general rehabilitation department. Thus, the physician plays an important role in identifying rehabilitation problems and coordinating the patients' care in the community.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     The physician",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cost-efficient and timely methods of evaluation and referral must be developed. The physician must also provide the emotional support necessary to ensure that the patient will follow through on the recommendations and referrals that are made. Effective combinations of skilled interviewing techniques (exploratory questions, such as \"Is this a problem for you?\" or \"Have you experienced the following?\") and the use of problem inventories (eg, the Cancer Rehabilitation Evaluation System, [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43719/abstract/14\">",
"     14",
"    </a>",
"    ]) can facilitate identification of critical problems.",
"   </p>",
"   <p>",
"    Recommendations and specific referrals can be made once the physician reviews the problem list for a specific patient. The physician can refer patients to a hospital rehabilitation department or to community agencies that deal with rehabilitation of the cancer patient. Home care agencies are another excellent source of rehabilitation services for homebound patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     The rehabilitation team",
"    </span>",
"    &nbsp;&mdash;&nbsp;Members of the rehabilitation team include the physiatrist, physical therapist, occupational therapist, enterostomal therapist, vocational counselor, social worker, psychologist, prosthetist-orthotist, rehabilitation nurse, speech pathologist, and the maxillofacial prosthetist. Other members might include a psychiatrist, dietitian, sex therapist, dentist, and a dental hygienist. Ideally, a team approach should be used to determine the rehabilitation plan for each patient; in some centers, site specific rehabilitation teams have been organized to most effectively plan and deliver rehabilitation services. Team members should evaluate the patient prior to primary treatment in preparation for the anticipated functional limitations and to provide education about the required posttreatment rehabilitation interventions. Posttreatment morbidity can be reduced by taking a preventive approach, rather than by waiting until problems become severe and more difficult to manage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Community resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community resources are invaluable to both staff and patients. Resources range from concrete services (durable medical equipment, assistive devices, nursing, and other home care services), to information and psychological support services. Support societies include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      American Cancer Society &mdash; (800) ACS-2345,",
"      <a class=\"external\" href=\"file://www.cancer.org/\">",
"       www.cancer.org",
"      </a>",
"     </li>",
"     <li>",
"      United Ostomy Association &mdash; (800) 826-0826,",
"      <a class=\"external\" href=\"file://www.uoa.org/\">",
"       www.uoa.org",
"      </a>",
"     </li>",
"     <li>",
"      Lost Chord Society (Contact International Association of Laryngectomees, (317) 570-4568)",
"     </li>",
"     <li>",
"      Reach-to-Recovery (Contact local office of American Cancer Society)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assistance with financial and insurance problems may be found at the Department of Social Services, Veterans Services, Social Security, Medicare, Medicaid, Office of Vocational Rehabilitation-State Education Department, and the Legal Aid Society. More specialized resources may be available depending on the community, with many cancer-specific services associated with hospitals and cancer centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practitioners who are likely to come in contact with cancer patients should attempt to make an assessment of the impact that the cancer and its treatment had on the patient's functional status. In the haste of the diagnosis and treatment planning, few clinicians pay attention to these issues, yet they may be the source of ongoing problems for the patient. Taking the time to do a systematic review of the physical, emotional, and social consequences of cancer can be an important first step in understanding the patient's response to the cancer experience.",
"   </p>",
"   <p>",
"    While most cancer survivors recover from treatment and find positive meaning in the cancer experience, many will have specific problems and functional complaints as a result of treatment. Providing these patients with a forum to discuss their concerns, as well as to receive appropriate rehabilitative and supportive interventions, can be critical for the maintenance of their health. Patients with advanced cancer often have many symptomatic problems (eg, pain, problems with mobility, depression) that are amenable to clinical intervention, even if the underlying disease cannot be reversed. Promoting effective symptom management is critical for maintaining patient functioning. Alliance with physical and rehabilitation services, along with hospice programs, are essential for physicians caring for patients with advanced cancer.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/1\">",
"      Cole P, Rodu B. Declining cancer mortality in the United States. Cancer 1996; 78:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/2\">",
"      Sweeney C, Schmitz KH, Lazovich D, et al. Functional limitations in elderly female cancer survivors. J Natl Cancer Inst 2006; 98:521.",
"     </a>",
"    </li>",
"    <li>",
"     Karnofsky DA, Burchenal JH. Evaluation of Chemotherapeutic Agents, Macleod CM (Ed), Columbia University Press, New York 1949.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/4\">",
"      Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984; 2:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/5\">",
"      Ganz PA. Quality of life and the patient with cancer. Individual and policy implications. Cancer 1994; 74:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/6\">",
"      Kroenke CH, Rosner B, Chen WY, et al. Functional impact of breast cancer by age at diagnosis. J Clin Oncol 2004; 22:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/7\">",
"      Liavaag AH, D&oslash;rum A, Foss&aring; SD, et al. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol 2007; 25:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/8\">",
"      Morey MC, Snyder DC, Sloane R, et al. Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. JAMA 2009; 301:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/9\">",
"      Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994; 3:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/10\">",
"      Lehmann JF, DeLisa JA, Warren CG, et al. Cancer rehabilitation: assessment of need, development, and evaluation of a model of care. Arch Phys Med Rehabil 1978; 59:410.",
"     </a>",
"    </li>",
"    <li>",
"     Dietz JH Jr. Rehabilitation Oncology, John Wiley &amp; Sons, Somerset, NJ 1981.",
"    </li>",
"    <li>",
"     Gunn AE. Cancer Rehabilitation, Raven Press, New York 1984.",
"    </li>",
"    <li>",
"     Ganz PA, Coscarelli A. Cancer Rehabilitation. In: Cancer Treatment, 4th, Haskell CM (Ed), WB Saunders, Philadelphia 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/14\">",
"      Ganz PA, Schag CA, Lee JJ, Sim MS. The CARES: a generic measure of health-related quality of life for patients with cancer. Qual Life Res 1992; 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/15\">",
"      Schag CA, Ganz PA, Wing DS, et al. Quality of life in adult survivors of lung, colon and prostate cancer. Qual Life Res 1994; 3:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/16\">",
"      Short PF, Vasey JJ, Tunceli K. Employment pathways in a large cohort of adult cancer survivors. Cancer 2005; 103:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/17\">",
"      Buckwalter AE, Karnell LH, Smith RB, et al. Patient-reported factors associated with discontinuing employment following head and neck cancer treatment. Arch Otolaryngol Head Neck Surg 2007; 133:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/18\">",
"      Lauzier S, Maunsell E, Drolet M, et al. Wage losses in the year after breast cancer: extent and determinants among Canadian women. J Natl Cancer Inst 2008; 100:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/19\">",
"      de Boer AG, Taskila T, Ojaj&auml;rvi A, et al. Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA 2009; 301:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/20\">",
"      Earle CC, Chretien Y, Morris C, et al. Employment among survivors of lung cancer and colorectal cancer. J Clin Oncol 2010; 28:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/21\">",
"      The physician as the patient's advocate. American Society of Clinical Oncology Committee of Patient Advocacy. J Clin Oncol 1993; 11:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/22\">",
"      Lansky SB, Cairns NU, Clark GM, et al. Childhood cancer: nonmedical costs of the illness. Cancer 1979; 43:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/23\">",
"      Houts PS, Lipton A, Harvey HA, et al. Nonmedical costs to patients and their families associated with outpatient chemotherapy. Cancer 1984; 53:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/24\">",
"      Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/25\">",
"      Andersen BL. Sexual functioning morbidity among cancer survivors. Current status and future research directions. Cancer 1985; 55:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/26\">",
"      Schover LR. Sexuality and fertility in urologic cancer patients. Cancer 1987; 60:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/27\">",
"      Schover LR. The impact of breast cancer on sexuality, body image, and intimate relationships. CA Cancer J Clin 1991; 41:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/28\">",
"      Ganz PA, Kwan L, Stanton AL, et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 2004; 96:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/29\">",
"      Holmberg L, Anderson H, HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet 2004; 363:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/30\">",
"      Schover LR, Fife M. Sexual counseling of patients undergoing radical surgery for pelvic or genital cancer. J Psychosoc Onc 1985; 3:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43719/abstract/31\">",
"      Andersen BL. How cancer affects sexual functioning. Oncology (Williston Park) 1990; 4:81.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2818 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-41.196.66.12-1617F87D8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43719=[""].join("\n");
var outline_f42_44_43719=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      QUALITY OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXTENT OF DISEASE AND IMPACT UPON FUNCTIONAL STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Localized disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Advanced metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FUNCTIONAL ASSESSMENT AND INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Psychological and emotional problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Social issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vocational issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Economic issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sexuality issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      REHABILITATION RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      The physician",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      The rehabilitation team",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Community resources",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2818\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2818|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=related_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4120?source=related_link\">",
"      Evaluation of health-related quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=related_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29769?source=related_link\">",
"      Psychosocial issues at the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32326?source=related_link\">",
"      Social Security Disability Insurance and workers' compensation in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3690?source=related_link\">",
"      Various rehabilitation issues in patients treated for cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_44_43720="Use of neuromuscular blocking medications in critically ill patients";
var content_f42_44_43720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of neuromuscular blocking medications in critically ill patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/44/43720/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43720/contributors\">",
"     Karen J Tietze, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/44/43720/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43720/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/44/43720/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43720/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/44/43720/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromuscular blocking agents (NMBAs) paralyze skeletal muscles by blocking the transmission of nerve impulses at the myoneural junction. NMBAs do not have sedative, amnestic, or analgesic properties and do not prevent muscles from contracting if directly stimulated. These drugs may be useful in the intensive care unit (ICU) to improve patient-ventilator synchrony, enhance gas exchange, and diminish the risk of barotrauma. They can also be employed to reduce muscle oxygen consumption, facilitate short procedures, prevent unwanted movements in patients with increased intracranial pressure, and facilitate treatment of acute neurologic conditions such as tetanus (",
"    <a class=\"graphic graphic_table graphicRef75880 \" href=\"mobipreview.htm?12/37/12891\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of action, clinical use, and potential adverse effects of NMBAs will be discussed here. Adequate sedation and analgesia, which are essential prior to initiating therapy with NMBAs, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROMUSCULAR TRANSMISSION AND BLOCKADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neuromuscular junction consists of the nerve terminal, the synaptic cleft, and the motor endplate. Acetylcholine (ACh) is released into the synaptic cleft when nerve impulses reach the nerve terminal and diffuses across the synaptic cleft to the motor endplate. Attachment of ACh to the nicotinic (not muscarinic) receptors on skeletal muscle causes a conformational change in the receptor that increases myocyte cell membrane permeability to sodium, potassium, chloride, and calcium ions and releases calcium from the sarcoplasmic reticulum, leading to transmission of an action potential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Depolarization terminates when ACh unbinds from the receptor. ACh either diffuses back into the nerve terminal or is broken down by acetylcholinesterase.",
"   </p>",
"   <p>",
"    NMBAs are structurally related to ACh and act by interfering with the binding of ACh to the motor endplate. They are divided into depolarizing or nondepolarizing agents based upon their mechanism of action [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/2,6-8\">",
"     2,6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depolarizing NMBAs bind to cholinergic receptors on the motor endplate, causing initial depolarization on the endplate membrane followed by blockade of neuromuscular transmission. Because calcium is not resequestered in the sarcoplasmic reticulum, muscles are refractory to repeat depolarization until depolarizing NMBAs diffuse from the receptor to the circulation and are hydrolyzed by plasma pseudocholinesterase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nondepolarizing NMBAs competitively inhibit the ACh receptor on the motor endplate. Drug binding to the ACh receptor either prevents the conformational change in the receptor or physically obstructs the ion channels so that an endplate potential is not generated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/5,9\">",
"       5,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ideal NMBA for use in intensive care produces an early, titratable paralysis, has a moderately rapid offset of action (less than 15 minutes) to allow for repeated neurologic assessment, no adverse hemodynamic or other adverse physiologic effects, elimination independent of hepatic or renal function, inactive metabolites, no propensity to accumulate, stability over 24 hours to allow for continuous infusion, and modest cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEPOLARIZING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    is the only depolarizing agent available in the United States and is utilized almost exclusively to facilitate intubation or treat laryngospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Although succinylcholine has a rapid onset (less than one minute) and brief duration of action (seven to eight minutes), its use is limited because its actions cannot be reversed by the administration of other medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/10\">",
"     10",
"    </a>",
"    ]. Approximately 1 in 3200 patients is homozygous for a defective pseudocholinesterase and may remain paralyzed for three to eight hours after a single dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant adverse effects include hypertension, tachycardia, bradycardia, ventricular arrhythmias, hyperkalemia, and, less commonly, increased intracranial pressure or malignant hyperthermia. Malignant hyperthermia is a rare complication, occurring in patients with mutations in the ryanodine receptor, a homotetrameric calcium channel found in the sarcoplasmic reticulum of skeletal muscle. The onset of hyperthermia is usually within the first hour after administration but may be delayed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum potassium concentrations increase by 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    due to an efflux of potassium from muscle cells; as a result, the drug must be used cautiously in patients with preexisting hyperkalemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/12\">",
"     12",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    is contraindicated after the acute phase of major thermal injury. Following thermal injury, extrajunctional acetylcholine receptor expression increases in proportion to the magnitude of the burn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/13\">",
"     13",
"    </a>",
"    ]. This results in an exaggerated release of potassium after administration of succinylcholine; profound hyperkalemia associated with cardiac arrest may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/13\">",
"     13",
"    </a>",
"    ]. Although the precise onset and duration of risk are not well described, the risk increases over the first few days following the injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NONDEPOLARIZING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of nondepolarizing neuromuscular blocking agents are available. The onset of action, half-life, and route of elimination are variable and drug-specific (",
"    <a class=\"graphic graphic_table graphicRef61184 \" href=\"mobipreview.htm?13/40/13965\">",
"     table 2",
"    </a>",
"    ). The onset of action of these drugs ranges from 1 to 5 minutes, but all are slower than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    . The half-life ranges from 5 minutes for mivacurium to 180 minutes for tubocurarine. Older agents such as tubocurarine are more commonly associated with cardiovascular side effects and hypotension due to histamine release than are newer nondepolarizing NMBAs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"     cisatracurium",
"    </a>",
"    , pipecuronium,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef75857 \" href=\"mobipreview.htm?43/6/44139\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/6-8,10\">",
"     6-8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although nondepolarizing NMBAs are structurally divided into the aminosteroid compounds (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"     pancuronium",
"    </a>",
"    , pipecuronium,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    ) and the benzylisoquinolines (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"     cisatracurium",
"    </a>",
"    , mivacurium, tubocurarine), this classification has little clinical significance.",
"   </p>",
"   <p>",
"    The major nondepolarizing NMBAs that are currently available are discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Atracurium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     Atracurium",
"    </a>",
"    , a mixture of 10 stereoisomers, is a benzylisoquinoline with an intermediate duration of action. Atracurium is degraded by both pH- and temperature-dependent Hofmann elimination (autolysis) and by ester hydrolysis; it therefore does not require a dosage adjustment in patients with renal or hepatic failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. However, acidosis and severe hypothermia decrease the rate of drug metabolism and should prompt dose reduction. Specific dosing recommendations are not available, and the dose should be titrated according to neurologic response.",
"   </p>",
"   <p>",
"    The major side effect associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    is hypotension caused by histamine release and sympathetic ganglionic blockade. In addition, laudanosine, an inactive Hofmann elimination metabolite, causes seizures in dogs at very high doses, but is unlikely to be of clinical significance in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. As an example, after an infusion of atracurium at a rate of 0.3 to 0.96",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour for 38 days in a 23 year-old woman with multiple medical problems, no EEG abnormalities were apparent, and the plasma laudanosine level was only 37 percent of concentrations associated with epileptic EEG spiking in dogs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cisatracurium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"     Cisatracurium",
"    </a>",
"    is an isomer of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    with three times its potency. Like atracurium, cisatracurium is degraded by pH- and temperature-dependent Hofmann elimination to laudanosine, and acidosis and severe hypothermia delay its metabolism. However, the greater potency of cisatracurium allows the administration of smaller doses, which results in less laudanosine production, less histamine release, and fewer adverse cardiovascular side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/18\">",
"     18",
"    </a>",
"    ]. Its usefulness in the intensive care unit (ICU) is limited somewhat by its relatively slow onset of action (3 to 6 minutes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mivacurium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mivacurium is a short-acting benzylisoquinoline with an onset of action comparable to that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    but with one-third its duration of action because of rapid hydrolysis by plasma pseudocholinesterase. However, patients with renal or hepatic insufficiency may have depressed pseudocholinesterase activity leading to delayed elimination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mivacurium is associated with few adverse cardiovascular side effects following small (0.15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    doses, but hypotension, caused by histamine release, may occur following larger bolus injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/21\">",
"     21",
"    </a>",
"    ]. Little information is available about the use of mivacurium in the ICU, but it is unlikely to have any advantages over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    . Mivacurium is no longer available in the United States or Canada, but it is available elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pancuronium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"     Pancuronium",
"    </a>",
"    is a long-acting aminosteroid that is metabolized to the active compound 3-hydroxypancuronium in the liver and then eliminated equally in the urine and bile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/5,22\">",
"     5,22",
"    </a>",
"    ]. Adverse cardiovascular effects associated with pancuronium include tachycardia, hypertension, and increased cardiac output due to vagal blockade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pipecuronium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pipecuronium is an aminosteroid with a longer duration of action than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"     pancuronium",
"    </a>",
"    , and is primarily eliminated unchanged by the kidney. It does not cause histamine release and is associated with minimal adverse cardiovascular side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/23\">",
"     23",
"    </a>",
"    ]. Pipecuronium is no longer available in the United States or Canada, but it may be available elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rocuronium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     Rocuronium",
"    </a>",
"    is similar to but less potent than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    . It has a rapid onset and short-to-intermediate duration of action [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/8\">",
"     8",
"    </a>",
"    ]. The drug is eliminated primarily by the liver and is associated with few adverse cardiovascular side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tubocurarine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubocurarine is a long-acting benzylisoquinoline that is eliminated by both renal excretion and hepatic metabolism. It causes dose- and rate-dependent histamine release and is associated with profound drops in blood pressure following rapid infusions of large doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/7,24\">",
"     7,24",
"    </a>",
"    ]. Histamine-associated hypotension can be minimized by slow injection, incremental dose increases, and coadministration of histamine-1 and histamine-2 receptor blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Tubocurarine is no longer available in the United States or Canada, but it may be available elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vecuronium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     Vecuronium",
"    </a>",
"    is an aminosteroid compound with an intermediate duration of action. It is hepatically metabolized to three active metabolites, all of which are eliminated by the kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/5,26,27\">",
"     5,26,27",
"    </a>",
"    ]. Minimal adverse cardiovascular side effects have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICU staff must be trained in the administration and monitoring of NMBAs. Appropriate airway control, mechanical ventilatory support, and adequate sedation and analgesia are essential prior to the initiation of NMBA therapy. Appropriate equipment for monitoring cardiorespiratory function and the capability of assessing the degree of paralysis must be available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/1,3,28\">",
"     1,3,28",
"    </a>",
"    ]. The Society of Critical Care Medicine (SCCM) has developed clinical practice guidelines to help clinicians manage critically ill adults requiring sustained neuromuscular blockade (",
"    <a class=\"graphic graphic_algorithm graphicRef59945 \" href=\"mobipreview.htm?29/28/30158\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Selecting an agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a national survey of SCCM attending physicians,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"     pancuronium",
"    </a>",
"    were the most commonly prescribed agents for use &gt; 24 hours; vecuronium was the most commonly prescribed agent overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/30\">",
"     30",
"    </a>",
"    ]. In contrast, a national survey of Canadian intensivists found that the most commonly used NMBA agents were pancuronium,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    , and vecuronium; all three agents were most commonly administered by intermittent intravenous bolus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A patient's renal and hepatic function, cardiovascular status, and age must be considered when selecting an NMBA agent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal hepatic and renal function &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"       Pancuronium",
"      </a>",
"      is the drug of choice for patients with normal hepatic and renal function who require paralysis for more than one hour [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepatic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal insufficiency &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"       Atracurium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"       cisatracurium",
"      </a>",
"      is preferred in patients with hepatic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal insufficiency. Both drugs undergo spontaneous degradation at physiologic pH and temperature (via Hofmann elimination) and therefore are less dependent on renal or hepatic function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/1,10\">",
"       1,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiovascular disease &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"       Vecuronium",
"      </a>",
"      has the least adverse cardiovascular effects and is the drug of choice for patients with cardiovascular disease or hemodynamic instability. Pipecuronium and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"       rocuronium",
"      </a>",
"      are acceptable alternatives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elderly patients &mdash; Drug selection is dictated by age-associated decreases in renal and hepatic function. Decreased cardiac output prolongs drug delivery and slows the onset of action of NMBAs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Obesity may also affect dosing requirements, but there is a paucity of evidence to guide clinicians. This is especially true for critically ill patients in the ICU, since most data were derived from patients who received a NMBA during surgery. Existing evidence includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity does not appear to alter the pharmacokinetics or pharmacodynamics of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"       rocuronium",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. This suggests that these agents can be dosed according to actual body weight rather than predicted body weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"       atracurium",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"       vecuronium",
"      </a>",
"      have a prolonged duration of action if they are dosed according to actual body weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/35-37\">",
"       35-37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the variability among NMBAs and the overall paucity of dosing information from critically ill obese patients, we suggest starting with low doses and titrating the dose using train-of-four or tetanic stimulation as described below (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Administration'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Finally, the degree of NMBA activity can be affected by a number of drugs or medical conditions, which may make dosing adjustments necessary (",
"    <a class=\"graphic graphic_table graphicRef68504 \" href=\"mobipreview.htm?38/15/39165\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57177 \" href=\"mobipreview.htm?26/60/27596\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/6,8,38\">",
"     6,8,38",
"    </a>",
"    ]. Drugs or conditions that inhibit presynaptic ACh release or depress postjunctional sensitivity enhance the degree and duration of neuromuscular blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Conversely,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    significantly increase the requirement for nondepolarizing NMBAs by an unknown mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;NMBAs can be administered by continuous infusion or intermittent intravenous injection, but should not be prescribed intramuscularly due to erratic absorption (",
"    <a class=\"graphic graphic_table graphicRef79930 \" href=\"mobipreview.htm?37/23/38268\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/4,8,38\">",
"     4,8,38",
"    </a>",
"    ]. Generally speaking, long-acting NMBAs are best given by intermittent injection, while shorter-acting NMBAs are best given as a continuous intravenous infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/38\">",
"     38",
"    </a>",
"    ]. Dose and frequency should be titrated to the desired clinical effect.",
"   </p>",
"   <p>",
"    Complete (100 percent) neuromuscular blockade is not necessary for all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/8\">",
"     8",
"    </a>",
"    ]. As an example, patients with respiratory failure require only 50 to 70 percent neuromuscular blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/39\">",
"     39",
"    </a>",
"    ]. The intended level of paralysis depends on the clinical situation. When NMBAs are administered, it is more appropriate to think in terms of controlling motor activity rather than completely paralyzing the patient. Some patients can be maintained light enough (eg, 50 percent blockade) that the patient maintains some modest muscle tone and even motor activity, whereas other patients require nearly complete paralysis and motor (eg, 80 to 90 percent) blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensitivity to NMBAs varies and the metabolism of NMBAs cannot always be predicted in the critically ill. Monitoring the degree of neuromuscular blockade with peripheral nerve stimulation (PNS) using train-of-four or tetanic stimulation is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/4\">",
"     4",
"    </a>",
"    ]. Train-of-four is the more commonly used method and involves electrical stimulation of a peripheral motor nerve with four sequential stimuli over a two second period and observation of the responses of a muscle innervated by the stimulated nerve. Patients treated with NMBAs have progressive reduction in the magnitude of response to the four stimuli. Although the train-of-four goal depends on the intended degree of paralysis, the NMBA dose is generally titrated such that only two visible muscle twitches occur in response to each train-of-four. Because electrical stimulation can directly trigger myocyte contraction even in the presence of profound ACh receptor blockade, nerve stimulation should be performed several centimeters from the indicator muscle. The ulnar nerve is commonly stimulated at the wrist, and response of the adductor pollicis is observed (",
"    <a class=\"graphic graphic_figure graphicRef64177 \" href=\"mobipreview.htm?8/41/8863\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The depth of blockade should be assessed with PNS every 2 to 3 hours until the NMBA dose is stable, then every 8 to 12 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/40\">",
"     40",
"    </a>",
"    ]. If no or one twitch is present, the dose should be reduced by 10 percent; if three or four twitches are present, the dose should be increased by 10 percent.",
"   </p>",
"   <p>",
"    The use of PNS monitoring in this setting is widely accepted, but data supporting its use are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Few prospective, controlled, randomized studies assessing the utility of PNS have been published, and conflicting results have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial randomly assigned 77 patients in a medical ICU to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"       vecuronium",
"      </a>",
"      guided either by clinical assessment or PNS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/43\">",
"       43",
"      </a>",
"      ]. The PNS group used significantly less drug and recovered neuromuscular function and spontaneous ventilation approximately 55 percent faster than the control group; patients with renal insufficiency appeared to derive the most benefit for PNS-guided therapy.",
"     </li>",
"     <li>",
"      In a trial of 36 patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"       atracurium",
"      </a>",
"      , the impact of monitoring the train-of-four was compared to clinical assessment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/44\">",
"       44",
"      </a>",
"      ]. There was no difference in the total amount of drug administered or the time to clinical recovery.",
"     </li>",
"     <li>",
"      A trial randomly assigned 30 patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"       cisatracurium",
"      </a>",
"      to be monitored using the train-of-four or clinical assessment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/45\">",
"       45",
"      </a>",
"      ]. There was no difference in the total amount of drug administered or the time to clinical recovery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The different outcomes of the three trials may be due, in part, to differences in the drugs studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/46\">",
"     46",
"    </a>",
"    ]. Train-of-four monitoring may eventually prove more useful for monitoring patients who are receiving renally or hepatically eliminated drugs, than for monitoring patients who are receiving drugs that undergo Hofmann elimination. There is insufficient evidence to warrant a change of current clinical practice.",
"   </p>",
"   <p>",
"    Daily discontinuation of NMBA for a few hours is recommended to potentially decrease the incidence of prolonged recovery secondary to drug and metabolite accumulation and to potentially decrease the incidence of the postparalytic paralytic quadriparesis, also known as critical illness myopathy (CIM) and acute quadriplegic myopathy syndrome (AQMS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The strongest risk factor for CIM is the use of intravenous glucocorticoids in critically ill patients, although use of NMBAs is another potential risk factor for CIM. The pathogenesis of CIM is probably related to steroid-induced denervation. Major histopathologic findings include myopathy and myosin loss. Serum CK elevation is seen in approximately one-half of patients. CIM is usually reversible over weeks to months but it leads to prolonged ICU stays and increased length of hospital stay overall. Treatment is directed toward discontinuation or reduction of glucocorticoids as soon as possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43976?source=see_link&amp;anchor=H6#H6\">",
"     \"Neuromuscular weakness related to critical illness\", section on 'Critical illness myopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients receiving NMBAs require meticulous care because the potential for complications is great [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/47\">",
"     47",
"    </a>",
"    ]. All paralyzed patients require the following precautions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ensure adequate sedation and analgesia prior to paralyzing the patient",
"     </li>",
"     <li>",
"      Supervise patients closely because interruption of the ventilator circuit can be fatal",
"     </li>",
"     <li>",
"      Since all NMBAs inhibit the cough reflex, suctioning of the endotracheal tube to remove accumulated secretions should be performed as needed based on the amount of secretions present",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"       Artificial tears",
"      </a>",
"      should be instilled every two to four hours and eyelids should be taped shut to prevent corneal drying and ulceration",
"     </li>",
"     <li>",
"      Patients require frequent turning and dry, wrinkle-free bedding in order to prevent skin breakdown and decubitus ulcers",
"     </li>",
"     <li>",
"      Prophylactic deep venous thrombosis therapy with either low dose subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or mechanical compression devices is required",
"     </li>",
"     <li>",
"      The head of the bed should be elevated to reduce the risk of aspiration, particularly during enteral feeding",
"     </li>",
"     <li>",
"      Pupillary reflexes should be closely monitored to assess neurologic status (but are unreliable if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"       pancuronium",
"      </a>",
"      is used because of its antimuscarinic effects)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tapering the dose in not necessary when neuromuscular blockade is discontinued. Sedation and analgesia adequate for patient comfort must be maintained as the NMBA is discontinued.",
"   </p>",
"   <p>",
"    The action of nondepolarizing NMBAs can be reversed by administration of an anticholinesterase drug such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    , 0.035 to 0.07",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/7\">",
"     7",
"    </a>",
"    ]. Acetylcholine-related side effects such as salivation, bradycardia, and cardiac standstill are prevented by coadministration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    (7",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28260184\">",
"    <span class=\"h2\">",
"     Role in ARDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of NMBAs in the management of patients with acute respiratory distress syndrome (ARDS) has been specifically studied. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9065?source=see_link&amp;anchor=H4#H4\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\", section on 'Paralysis'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis to NMBAs is extremely rare, and the drugs have no known effects outside of muscles and autonomic ganglia. Nevertheless, NMBAs have the potential for severe adverse effects such as hypotension and prolonged paralysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiovascular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse cardiovascular side effects associated with NMBAs are related to stimulation or blockade of the autonomic nervous system and vasodilatation due to histamine release. The drugs with the lowest risk of cardiovascular complications are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"     cisatracurium",
"    </a>",
"    , pipecuronium,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef75857 \" href=\"mobipreview.htm?43/6/44139\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prolonged paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged paralysis following drug discontinuation results from accumulation of drug or active metabolites, or an acute myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/48\">",
"     48",
"    </a>",
"    ]. It is a rare disorder related to prolonged use (days) of paralytic agents, often in the setting of renal or hepatic insufficiency. NMBAs that are dependent upon renal clearance &mdash;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"     pancuronium",
"    </a>",
"    , pipecuronium, and tubocurarine &mdash; accumulate in patients with renal insufficiency if they are not properly dose-adjusted to PNS response. Affected patients have flaccid areflexic tetraplegia. This complication is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43976?source=see_link&amp;anchor=H21#H21\">",
"     \"Neuromuscular weakness related to critical illness\", section on 'Prolonged neuromuscular junction blockade'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medication errors continue to occur. Examples include administration of the wrong medication due to look-alike packaging or sound-alike names, as well as dosing errors due to use of the wrong concentration of a drug. Given the potential for death if a NMBA is administered to a patient without appropriate ventilatory support, the United States Pharmacopoeia Safe Medication Use Expert Committee has issued recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43720/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NMBA packaging and labeling should clearly differentiated NMBAs from other medications",
"     </li>",
"     <li>",
"      Special safeguards for storage, labeling, and the use of drugs should be instituted",
"     </li>",
"     <li>",
"      Health care professionals should be especially vigilant with these drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuromuscular blocking agents (NMBAs) paralyze skeletal muscles by blocking the transmission of nerve impulses at the myoneural junction. NMBAs do not have sedative, amnestic, or analgesic properties. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adequate sedation and analgesia are essential prior to initiating therapy with NMBAs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depolarizing NMBAs cause initial depolarization of the muscle's membrane, which renders the muscle refractory to repeat depolarization. In contrast, nondepolarizing NMBAs competitively inhibit cholinergic receptors on the muscle's membrane. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Neuromuscular transmission and blockade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       Succinylcholine",
"      </a>",
"      is the most common depolarizing NMBA. Its onset of action is rapid (less than one minute) and its duration of effect is brief (seven to eight minutes). Succinylcholine is generally used to facilitate intubation or treat laryngospasm. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Depolarizing agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many nondepolarizing NMBAs, each with a different time to onset and duration of effect. In general, the nondepolarizing NMBAs have an onset of action of one to five minutes and a half-life ranging from 5 to 300 minutes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nondepolarizing agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who require paralysis for more than one hour:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"       Pancuronium",
"      </a>",
"      is appropriate for patients with normal hepatic and renal function.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"       Cisatracurium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"       atracurium",
"      </a>",
"      is appropriate for patients with hepatic or renal insufficiency. For patients who are hemodynamically unstable or have cardiovascular disease,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"       vecuronium",
"      </a>",
"      , pipecuronium, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"       rocuronium",
"      </a>",
"      may be used. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NMBAs are preferably administered by intermittent intravenous injection. Continuous intravenous infusion is an acceptable alternative. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The depth of neuromuscular blockade should be monitored by peripheral nerve stimulation (PNS). Assess the PNS every two to three hours until the NMBA dose is stable, then every eight to 12 hours. Although the depth of paralysis should be tailored to the clinical situation, in most settings two twitches is an appropriate goal. Reduce the dose approximately 10 percent if zero or one twitch is present. Increase the dose by 10 percent if three or four twitches are present. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When clinically feasible, stop the NMBA daily to reassess the need for continued paralysis. This may reduce the incidence of prolonged recovery secondary to drug and metabolite accumulation and may reduce the risk of post paralytic quadriparesis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NMBAs do not need to be tapered (ie, they can be abruptly discontinued). Nondepolarizing NMBAs can be reversed by an anticholinesterase agent (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/41/10901?source=see_link\">",
"       neostigmine",
"      </a>",
"      0.035 to 0.07",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Discontinuation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Numerous adverse effects have been attributed to NMBAs, most commonly cardiovascular effects and prolonged paralysis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/1\">",
"      Elliot JM, Bion JF. The use of neuromuscular blocking drugs in intensive care practice. Acta Anaesthesiol Scand Suppl 1995; 106:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/2\">",
"      Wheeler AP. Sedation, analgesia, and paralysis in the intensive care unit. Chest 1993; 104:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/3\">",
"      Berger I, Waldhorn RE. Analgesia, sedation and paralysis in the intensive care unit. Am Fam Physician 1995; 51:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/4\">",
"      Isenstein DA, Venner DS, Duggan J. Neuromuscular blockade in the intensive care unit. Chest 1992; 102:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/5\">",
"      Hanson CW 3rd. Pharmacology of neuromuscular blocking agents in the intensive care unit. Crit Care Clin 1994; 10:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/6\">",
"      Topulos GP. Neuromuscular blockade in adult intensive care. New Horiz 1993; 1:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/7\">",
"      Durbin CG Jr. Neuromuscular blocking agents and sedative drugs. Clinical uses and toxic effects in the critical care unit. Crit Care Clin 1991; 7:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/8\">",
"      Prielipp RC, Coursin DB. Applied pharmacology of common neuromuscular blocking agents in critical care. New Horiz 1994; 2:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/9\">",
"      Martyn JA, Fagerlund MJ, Eriksson LI. Basic principles of neuromuscular transmission. Anaesthesia 2009; 64 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/10\">",
"      Hunter JM. New neuromuscular blocking drugs. N Engl J Med 1995; 332:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/11\">",
"      Whittaker M. Plasma cholinesterase variants and the anaesthetist. Anaesthesia 1980; 35:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/12\">",
"      Yentis SM. Suxamethonium and hyperkalaemia. Anaesth Intensive Care 1990; 18:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/13\">",
"      MacLennan N, Heimbach DM, Cullen BF. Anesthesia for major thermal injury. Anesthesiology 1998; 89:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/14\">",
"      Gronert GA. Succinylcholine hyperkalemia after burns. Anesthesiology 1999; 91:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/15\">",
"      Fisher DM, Canfell PC, Fahey MR, et al. Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. Anesthesiology 1986; 65:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/16\">",
"      Chapple DJ, Miller AA, Ward JB, Wheatley PL. Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anaesthetized dogs. Br J Anaesth 1987; 59:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/17\">",
"      Grigore AM, Brusco L Jr, Kuroda M, Koorn R. Laudanosine and atracurium concentrations in a patient receiving long-term atracurium infusion. Crit Care Med 1998; 26:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/18\">",
"      Caldwell, JE, Miller, RD. Muscle relaxants in the intensive care unit. Hosp Physician 1996; 9:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/19\">",
"      Devlin JC, Head-Rapson AG, Parker CJ, Hunter JM. Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis. Br J Anaesth 1993; 71:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/20\">",
"      Phillips BJ, Hunter JM. Use of mivacurium chloride by constant infusion in the anephric patient. Br J Anaesth 1992; 68:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/21\">",
"      Stoops CM, Curtis CA, Kovach DA, et al. Hemodynamic effects of mivacurium chloride administered to patients during oxygen-sufentanil anesthesia for coronary artery bypass grafting or valve replacement. Anesth Analg 1989; 68:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/22\">",
"      Vandenbrom RH, Wierda JM. Pancuronium bromide in the intensive care unit: a case of overdose. Anesthesiology 1988; 69:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/23\">",
"      Khuenl-Brady KS, Reitst&auml;tter B, Schlager A, et al. Long-term administration of pancuronium and pipecuronium in the intensive care unit. Anesth Analg 1994; 78:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/24\">",
"      Basta SJ, Savarese JJ, Ali HH, et al. Histamine-releasing potencies of atracurium, dimethyl tubocurarine and tubocurarine. Br J Anaesth 1983; 55 Suppl 1:105S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/25\">",
"      Scott RP, Savarese JJ, Basta SJ, et al. Atracurium: clinical strategies for preventing histamine release and attenuating the haemodynamic response. Br J Anaesth 1985; 57:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/26\">",
"      Segredo V, Caldwell JE, Matthay MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992; 327:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/27\">",
"      Partridge BL, Abrams JH, Bazemore C, Rubin R. Prolonged neuromuscular blockade after long-term infusion of vecuronium bromide in the intensive care unit. Crit Care Med 1990; 18:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/28\">",
"      Farquhar-Mayes A. Ethical considerations in the use of neuromuscular blockades. Crit Care Nurs Q 1995; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/29\">",
"      Murray MJ, Cowen J, DeBlock H, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 2002; 30:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/30\">",
"      Rhoney DH, Murry KR. National survey of the use of sedating drugs, neuromuscular blocking agents, and reversal agents in the intensive care unit. J Intensive Care Med 2003; 18:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/31\">",
"      Mehta S, Burry L, Fischer S, et al. Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. Crit Care Med 2006; 34:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/32\">",
"      Rose JB, Theroux MC, Katz MS. The potency of succinylcholine in obese adolescents. Anesth Analg 2000; 90:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/33\">",
"      P&uuml;hringer FK, Keller C, Kleinsasser A, et al. Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol 1999; 16:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/34\">",
"      P&uuml;hringer FK, Khuenl-Brady KS, Mitterschiffthaler G. Rocuronium bromide: time-course of action in underweight, normal weight, overweight and obese patients. Eur J Anaesthesiol Suppl 1995; 11:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/35\">",
"      Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, et al. Anthropometric variables as predictors for duration of action of atracurium-induced neuromuscular block. Anesth Analg 1996; 83:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/36\">",
"      Schwartz AE, Matteo RS, Ornstein E, et al. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesth Analg 1992; 74:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/37\">",
"      Suzuki T, Masaki G, Ogawa S. Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. Br J Anaesth 2006; 97:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/38\">",
"      Ellender, PJ. The use of neuromuscular blocking agents in ICU patients. Hosp Pharm 1994; 29:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/39\">",
"      Dulin PG, Williams CJ. Monitoring and preventive care of the paralyzed patient in respiratory failure. Crit Care Clin 1994; 10:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/40\">",
"      Rudis MI, Guslits BG, Zarowitz BJ. Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit. Ann Pharmacother 1996; 30:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/41\">",
"      Kleinpell R, Bedrosian C, McCormick L, et al. Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU. Am J Crit Care 1996; 5:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/42\">",
"      Shapiro BA, Warren J, Egol AB, et al. Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: an executive summary. Society of Critical Care Medicine. Crit Care Med 1995; 23:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/43\">",
"      Rudis MI, Sikora CA, Angus E, et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 1997; 25:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/44\">",
"      Strange C, Vaughan L, Franklin C, Johnson J. Comparison of train-of-four and best clinical assessment during continuous paralysis. Am J Respir Crit Care Med 1997; 156:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/45\">",
"      Baumann MH, McAlpin BW, Brown K, et al. A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis. Chest 2004; 126:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/46\">",
"      Sessler CN. Train-of-four to monitor neuromuscular blockade? Chest 2004; 126:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/47\">",
"      Shalansky, KF, Shalansky, SJ. Selection and monitoring of muscle relaxants during mechanical ventilation. Can J Hosp Pharm 1992; 45:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/48\">",
"      Raps EC, Bird SJ, Hansen-Flaschen J. Prolonged muscle weakness after neuromuscular blockade in the intensive care unit. Crit Care Clin 1994; 10:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43720/abstract/49\">",
"      Phillips MS, Williams RL. Improving the safety of neuromuscular blocking agents: a statement from the USP Safe Medication Use Expert Committee. Am J Health Syst Pharm 2006; 63:139.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1590 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43720=[""].join("\n");
var outline_f42_44_43720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROMUSCULAR TRANSMISSION AND BLOCKADE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEPOLARIZING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NONDEPOLARIZING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Atracurium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cisatracurium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mivacurium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pancuronium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pipecuronium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rocuronium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tubocurarine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vecuronium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Selecting an agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28260184\">",
"      Role in ARDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prolonged paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1590\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1590|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?29/28/30158\" title=\"algorithm 1\">",
"      Algorithm for NMBAs in ICU",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1590|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/41/8863\" title=\"figure 1\">",
"      Peripheral nerve stimulator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1590|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/37/12891\" title=\"table 1\">",
"      Indications for NMB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/40/13965\" title=\"table 2\">",
"      Nondepolarizing NMBAs in ICU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/6/44139\" title=\"table 3\">",
"      Side effects of NMBAs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/15/39165\" title=\"table 4\">",
"      Drug interactions with NMBAs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/60/27596\" title=\"table 5\">",
"      Clinical interaction with NMBAs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/23/38268\" title=\"table 6\">",
"      Doses of NMBAs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43976?source=related_link\">",
"      Neuromuscular weakness related to critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_44_43721="Pancreaticoduodenectomy (Whipple procedure): Techniques";
var content_f42_44_43721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pancreaticoduodenectomy (Whipple procedure): Techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/44/43721/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43721/contributors\">",
"     Howard A Reber, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/44/43721/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43721/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/44/43721/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/44/43721/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/44/43721/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard operation for pancreatic cancer within the head or uncinate process of the pancreas is pancreaticoduodenectomy, also called the \"Whipple procedure.\" Although first performed by the German surgeon Kausch in 1909, the operation was popularized by Dr. Allen Whipple, who performed 37 pancreaticoduodenectomies during his career [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A standard pancreaticoduodenectomy involves a distal gastrectomy with removal of the pancreatic head, duodenum, first 15 cm of the jejunum, common bile duct, and gallbladder (",
"    <a class=\"graphic graphic_figure graphicRef82519 \" href=\"mobipreview.htm?16/57/17303\">",
"     figure 1",
"    </a>",
"    ). A pylorus-preserving pancreaticoduodenectomy preserves the gastric antrum, pylorus, and the proximal 2 to 3 cm of the duodenum, which is anastomosed to the jejunum to restore gastrointestinal continuity (",
"    <a class=\"graphic graphic_figure graphicRef60689 \" href=\"mobipreview.htm?5/43/5810\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pancreaticoduodenectomy is a complex, high risk surgical procedure. The lowest operative mortality rates and best long term cancer outcomes have been demonstrated at high volume centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link&amp;anchor=H7#H7\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Perioperative morbidity and mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In experienced hands, the median operative time for the Whipple procedure is 5.5 hours, with a median blood loss of 350 mL and mortality of less than 4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique of pancreaticoduodenectomy will be discussed here. An overview of the surgical management of cancers involving the exocrine pancreas is presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Please note that technical details such as suture choice presented here reflect the author's preferences and are not meant to imply that these are requirements for successful surgical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indication for pancreaticoduodenectomy is the presence of a malignant or premalignant neoplasm in the head of the pancreas or one of the other periampullary structures (bile duct, ampulla, or duodenum) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. These neoplasms are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13897?source=see_link\">",
"     \"Treatment of ampullary adenomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43848?source=see_link\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=see_link\">",
"     \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/8/21642?source=see_link\">",
"     \"Treatment of small bowel neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Painful chronic pancreatitis is also effectively treated by this operation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General health status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation must include a thorough assessment of the patient's ability to tolerate the operation and is not based on age alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As in all patients about to undergo major surgery, it is important to optimize cardiac, pulmonary, and renal function preoperatively. This can usually be done in the outpatient setting. A detailed description of the medical evaluation of preoperative patients can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/40/24201?source=see_link\">",
"     \"Preoperative management of patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients undergo careful preoperative evaluation including a high resolution computerized tomographic (CT) scan with 1-2 mm cuts through the pancreas during the early arterial phase (pancreatic protocol) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. In some centers, magnetic resonance imaging (MRI) or magnetic resonance imaging cholangiopancreatography (MRCP) are used. In patients with malignant disease where the CT scan raises a question about vascular involvement by the tumor, endoscopic ultrasound (EUS) may be indicated to better delineate the local extent of the lesion and its relationship to the adjacent vessels. EUS-guided fine needle aspirate is also the best modality for obtaining a tissue diagnosis, although this is not required routinely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preoperative imaging evaluation to assess resectability, the role of EUS, and radiographic staging are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'Imaging studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1929?source=see_link\">",
"     \"Endoscopic ultrasound in the staging of exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many of these patients have lost weight, most are still adequately nourished to safely undergo the operation. However, if the serum albumin is &lt;3",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    or if surgery must be delayed for more than two weeks, we prescribe supplemental nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29770?source=see_link&amp;anchor=H5#H5\">",
"     \"The role of parenteral and enteral/oral nutritional support in patients with cancer\", section on 'The perioperative setting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nutrition can usually be provided enterally, but occasionally parenteral alimentation is indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6664?source=see_link\">",
"     \"Perioperative nutritional support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29770?source=see_link\">",
"     \"The role of parenteral and enteral/oral nutritional support in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pancreatic enzyme replacement may also be useful, given that some of these patients have pancreatic exocrine insufficiency related either to underlying chronic pancreatitis or, sometimes, to the cancer itself (eg, a pancreatic head cancer causing obstruction of the main pancreatic duct). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of chronic pancreatitis\", section on 'Pancreatic enzyme supplements'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link&amp;anchor=H10#H10\">",
"     \"Exocrine pancreatic cancer: Palliation of symptoms\", section on 'Malabsorption and weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because obstructive jaundice can cause defects in hepatic, renal, and immune function, it was hoped that preoperative relief of the jaundice would correct these defects and decrease postoperative morbidity and mortality rates.",
"   </p>",
"   <p>",
"    Uncertainty as to the benefit of preoperative drainage has led to differing approaches. Some surgeons routinely decompress jaundiced patients with an endoscopically placed stent prior to surgery. However, others reserve biliary decompression for selected patients in whom surgery will be delayed for longer than two weeks and those with debilitating pruritus or cholangitis. This subject is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link&amp;anchor=H4#H4\">",
"     \"Exocrine pancreatic cancer: Palliation of symptoms\", section on 'Stents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link&amp;anchor=H5#H5\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Role of biliary drainage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If stenting is performed for jaundiced patients, a plastic biliary stent (at least 10 French) should be placed endoscopically, keeping the proximal end of the stent at or below the level of the cystic duct takeoff. (French refers to a measurement of tubing circumference. One French is approximately one third of a millimeter: 0.013 inch). Metal stents often incite a severe inflammatory reaction and may be incorporated into the bile duct wall, making it difficult to remove them at the time of surgery. A metal stent that is placed too high in the duct can complicate or even prevent the resection. Ideally, the use of a metal rather than plastic stent in a patient who is a candidate for resection should be reviewed with the surgeon prior to placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bowel preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are instructed to begin a clear liquid diet two days prior to surgery and are given a standard mechanical bowel cleansing preparation one day before surgery. We employ the classic Nichols-Condon bowel preparation, which calls for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    (1 gm) and an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    base (1 gm) at 1 pm, 2 pm, and 11 pm the day before surgery, in combination with mechanical cleansing (cathartics and enemas) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should receive prophylactic antibiotics within a one hour \"window\" before the initial incision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The recommended antibiotics are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 to 2 g intravenously) or, in patients allergic to penicillins and cephalosporins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    plus one of the following:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    . Antibiotics are continued for 24 hours postoperatively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Deep venous thrombosis prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients receive 5000 units aqueous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    subcutaneously preoperatively. Thigh-length sequential compression devices are applied. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SURGEON'S SAFETY CHECKLIST FOR PANCREATICODUODENECTOMY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical consent includes the possibility that completion of the pancreatic resection may not be possible if there is unrecognized metastatic or locally advanced unresectable disease. Discussion with the patient should include the possibility of pancreatic fistula, a leak from the biliary anastomosis, intraabdominal abscess, delayed gastric emptying, small bowel obstruction, and postoperative bleeding.",
"     </li>",
"     <li>",
"      The patient has been typed and crossed in case transfusion is needed.",
"     </li>",
"     <li>",
"      Anesthetic concerns specific to the patient have been reviewed.",
"     </li>",
"     <li>",
"      Proper staplers and drains are available.",
"     </li>",
"     <li>",
"      Prophylactic antibiotics have been administered.",
"     </li>",
"     <li>",
"      Imaging studies have been reviewed and are displayed in the operating room.",
"     </li>",
"     <li>",
"      Appropriate deep venous thromboembolism (DVT) prophylaxis has been ordered.",
"     </li>",
"     <li>",
"      A Foley catheter is placed in the bladder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SURGICAL TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all of our patients undergo a pylorus-preserving pancreaticoduodenectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. A standard Whipple operation is performed if the tumor involves the proximal duodenum, pylorus, or gastric antrum. There is a 15 percent incidence of delayed gastric emptying following either standard or pylorus-preserving pancreaticoduodenectomy, in our experience.",
"   </p>",
"   <p>",
"    There is no evidence to support benefit from extended lymphadenectomy, and we do not perform extended lymph node dissection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link&amp;anchor=H436302189#H436302189\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Ultraradical surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Summary of surgical steps",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following maneuvers are performed, usually in the following sequence (",
"    <a class=\"graphic graphic_figure graphicRef65975 \" href=\"mobipreview.htm?33/4/33863\">",
"     figure 3",
"    </a>",
"    ). Each is described in detail below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of the abdomen for metastatic disease",
"     </li>",
"     <li>",
"      Mobilization of the duodenum and the head of the pancreas, with identification of the superior mesenteric vein (SMV)",
"     </li>",
"     <li>",
"      Mobilization of the stomach and proximal duodenum, with transection of the proximal duodenum (or stomach) as soon as the decision for resection has been made",
"     </li>",
"     <li>",
"      Skeletonization of the structures of the porta hepatis",
"     </li>",
"     <li>",
"      Cholecystectomy and division of the bile duct",
"     </li>",
"     <li>",
"      Mobilization and division of the proximal jejunum",
"     </li>",
"     <li>",
"      Transection of the neck of the pancreas and division of the remaining attachments of the specimen to the SMV and PV, and the superior mesenteric artery (SMA)",
"     </li>",
"     <li>",
"      Reconstruction of gastrointestinal continuity (",
"      <a class=\"graphic graphic_figure graphicRef53080 \" href=\"mobipreview.htm?16/56/17286\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patient positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is placed in the supine position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Staging laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 10 to 15 percent of cases, small hepatic or peritoneal metastases, which were not evident from the preoperative studies, may be found at exploration. For this reason, some surgeons prefer to begin the operation with laparoscopy, which permits examination of the liver and peritoneal surfaces, and biopsy of any suspicious areas. If a metastatic tumor is found, laparotomy may be avoided.",
"   </p>",
"   <p>",
"    The major drawbacks of laparoscopy are the additional time and expense required for the procedure and the inability to determine the presence of vascular invasion that precludes an attempt at resection. The latter requires more extensive dissection and is aided by the tactile senses only available during laparotomy.",
"   </p>",
"   <p>",
"    We restrict the use of laparoscopy to cases where there is a high likelihood of unresectability that has not been confirmed preoperatively. Examples include some patients with pancreatic cancer and CT evidence of liver surface or other intraperitoneal metastases that have not been proven with biopsy; patients with pancreatic body or tail cancers, all of whom have a very low chance of having a resectable lesion; and patients with pancreatic cancer and ascites, which is probably due to unrecognized peritoneal metastases.",
"   </p>",
"   <p>",
"    In the event that unresectable disease is encountered at the time of laparoscopy, and the patient has unrelieved obstructive jaundice and is at risk for gastric outlet obstruction, palliative gastric and biliary bypasses may be done laparoscopically in many cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/22\">",
"     22",
"    </a>",
"    ]. The data on surgical bypass versus nonsurgical palliation (ie, stenting) for biliary or gastric outlet obstruction in patients with pancreatic cancer are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link&amp;anchor=H2#H2\">",
"     \"Exocrine pancreatic cancer: Palliation of symptoms\", section on 'Jaundice'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link&amp;anchor=H5#H5\">",
"     \"Exocrine pancreatic cancer: Palliation of symptoms\", section on 'Duodenal obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The operation is performed either through a midline or a bilateral subcostal incision. The latter is preferred in obese patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30265?source=see_link\">",
"     \"Principles of abdominal wall incisions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Assessment of metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the abdomen has been entered, an initial assessment of the peritoneal cavity is performed. Both lobes of the liver are inspected and palpated and all of the peritoneal surfaces are assessed for metastatic disease. The transverse colon is elevated and its mesocolon, especially overlying the duodenum and head of the pancreas, is inspected.",
"   </p>",
"   <p>",
"    Occasionally the tumor will have grown through the mesocolon at this point, where it can be seen and palpated as a firm nodularity. If this is present, it suggests the possibility that the SMV may also be involved by tumor. The areas of the ligament of Treitz, the proximal jejunum, and the root of the small bowel mesentery are also inspected.",
"   </p>",
"   <p>",
"    A biopsy with frozen section should be taken of any suspicious lesion to rule out metastatic disease. If none is found, any adhesions that may interfere with later exposure are cut, and a self retaining retractor is placed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mobilization of the duodenum and pancreatic head",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use a self-retaining Bookwalter type retractor. Two deep Richardson retractors are placed first:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Retractor 1 - retracts the gallbladder and the right lobe of the liver cranially",
"     </li>",
"     <li>",
"      Retractor 2 - retracts the left lobe",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We usually begin by performing an extensive Kocher maneuver to mobilize the duodenum and the head of the pancreas. The vena cava and the aorta are cleaned of soft tissue in the process; the left renal vein is exposed, but we do not routinely remove the soft tissue and nodes between the vena cava and aorta. Indeed, if the tumor is adherent to these structures or if the nodes are firm and appear to be involved by tumor, we confirm the presence of cancer by biopsy. Tumor involvement here is considered a contraindication to resection.",
"   </p>",
"   <p>",
"    As the duodenal mobilization proceeds distally, the hepatic flexure of the colon must be separated from it, which begins to identify its mesocolon as a distinct structure.",
"   </p>",
"   <p>",
"    It is helpful at this point to place another retractor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retractor 3 - pulls the hepatic flexure and right colon caudally",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Now the mobilization of the third and fourth portions of the duodenum continues until an opening is made in the peritoneum caudal to the duodenum and anterior to the aorta, to the left side of the peritoneal cavity. This allows the surgeon to place a finger through to the area where the ligament of Treitz and proximal jejunum will be dealt with later in the operation. This maneuver usually signals the end of the duodenal mobilization and attention is now turned to the anterior aspect of the head of the pancreas and the still adherent portion of the transverse mesocolon, which needs to be separated further to expose the SMV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Identification of the superior mesenteric vein (SMV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful inspection of the anterior aspect of the exposed pancreatic head will reveal the avascular line of fusion between the mesocolon and the pancreas. The mesocolon should be separated from the head of the pancreas along this line and reflected medially to expose the SMV that runs along the right lateral margin of this tissue.",
"   </p>",
"   <p>",
"    The SMV limits further medial separation of the transverse mesocolon from the neck of the pancreas and the retroperitoneal third part of the duodenum. The plane of dissection on the vein should be at the level of its adventitia, and it is important to incise through the fibrous and avascular capsule that surrounds the vein in order to reach this plane. Several venous tributaries from the head of the pancreas run directly into the vein and the larger ones should be ligated in continuity and divided at this point. The middle colic vein usually is preserved (it can be sacrificed if it is involved by tumor), but either now or at a later stage in the dissection, the large gastroepiploic vein from the greater curve of the stomach should be divided close to where it enters the SMV. The gastroepiploic vein may also join the middle colic vein where the two run together for a short distance as the gastrocolic trunk, which then enters the SMV as a single vessel.",
"   </p>",
"   <p>",
"    Once the SMV has been cleaned of adherent tissue and the larger tributaries from the pancreas proximal to the middle colic vein have been divided, we usually begin the dissection of the stomach and proximal duodenum. Separation of the neck of the pancreas from the vein is usually postponed until after that dissection has been done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mobilization of the stomach and proximal duodenum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stomach is elevated and pulled caudally and the gastrocolic omentum is opened to enter the lesser sac, taking care to preserve the gastroepiploic arcade of vessels along the greater curve. Major vessels are ligated and divided, and an opening is created so that the avascular adhesions from the posterior surface of the stomach to the pancreas can be exposed and lysed with electrocautery. As we develop the dissection distally toward the pylorus, the avascular attachments of the transverse mesocolon to the gastrocolic omentum can be separated. Transillumination of the tissue allows for identification of the gastroepiploic vein, which should be ligated and divided before it enters the SMV or joins with the middle colic vein.",
"   </p>",
"   <p>",
"    The gastroepiploic artery should also be ligated and divided. The dissection of the posterior duodenum should continue at least 1 to 2 cm past the gastroduodenal artery where it can be seen and felt on the surface of the pancreas. By this time the dissection should have reached the same level and be in the same plane as the earlier dissection of the SMV and where the vein disappears beneath the neck of the pancreas. Now we incise along the inferior margin of the pancreas for a distance of about 3 to 4 cm along the body of the gland. This allows us to deepen the dissection to the left of the neck of the gland and to reach the level where the later pancreaticojejunal anastomosis will take place. At this point the dissection is usually through fatty areolar tissue, but occasionally a vessel will be encountered that should be ligated and divided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Transection of the proximal duodenum or stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;By this time, it is often evident that the tumor is resectable (ie, the tumor mass can be palpated and its position away from the SMV and PV can be confirmed). If this is the case, we next mobilize the lesser curve side of the distal stomach and proximal duodenum, and ligate and divide the right gastric and duodenal vessels to a point opposite where the duodenum was mobilized and its surface cleaned on the greater curve side. This is done a centimeter or so away from the duodenum so as to preserve collateral vessels to the gastroduodenal wall, and in a fashion that avoids injury to the nerve of Latarjet. When the duodenum has been cleaned circumferentially, it is then transected with a stapling device.",
"   </p>",
"   <p>",
"    Over 90 percent of our resections are done as pylorus-preserving operations, but if a standard pancreaticoduodenectomy is to be done, the duodenal dissection just described is not necessary, and the stomach is transected at the level of the gastric antrum. Then the gastric staple line starting from the lesser curve side is buried using 3-0 seromuscular non-absorbable (silk) sutures, stopping about 4 to 5 cm from the greater curve margin. This will be the site of the eventual gastrojejunostomy (Hofmeister) during the later gastrointestinal reconstruction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retractor 4 - The preserved stomach (and duodenum) is then retracted toward the left upper quadrant. This provides wide exposure of the hepatoduodenal ligament, which is dissected next.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If it is still uncertain whether resection is possible after the duodenum has been cleaned circumferentially, we would delay duodenal transection until later in the operation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Skeletonization of the portal structures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatoduodenal ligament is dissected next. The soft tissue of the gastrohepatic ligament is opened in an avascular area to the left of the hepatic artery. The hepatic artery is then cleaned of its attached tissues which contain fat, lymphatic channels and lymph nodes. The right gastric and gastroduodenal arteries are ligated and divided close to their origins; the gastroduodenal artery stump is secured with both a 2-0 silk tie and a metal clip. (Occasionally, the right gastric artery is particularly large and well developed, which suggests that it should be preserved to maintain the blood supply of the distal stomach and duodenum.) This dissection is carried caudally to the superior border of the pancreas which is also cleaned of adherent tissue.",
"   </p>",
"   <p>",
"    The lymph nodes that typically are found along the superior border of the neck of the pancreas, where the pancreatic transection will later occur, should be removed. This dissection should be sufficiently deep to expose the splenic artery as it begins its course toward the spleen, and the anterior surface of the PV. If there is still a question about whether the tumor is adherent to the anterior surface of the PV, this can be resolved since the SMV below and the PV above are now exposed. The anterior surface of the PV is then cleaned cranially along with the right and left hepatic arteries to the level at which the bile duct will be transected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Cholecystectomy and division of the bile duct",
"    </span>",
"    &nbsp;&mdash;&nbsp;Next the gallbladder is removed. This requires replacement of Retractor 1 with a more shallow retractor to expose the undersurface of the liver. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Mobilization of the duodenum and pancreatic head'",
"    </a>",
"    above.) The original retractor is replaced after the cholecystectomy.",
"   </p>",
"   <p>",
"    We next transect the common hepatic duct. A right angled dissecting clamp is inserted behind it, keeping close to its posterior surface, and a vessel loop is pulled through the opening. At this time the surgeon should feel for arterial pulsation along the right lateral or posterior surface of the bile duct. This may be due to the presence of a replaced right hepatic artery or an early division of the hepatic artery into right and left hepatic arteries. One must be careful to not injure the artery during this and subsequent dissection. The duct is elevated so that a curved bulldog clamp can be applied to its proximal portion. The distal part is clamped and the duct is cut. If a stent had been placed preoperatively, it is removed at this time. The distal duct is suture ligated and the ends of the sutures cut long to aid the pathologist in identifying the bile duct margin after the specimen has been removed. The proximal duct usually does not bleed since the bulldog clamp effectively compresses the vessels that run along its wall, and it remains in place until later.",
"   </p>",
"   <p>",
"    Finally, the soft tissue and lymph nodes behind the bile duct are cut, separated from it, and allowed to remain in continuity with the specimen. Because this tissue is quite vascular, it needs to be ligated as it is separated piece by piece from the tissues that are to remain. Finally we pass a",
"    <span class=\"nowrap\">",
"     1/4",
"    </span>",
"    inch Penrose drain behind the neck of the pancreas and anterior to the",
"    <span class=\"nowrap\">",
"     SMV/PV.",
"    </span>",
"    This protects the vessels later when the neck of the pancreas is transected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Mobilization and division of the proximal jejunum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Next, the ligament of Treitz and the proximal jejunum are exposed, which requires modifying the original exposure. The transverse and splenic flexures of the colon are retracted cranially and the distal small bowel, covered with moist laparotomy pads, is retracted caudally.",
"   </p>",
"   <p>",
"    Next the transverse and splenic flexures of the colon should be retracted cranially by repositioning Retractors 2 and 4 so that the colon can be placed behind them. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Mobilization of the duodenum and pancreatic head'",
"    </a>",
"    above.) This allows for the exposure of the opening in the peritoneum created earlier during the Kocher maneuver, the entire root of the small bowel mesentery, the ligament of Treitz, and the inferior mesenteric vein.",
"   </p>",
"   <p>",
"    Staying anterior and medial to the vein at all times, the avascular peritoneal folds that form the ligament of Treitz are cut with electrocautery. Then the mesentery of the proximal jejunum is displayed and the vascular arcades of the bowel are ligated and divided beginning about 6 to 8 inches from the ligament of Treitz. When a large enough opening has been created in the mesentery, an automatic stapler is inserted through it and the jejunum is divided. Then the stapled end of the distal segment is turned in with seromuscular silk sutures. With an Allis clamp providing tension on the proximal stapled end of the jejunum, the vessels in the mesentery are ligated and divided, progressing proximally until the retroperitoneal portion of the duodenum has been reached. These repetitive maneuvers are hastened with the use of the Harmonic Scalpel.",
"   </p>",
"   <p>",
"    Now the proximal duodenal-jejunal segment, which is part of the specimen, is delivered to the right side through the peritoneal opening. We then release the retractors holding the colon and small bowel and reposition them for the final phase of the resection. The small bowel is returned to the peritoneal cavity, the transverse and splenic flexures of the colon are released from Retractors 2 and 4, and the colon too is replaced into the abdomen covering the small bowel. Retractors 1, 2, and 4 are repositioned to elevate the right and left lobes of the liver and retract the stomach, as they did initially. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Mobilization of the duodenum and pancreatic head'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21\">",
"     'Transection of the proximal duodenum or stomach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retractors 5 and 6 - These retractors are then placed along the patient's left side to flatten and keep in place the colon and its mesocolon. Even in obese patients, this provides excellent exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Transection of the pancreatic neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neck of the pancreas is elevated from the underlying vein with the help of the Penrose drain. In a soft pancreas, hemostatic synthetic, nonabsorbable polypropylene suture (Prolene) (3-0) are placed through the pancreatic parenchyma at both the inferior and superior margin of the pancreas, on either side of the proposed line of transection (ie, four sutures total), which usually overlies the vein. On the specimen side, the sutures can be placed so as to occlude most or all of the pancreatic parenchyma and the duct.",
"   </p>",
"   <p>",
"    On the side of the pancreas that will remain, the surgeon should try to avoid placing the superior margin suture in a way that might obstruct the pancreatic duct, which normally is situated closer to that margin and quite posterior in the gland. All of the sutures are tied tightly, but care should be taken to avoid tearing the pancreatic parenchyma. Next the pancreatic parenchyma is divided with electrocautery. Any bleeding can usually be stopped with electrocoagulation; if not, vascular suture should be used (4-0 or 5-0). When the transection is complete, the Penrose drain is removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Division of attachments to the SMV, SMA and PV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgeon, who stands on the patient's left side, grasps the duodenum and head of the pancreas in the left hand and retracts it away from the PV. The dissection begins at the cranial end of the specimen progressing distally, and the remaining attachments to the",
"    <span class=\"nowrap\">",
"     PV/SMV",
"    </span>",
"    and retroperitoneal tissues are ligated and divided. The surgeon defines each bit of tissue for transection by separating it from surrounding structures with a right-angled clamp, into which the first assistant places 2-0 silk ties that are pulled through the opening. The clamp is then applied to the side of the tissue that is to remain, the assistant ties the specimen side, the surgeon cuts the tissue, and the assistant then ties the tissue in the clamp. This process is repeated until the entire specimen is free. Individual vessels that can be seen entering into the SMV or PV are tied in continuity, usually with 4-0 silk, and cut. Occasionally vascular suture ligatures of 4-0 or 5-0 synthetic, nonabsorbable polypropylene suture (Prolene) may be required to stop bleeding from the veins themselves or tissue deep to them (",
"    <a class=\"graphic graphic_figure graphicRef65975 \" href=\"mobipreview.htm?33/4/33863\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Occasionally, the tumor will be found to be adherent to the right lateral or posterior part of the SMV or PV, which was not suspected before the neck of the pancreas was divided. In this circumstance, the segment of involved vein should be resected, either as a lateral venorrhaphy or a segmental resection of a cylinder of the vessel. In the latter case, end to end anastomoses are almost always possible even if a length of 2 to 3 cm of vein is removed. Vascular clamps prevent bleeding, while venous continuity is restored with suture of 5-0 Prolene.",
"   </p>",
"   <p>",
"    The entire specimen is then sent to the pathology laboratory for frozen section examination of the resection margins (duodenal, jejunal, pancreas, bile duct). If invasive cancer is seen in any of them, more tissue is resected until a negative margin is obtained. During the time that it takes for the specimen to be examined, the operative field is irrigated with warm saline, meticulous hemostasis is assured, and the pancreatic anastomosis is begun.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Reconstruction of gastrointestinal continuity",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Pancreatic anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An end to side pancreaticojejunostomy is performed first, usually by bringing the jejunum behind the SMA and SMV, in a position similar to that occupied originally by the retroperitoneal duodenum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/23\">",
"     23",
"    </a>",
"    ]. However, in patients with cancers arising in the third or fourth part of the duodenum, we prefer to bring the jejunum through a hole in the transverse mesocolon instead. This minimizes the potential for later obstruction of the jejunum if the cancer should recur in the retroperitoneum (",
"    <a class=\"graphic graphic_figure graphicRef53080 \" href=\"mobipreview.htm?16/56/17286\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The cut end of the pancreas is mobilized from the retroperitoneal tissues for a distance of 2 to 3 cm, which may require ligation and division of a few venous tributaries to the splenic vein. The pancreatic duct is probed and its patency assured past the point where the Prolene hemostatic suture had been placed earlier in the superior margin of the gland. Depending on the size of the duct, a 5 or 8 French Pediatric Feeding tube is inserted well into the duct so that it can be easily seen during the anastomosis (French refers to a measurement of tubing circumference. One French is approximately one third of a millimeter: .013 inch). We do not use a pancreatic duct stent, so this tube will be removed when the anastomosis is almost complete.",
"   </p>",
"   <p>",
"    The two layer anastomosis is begun by placing a posterior row of three or four 3-0 or 4-0 horizontal silk mattress sutures from the pancreas to the bowel; after they are all placed, the sutures are tied as the first assistant brings the bowel to the pancreas to minimize the chances that the pancreatic parenchyma will tear. They are placed horizontally so that when they are tied, any pancreatic parenchymal vessels (which generally run transversely) are likely to be compressed; this minimizes bleeding from needle placement. The jejunum is then opened with electrocautery about 1 cm anterior to the line where the silk sutures have been tied. Two 3-0 or 4-0 polydioxanone (PDS) sutures are then placed at the posterosuperior margin of the anastomosis, each end is tied, and the short end is cut. Both of these sutures are placed from the mucosal side of the bowel and then through the pancreatic parenchyma about 1 cm back from the cut edge of the pancreas. The first suture will be continued as the posterior row, and should be placed through the lumen of the pancreatic duct as it passes near the duct, and then through the full thickness of the bowel wall about 5 mm from the cut edge. This usually requires two or three sutures placed into the duct lumen in this fashion, even with the largest ducts. This posterior row suture is held after the inferior corner of the anastomosis is completed. Then the second suture is brought from the inside of the bowel lumen where it was tied, through the bowel wall so that the anterior row of sutures can be placed. Again, the sutures are placed through the lumen of the pancreatic duct before traversing the full thickness of the anterior bowel wall.",
"   </p>",
"   <p>",
"    The feeding tube helps to identify the duct lumen and aids in suture placement. When the sutures progress past the duct, the feeding tube should be removed. When the anterior row of sutures reaches the posterior one, the two PDS sutures are tied to each other. The anastomosis is completed with the placement of the anterior row of 3-0 or 4-0 silk sutures in a fashion similar to the posterior row. The assistant again brings the bowel wall up to the pancreas as the sutures are tied to minimize the chance that the pancreas will tear. This anastomosis results in the invagination of the cut end of the pancreas into the lumen of the bowel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Biliary anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatico (choledocho) jejunal anastomosis is performed next at a sufficient distance from the pancreas to avoid tension on the suture line, but not too long to allow kinking of the bowel. The bulldog clamp is removed from the bile duct, a bile culture is taken, and hemostasis is obtained. A single layer anastomosis using interrupted sutures of 4-0 or 5-0 polydioxanone (PDS) is performed. (If the duct is 2 cm or more in diameter, running sutures are also satisfactory.) Initially, the sutures are placed through the anterior wall of the duct about 2 to 3 mm from the edge, and from the outside of the duct into its lumen. The corner sutures are placed first, then the middle, etc. so as to place them evenly along the length of the anastomosis, and at a distance of about 4 to 5 mm from each other. These sutures are held with the needles attached until the posterior row of sutures has been placed, which is done next.",
"   </p>",
"   <p>",
"    The bowel lumen is opened with electrocautery for a length equivalent to that of the bile duct diameter, and the sutures are placed between the duct and the jejunum and tied with the knots placed inside the lumen of the duct. Finally, the anterior row of sutures that had been placed on the bile duct side are placed through the bowel wall and tied. Here the knots are on the outside. If the duct is smaller than 1 cm in diameter, a small T tube inserted through the wall of the bile duct proximal to the anastomosis. The distal limb of the T-tube lies in the jejunal limb. The tube is removed in the office three to four weeks later, usually without a prior cholangiogram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Duodenal anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finally, an antecolic duodeno(gastro)jejunostomy is constructed approximately 30 cm distal to the choledochojejunostomy, in a standard two-layer fashion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Drains and closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A closed suction drain (eg, #10 Jackson Pratt) is placed close to both the pancreatic and hepatic duct anastomoses. The drain is led behind the stomach, between the pancreaticojejunostomy and the left lobe of the liver, with the tip placed behind the hepaticojejunostomy, then brought out of the abdomen on the left side. The T-tube is brought out of the abdomen on the right side. The drain and T-tube are sutured to the skin. After this the abdomen is irrigated and closed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10633?source=see_link\">",
"     \"Principles of abdominal wall closure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patients do not need to be transferred to an intensive care unit as a routine postoperatively. The nasogastric tube is removed on the morning of the first postoperative day and the patient is encouraged to ambulate. A clear liquid diet is usually started on the fifth postoperative day and most patients are able to advance to a regular diet over the next 24 to 48 hours. Most patients are released from the hospital within 7 to 10 days of operation.",
"   </p>",
"   <p>",
"    If there is no suspicion of a pancreatic or bile fistula, the drain should be removed after the patient is eating solid food. If there is any suspicion of a pancreatic leak, the amylase concentration of the fluid is measured to confirm the diagnosis and the patient is sent home with the drain in place. The patient continues an oral diet and the drain is removed in the outpatient clinic once the drainage has stopped. In our experience, all of these fistulas close spontaneously, usually within four to six weeks after discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/24\">",
"     24",
"    </a>",
"    ]. Although one study of 114 patients reported lower rates of complications with early drain removal in patients at low risk of pancreatic fistula (drainage fluid amylase value of &le;5000",
"    <span class=\"nowrap\">",
"     U/L),",
"    </span>",
"    most surgeons tailor drain care to the individual patient&rsquo;s progress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28903?source=see_link\">",
"     \"Clinical features, diagnosis, and prevention of pancreatic fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients who have undergone pancreaticoduodenectomy will not need pancreatic enzyme supplementation. Many patients will have several bowel movements a day for some weeks following discharge from the hospital, and if this is problematic, it can be treated symptomatically (",
"    <a class=\"graphic graphic_table graphicRef51385 \" href=\"mobipreview.htm?10/6/10349\">",
"     table 1",
"    </a>",
"    ). As the GI tract \"readjusts,\" bowel frequency almost always decreases and most patients end up with two to three formed movements daily.",
"   </p>",
"   <p>",
"    If steatorrhea is evident with oily floating stools, then pancreatic enzyme supplements should be prescribed in a quantity sufficient to provide at least 30,000 units of lipase with each meal, along with an antacid secretory inhibitor to decrease gastric acid secretion (",
"    <a class=\"graphic graphic_table graphicRef51385 \" href=\"mobipreview.htm?10/6/10349\">",
"     table 1",
"    </a>",
"    ). One-half of this dose should be administered with snacks. It is almost never necessary to limit fat intake. If this approach does not provide relief, the patient is referred to a gastroenterologist for management of the problem. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22279?source=see_link\">",
"     \"Overview of the treatment of malabsorption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vomiting after oral intake is resumed could be due to delayed gastric emptying. The mean incidence of delayed gastric emptying is 17 percent although the range varies widely among trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To manage postoperative vomiting, a nasogastric tube is reinserted and an abdominal CT scan is obtained. Rarely, this reveals a fluid collection near the stomach, which may represent an undrained pancreatic fistula or other process. Percutaneous drainage and culture of the fluid should be done.",
"   </p>",
"   <p>",
"    Although delayed gastric emptying can be due to several causes, it is important to not overlook a fistula, which is a treatable condition. Gastric function usually returns when the fluid collection is treated appropriately, or after a period of nasogastric suction if no other abnormalities are found. We also would administer a gastric promotility agent if gastric emptying is delayed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7226?source=see_link\">",
"     \"Malignancy-associated gastroparesis: Pathophysiology and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Bile leaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile leaks from the choledochal-jejunal anastomosis occur in 1 to 2 percent of cases, and are heralded by the appearance of bile in the drain fluid. If this occurs, the drain should be left in place until the leak stops. If it is still present when the patient is ready for discharge, the patient can go home with the drain in place. It can be removed in the office when there is no longer any bile present. If there is no evidence of a biliary leak, the biliary drain is removed the day after the patient begins oral intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Pancreatic fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic fistulas are defined by the International Study Group on Pancreatic Fistula Definition as a drain output of any measurable volume of fluid on or after postoperative day three with an amylase content greater than 3 times the serum amylase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/27\">",
"     27",
"    </a>",
"    ]. A pancreatic fistula complicates 2 to 22 percent of pancreaticoduodenectomy operations, when the pancreaticojejunostomy does not heal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/28\">",
"     28",
"    </a>",
"    ]. Pancreatic fistulas can lead to sepsis and hemorrhage. These complications are associated with mortality of 20 to 40 percent, prolonged hospitalization and increased hospital expenses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28903?source=see_link\">",
"     \"Clinical features, diagnosis, and prevention of pancreatic fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pancreatic leaks are more common when the pancreatic parenchyma is soft and holds sutures poorly (eg, cysts, ampullary cancers that do not obstruct the pancreatic duct), and when the pancreatic duct is small. In patients with pancreatic cancer where the pancreatic duct is commonly obstructed by the tumor, the pancreas is firm and a pancreatic fistula is uncommon. There is no clear evidence favoring any specific pancreaticoenteric anastomosis or pancreatic ductal obliteration to prevent fistula formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     BORDERLINE RESECTABLE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is not universal agreement on the criteria for the definition of borderline resectable disease. Some reserve the term \"borderline resectable\" for cases where there is focal (less than one-half of the circumference) tumor abutment of the visceral arteries or short-segment occlusion of the SMV or",
"    <span class=\"nowrap\">",
"     SMV/portal",
"    </span>",
"    vein confluence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Others suggest that venous narrowing without occlusion be included in the definition of borderline resectable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/32\">",
"     32",
"    </a>",
"    ]. Several groups have issued guidelines to define resectability based on imaging studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This is discussed in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=see_link&amp;anchor=H1472388#H1472388\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'Definitions of unresectable and borderline resectable disease'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients who are deemed to have borderline resectable pancreas cancer are potential candidates for downstaging with neoadjuvant therapy and should be referred for medical oncology and radiation therapy consultation. Encasement (more than one-half of the vessel circumference) or occlusion of the superior mesenteric vein (SMV) or the SMV-portal vein confluence used to be considered a criterion for unresectability. However, many centers have demonstrated the feasibility of SMV reconstruction, and this is now considered by many to represent borderline resectable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/35\">",
"     35",
"    </a>",
"    ]. However, such patients should undergo an attempt at downstaging with neoadjuvant therapy before surgery. Although vascular resection and reconstruction at the time of the initial exploration for pancreaticoduodenectomy is occasionally warranted, we prefer to postpone resection until after the patient has received a prolonged course of neoadjuvant therapy (eg, six months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/44/43721/abstract/36\">",
"     36",
"    </a>",
"    ]. Anecdotal evidence suggests that the tumor inevitably recurs if resection is performed in the presence of such locally extensive disease, unless neoadjuvant therapy has been given first. Long term survivors are occasionally seen when resection is done after treatment, however. Although vascular resection adds a measure of complexity to the standard pancreaticoduodenectomy, an experienced surgical team in a high volume center is able to safely perform the procedure when that is required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link\">",
"     \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'Assessing resectability'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     PALLIATIVE SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the patient is found to have unresectable disease and the surgeon believes that downstaging neoadjuvant therapy is unlikely to be successful (eg, liver or peritoneal metastases, very extensive local disease with complete major vascular occlusion, etc.), surgical biliary and gastric bypass should be considered. Biliary bypass (cholecysto- or choledocho- jejunostomy) effectively relieve biliary obstruction and eliminate the need for a stent. If the gallbladder is used for the decompression, the surgeon should be certain that the cystic duct is open and not likely to soon become obstructed by the cancer as it grows. A prophylactic antecolic gastrojejunostomy should also be done in most patients who are likely to survive for more than three months. It does not add to the morbidity of the operation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/55/31603?source=see_link\">",
"       \"Patient information: Pancreatic cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/45/26322?source=see_link\">",
"       \"Patient information: Chronic pancreatitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A standard pancreaticoduodenectomy, (Whipple procedure) includes a distal gastrectomy with removal of the pancreatic head, duodenum, first 15 cm of the jejunum, common bile duct, and gallbladder. A pylorus-preserving pancreaticoduodenectomy preserves the gastric antrum, pylorus, and the proximal 2 to 3 cm of the duodenum, which is anastomosed to the jejunum to restore gastrointestinal continuity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common indication for pancreaticoduodenectomy is the presence of a neoplasm in the head of the pancreas or one of the other periampullary structures (bile duct, ampulla, or duodenum). Painful chronic pancreatitis is also effectively treated by this operation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative imaging with high resolution computerized tomographic (CT) scan with 1 to 2 mm cuts through the pancreas during the early arterial phase (pancreatic protocol) provides the best assessment of resectability. EUS-guided fine needle aspirate is the best modality for obtaining a tissue diagnosis when appropriate. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with serum albumin &lt;3",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      or if surgery must be delayed for more than several weeks, supplemental nutrition should be provided. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not place biliary stents routinely. For patients with debilitating pruritus or cholangitis, or if surgery must be delayed for more than several weeks and jaundice is present, a stent should be placed. If a metal stent is used, the proximal end of the stent should be kept below the level of bifurcation of the common hepatic duct to avoid complicating the surgical resection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are unresectable either because of distant metastases or vascular invasion, we suggest evaluation by a medical and radiation oncologist for chemotherapy with or without radiation therapy. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Borderline resectable disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a high likelihood of unresectability that has not been confirmed preoperatively, staging laparoscopy permits examination of the liver and peritoneal surfaces and biopsy of any suspicious areas. If metastatic tumor is found, laparotomy may be avoided. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Surgical technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there is any suspicion of a pancreatic leak, the amylase concentration of the drain output is measured to confirm the diagnosis and the drain should be kept in place until the drainage stops. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who develop postoperative vomiting, a nasogastric tube should be reinserted and an abdominal CT scan obtained to look for a fluid collection causing delayed gastric emptying. If a collection is present it should be drained and cultured. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/1\">",
"      Whipple AO, Parsons WB, Mullins CR. TREATMENT OF CARCINOMA OF THE AMPULLA OF VATER. Ann Surg 1935; 102:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/2\">",
"      Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/3\">",
"      Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg 2007; 245:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/4\">",
"      Fong Y, Gonen M, Rubin D, et al. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg 2005; 242:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/5\">",
"      Duffy JP, Hines OJ, Liu JH, et al. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg 2003; 138:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/6\">",
"      Ryder NM, Ko CY, Hines OJ, et al. Primary duodenal adenocarcinoma: a 40-year experience. Arch Surg 2000; 135:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/7\">",
"      Ashley SW, Reber HA. The Whipple operation: The classical surgical procedure to treat chronic pancreatitis. Digestive Surgery 1996; 13:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/8\">",
"      Kazanjian KK, Hines OJ, Duffy JP, et al. Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg 2008; 143:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/9\">",
"      Gloor B, Todd KE, Reber HA. Diagnostic workup of patients with suspected pancreatic carcinoma: the University of California-Los Angeles approach. Cancer 1997; 79:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/10\">",
"      Steinberg WM, Barkin J, Bradley EL 3rd, et al. Workup of a patient with a mass in the head of the pancreas. Pancreas 1998; 17:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/11\">",
"      Taoka H, Hauptmann E, Traverso LW, et al. How accurate is helical computed tomography for clinical staging of pancreatic cancer? Am J Surg 1999; 177:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/12\">",
"      Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997; 168:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/13\">",
"      Vedantham S, Lu DS, Reber HA, Kadell B. Small peripancreatic veins: improved assessment in pancreatic cancer patients using thin-section pancreatic phase helical CT. AJR Am J Roentgenol 1998; 170:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/14\">",
"      American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999; 117:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/15\">",
"      Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/16\">",
"      Braga M, Ljungqvist O, Soeters P, et al. ESPEN Guidelines on Parenteral Nutrition: surgery. Clin Nutr 2009; 28:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/17\">",
"      Nichols RL, Broido P, Condon RE, et al. Effect of preoperative neomycin-erythromycin intestinal preparation on the incidence of infectious complications following colon surgery. Ann Surg 1973; 178:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/18\">",
"      Fry DE. Surgical site infections and the surgical care improvement project (SCIP): evolution of national quality measures. Surg Infect (Larchmt) 2008; 9:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/19\">",
"      Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/20\">",
"      Patel AG, Toyama MT, Kusske AM, et al. Pylorus-preserving Whipple resection for pancreatic cancer. Is it any better? Arch Surg 1995; 130:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/21\">",
"      Diener MK, Heukaufer C, Schwarzer G, et al. Pancreaticoduodenectomy (classic Whipple) versus pylorus-preserving pancreaticoduodenectomy (pp Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2008; :CD006053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/22\">",
"      Kazanjian KK, Reber HA, Hines OJ. Laparoscopic gastrojejunostomy for gastric outlet obstruction in pancreatic cancer. Am Surg 2004; 70:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/23\">",
"      Hines OJ, Reber HA. Technique of pancreaticojejunostomy reconstruction after pancreaticoduodenectomy. J Hepatobiliary Pancreat Surg 2006; 13:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/24\">",
"      Kazanjian KK, Hines OJ, Eibl G, Reber HA. Management of pancreatic fistulas after pancreaticoduodenectomy: results in 437 consecutive patients. Arch Surg 2005; 140:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/25\">",
"      Bassi C, Molinari E, Malleo G, et al. Early versus late drain removal after standard pancreatic resections: results of a prospective randomized trial. Ann Surg 2010; 252:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/26\">",
"      Traverso LW, Hashimoto Y. Delayed gastric emptying: the state of the highest level of evidence. J Hepatobiliary Pancreat Surg 2008; 15:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/27\">",
"      Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005; 138:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/28\">",
"      Lai EC, Lau SH, Lau WY. Measures to prevent pancreatic fistula after pancreatoduodenectomy: a comprehensive review. Arch Surg 2009; 144:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/29\">",
"      Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008; 206:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/30\">",
"      Greer SE, Pipas JM, Sutton JE, et al. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 2008; 206:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/31\">",
"      Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/32\">",
"      Chun YS, Milestone BN, Watson JC, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 2010; 17:2832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/33\">",
"      Abrams RA, Lowy AM, O'Reilly EM, et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009; 16:1751.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/35\">",
"      Bold RJ, Charnsangavej C, Cleary KR, et al. Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg 1999; 3:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/44/43721/abstract/36\">",
"      Evans DB, Farnell MB, Lillemoe KD, et al. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009; 16:1736.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5661 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43721=[""].join("\n");
var outline_f42_44_43721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General health status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nutritional status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bowel preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Deep venous thrombosis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SURGEON'S SAFETY CHECKLIST FOR PANCREATICODUODENECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SURGICAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Summary of surgical steps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patient positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Staging laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Assessment of metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mobilization of the duodenum and pancreatic head",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Identification of the superior mesenteric vein (SMV)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mobilization of the stomach and proximal duodenum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Transection of the proximal duodenum or stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Skeletonization of the portal structures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Cholecystectomy and division of the bile duct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Mobilization and division of the proximal jejunum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Transection of the pancreatic neck",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Division of attachments to the SMV, SMA and PV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Reconstruction of gastrointestinal continuity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Pancreatic anastomosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Biliary anastomosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Duodenal anastomosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Drains and closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Bile leaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Pancreatic fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      BORDERLINE RESECTABLE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      PALLIATIVE SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/5661\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/5661|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/57/17303\" title=\"figure 1\">",
"      Conventional pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/43/5810\" title=\"figure 2\">",
"      Pylorus-preserving pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/4/33863\" title=\"figure 3\">",
"      Resection pancreatic head",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/56/17286\" title=\"figure 4\">",
"      Pancreaticojejunostomy reconstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/5661|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/6/10349\" title=\"table 1\">",
"      Medications for malabsorption",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43848?source=related_link\">",
"      Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28903?source=related_link\">",
"      Clinical features, diagnosis, and prevention of pancreatic fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1929?source=related_link\">",
"      Endoscopic ultrasound in the staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=related_link\">",
"      Exocrine pancreatic cancer: Palliation of symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7226?source=related_link\">",
"      Malignancy-associated gastroparesis: Pathophysiology and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=related_link\">",
"      Management of locally advanced and borderline resectable exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22279?source=related_link\">",
"      Overview of the treatment of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/45/26322?source=related_link\">",
"      Patient information: Chronic pancreatitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/55/31603?source=related_link\">",
"      Patient information: Pancreatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6664?source=related_link\">",
"      Perioperative nutritional support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/40/24201?source=related_link\">",
"      Preoperative management of patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30265?source=related_link\">",
"      Principles of abdominal wall incisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=related_link\">",
"      Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29770?source=related_link\">",
"      The role of parenteral and enteral/oral nutritional support in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13897?source=related_link\">",
"      Treatment of ampullary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=related_link\">",
"      Treatment of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=related_link\">",
"      Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/8/21642?source=related_link\">",
"      Treatment of small bowel neoplasms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_44_43722="Asbestos body Photomicrograph";
var content_f42_44_43722=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61838%7EPULM%2F81274%7EPULM%2F70440%7EPULM%2F59362%7EPULM%2F50185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61838%7EPULM%2F81274%7EPULM%2F70440%7EPULM%2F59362%7EPULM%2F50185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Asbestos body",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph shows a dumbbell-shaped asbestos body in a bronchoalveolar lavage specimen from a patient with a history of occupational asbestos exposure. Asbestos bodies differ from other nonasbestos ferruginous bodies in that the central core is thin and colorless and is covered by hemosiderin distributed in a characteristic beaded fashion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Asbestosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 188px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAC8ARkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDvNUs7P/RomgEjyyBS8Vy37n/aBfIJwOmAOmOea0LaS6junSCyDSuT5dy0jTkfQK2V9xg1q/8ACGTPCDM9ovAYwLGWV/l+6ST0znpWLH4a1gI09vZPbswH7lbvlR3IA6+mK8aNSD0v9/8Aw59vHE0KseX2m3d/5v8AzXzK+p3vn2zeXoemx3JOPMkRDz/wNSMt9Bj1NaaqLO5hnu9ST5QBGpj+SAY/h2gEHPHDY96pKl7HbG71qGeeKJw0oSYMYl6Aeuc08zGY3hubiCzhhTeoZyZLskZ4XrjHHHetr6WX+Zc+W3KturWvyTd3+HXsT2jzIOQ0U0rnYPN43EnLAdST3646DJOK17HRJUjtlNhNbIJPKMyFTM6knDAZwiYZs5y3OPesW+eW2nsrqC3u7Ocw8LIdpSMEZdz3Y/Nhe3Fbvg7W5J9U+zzXMkkE0CvH5xBbzMc9Omfm47baiXNy3RyYl1fZOrTtbd/1/mWL3wi8tzJJBq9zBbO4PlJHGcLnldzKT+PX+dR+ItOtdLtpryF5MHB8s4wwHBXdxwR/eJrqVuVa6ktxHIGRQ+4oQmD6HoTUciRpJLPPOfJZBlHI8tQOp56Vy+0l1PHhjayknUei6d9vL8TzmEh7+2s4oxM0zAwq7FfkIy2fmAI7DjJ9qu3ujXt1IqxW8iW8MmSkQVBJx905yQBnOQQcjH1nS9Fz4ntkCpsN0fJlj5XYF3dPU88+nSotZ1bU7a9mFvdQLBJNtiCnc8mBnYM8LwDn6Vcm7nrylUnJRikrq+t+/l/W5FeW9xbpG88U0GRiMEnC4B685DdeAcYHUZxXK+Inu4NHjt7CCW/1KXDyAyCJpcnq5yAAfUAcgcGuqvNca+0GYSwQlYpEQOJN5wx+Vh3Bxk4PrVWe+a2hBRJGeRC2VXBZPu7/AKA+lO0ram9NVHG0lZ3tp/T7nM6Zpt5c+EZLe+laaaVNs8rwRzssinKxmRgUkxwOV465qx4eszcXLXdzeTCeMLmxt5mjSA4IJZIyqvkjuCD6YrpdNv3tLZYoIre5scbsbyHUnrkdPcGqEupQxahGtiMTMu19pBbAGcsvcj2pLW+g3Fybjb+l3HW63s8Mz2wjW6A/cQyTZ3Nu5HC9cdMg+2Ks3900M6eeqwqVLMX27lcdCSBuP4Hr7VQu9ShWe11C3v3tbaUMWniG1ZTjBHI/HtinaHf2el6g8l3bCcRSCT7TJb48sMcbojz1BBI9c1Su3dL+thtN3mo37L/glt7PUtR1OG409WuPKVf3n22RSu/r8pbYPXIQ5HpWsYL5ZzamS+uJ+AzoiwRkE8kvtOQB7c9MVq6Vrei3V79lsLoG5diNhjIYsBk5PqBz9K2cHaQTjqeOh96z53F6r+v67HkVMZKMuVwtbutf69LGBbeGkFqizzbbgKRvhdjzu4YdAOOCAv41XKXuh6l8qSXdmYwTcMilk54Rgu0Y7hveunyVIBPPU44FE0Uc9s8cyh45ByhHBHvSdV63MFjJtv2mqf8AWhyms61GxiS/j8l/MKorDepYDLA9T0I6A1m/2rai3nMsslj5bhR58xWOQH+7g7c+xVfeneJ7RdMv7MQSmKzw3lmQ4Az95VbrurOuLaJ4ZRfR+fa7ldI3+bDgjacHqSauPSx69GjTdJOHXb79v8y3dahpAgdFmgcXI4ee1iGdvOCAVBHvg1C1jY3aL5WnWlwHYN5iyukatjglFfB9sYP0qa68MSapc2V7e6cLhoJWeJHbY8JIwXYdDx0HaqVr4dvpb28uDbXIa4QQRJJPi3hjAwXwOd1NS7P8f+GNI1Ixvyzt8/8AKxYFpo8M7RI6xQYAeP7yl+mSrMxA9OasfYrN7f50triKNg/3m3KSOMBSo/HrU1r4WuYCokuoZfm3HI3eWAoAVe5z3z61Yn8OyxuHsbuNGU8LJF19gw5HahzXch4mm/8Al47/AD/rUzrvS4UHFraxRPwrtK6jkduxP1FZz6FPtQAyWyRgHzVRZQw7E7Sv6Cr99He20hS8s5HiAyLmyHmKD7o3p3qLT9UijhYu9quwBo5EJSMnuADyp/SmpO10dMJ1lC8Hf8f1f9dDBkt7+1vIv7RsYnTcFW7hPmbienPY/Wp7lIX3yIwRdh+dwSrepOPTnqfwrqVl0y4EpLGGSVNrKDtLt1wccGqd3olpqKGGaTzIMAvPGMMQPXHt1p+0exosYm17Rctjh9OjOrGG7uXkjsUlJtIdhKzMANrHH6Drx1PbYuGCRiQKpJBXaGClyOoz1/HI9615dEhtmJtJUNvGA/7sgeuGRemTg/iDUQ0eN5HlgvJTInzIJLcMGz1x/d/Cq50tWbvFU5Pmvp8zGltorgAXEEMLHBaAoH+gP19RmqslhCYXt2tohHLId26IHj3Vs5/EYrZGlTIsks14YX3EIZIzsQdgT1ANUJbS4jk2XkEaqAWWWObG8n0B5wfWmppvQ3hUjLRO/wDXnv8AiZWoaZpVyo+06dp10BJvBa3UHcQFAyRye2Dx07gVn/8ACGaP/wBAW2/78rXUmyuREzxwXJlxlBJtO8jsPQ/4VT8y6/6A+o/kP8ahzton+I1TpVNeWL9bHvR3FgQcDOenWvNpry4j1yNIb6R5Yp5JPIkOI4UHcsvVBnGD36V6YeASRn6VyeseDbS/sbi3a8vYpZ5zcPOjfMT2U4HKjsK56M1F+8fFYCtTpt+02flf+vzKH2uPTb/zoruO+mumV3gW3O5QR0XHv2NZWo2/9iaIJbuze1DPmO8kkHmhmbOwf3B0wPwrqrWw0vw3oDyySyMr7TJKgIkmbsABzk+gp9/Y33iDTmS+SKzhdg8cTJvdccgt2z7V0RqJa9DujioRmpfZvZt6Xt2S9ez8zDF3f2yyRXhE2HXa1yd43H/Z/L86p3OqzHU476CC33W821EijO09Vbcf4e+GNdfpuiGGS6uLy4W5upwq7tvCBQQNoPQ8mpL7S4m0m9htgVneJ0Lnqxxxn17VKqRvrqSsbQU7Wv0v01tc1wQRuBJDcioL20gvrOa2uoY5YJlKSIwyGB6g1Do95/aGlWt2oIE0aud3UHuKtEgg49cGubVbnjSjKEmnujlE8MC1v9JmsriRhaS4xK3PlbcbRjjj3pNe0oo8l7ZEoyAkwwxht3r8vdiMjI9ak8R3V9Y3MstuGe3nhMbKpCtbkDhwx4x61jNqUup6jaWEsJjQeWguI2DO4IGfnB4DDvWvvStJntUI152rcyatr6dboitLSbUbl7CyuIVsocFnEIBUqcEH1f7w+mK6m6NvZ2XmTLGscCLEm5c56ALWRYbNJ8QvbNvjs75M26EghZF6jPrggjPP5Vu+cVcsF+4pbkZ6CpqSWnYWKqOU4/y2v69/n0PNfHF0gnvHsJ5beedf3UsC5BKMFwwHBBycgdhVvRfDmoX9xHcrfW/lRy7EuVj8sKgXDJHH7+pNZEtxqD3FumnxwOqPuupJPlIWQklEA74Awa9NsLyK6s1ktEWOPaAExjb7f/XpzbgdmKlKhFcm+2u33en6kMfh/R0vPtS2KyTnAJlYsAQMZC9M1qRxxIOI1RPQAcfT2pobJBUYUjp6etDqXikRW2OykeZjO33xWV77s8aU5S+Js4TxktzY6rdXiQyR264kSa2I3YAzuHvxjHetSy8ZrBDZyX7C5064Kbb9V2su9dyh09u5HSqXjG5sNODR3d1IRFAHkLhilvHjG4Beu4kZzyKteEIdMgt/7NMEbRXhe4tkZdyFWX59p7Z649K6d4K56lTlnh486vZejt3/AK069juGwexAODuXoaaf9W3ACg8nPQVyFjo+teG5Gg0aY3+lbSY7e5bLRHPTJ5IxmtrTr3UpS32/TPsypyJPMBVv7xx1HAyKxlFdHc8qWHsuaEk162f3PUwfGV4Li/NmYN0FmnnsyjcxPQj2AyM0aPa/ar2OaZ4RhS8Np0BYdGc9QM9MVQuDPq8mp6lie3sFmRCynb5iA45HfA7d61PCEUUupzTwoxW13QbseoGOe5/lmtfhVj2JpUcNyrRxWvrb87s6lWkECm4ZWnC5couASPQUkmGJbjJwdpOM5/lS/MY0Yx7XP3kDZ2/jRINxQYBAHOf6+tYLU8NblWRjuOOMEZH0qNye3UdQO1Ssfn5Xvk1EeCMDBx0x+tNs3iNUEAFAAexB4qpPY2ksLJLaQyIwO7cgz9frVpQN3Ck8856fWiRhuZu3UkccdKSZpGTi9DEvfDmnyWAFjELWdCNkiEk8eueuaq2+oCGeOK/Ahu4iYpMDiTt1HX1zXTD5k3kADsDxj/69Vb7SLW/KvLvjmQZ82LguOnzDoRzVxqdJHVTxN/drNtfiv+AZ99fhJY7WCJPPnB8uOFcvtGCWY9AOaxLm4ZpcSG3jChhu3FtijqSf6V0cfh20kY/abm4aI4Uwx4iVh/tEcn/61Sw6ba2UUka6ZA1q2SzEmRgB04PWrVSKRrDEUaatG7f9d/yt89TkUF2fJlt5lnt5vmBZwoI9j6+nrUchmhbEFtDIztkgy5YZ5JweldHLZNcxSwXVsiLcS7LcRqAyYGQQOg46GuZutOnsbuKMJC8koby8v/rmXnr9OvvVKacrM76NaFR2dr/15/1YiiutPaaSG6jkhUncI953Kwz0PvUXk2v/AEFNQrQukvIGaWWKy8pUDhgMkDPXPqemKk/si5/55j/v4v8AjSlOK1bOhVYR15rX80/zPU5TKJk27DF0bruHuMUP5jROAVjkIwuQWCn39aVioySAO/HWkySTwGPYev1ri5j4dGPpWi3EGove6tqT6jPjbCDEI0iHso43e9b5ziowRkYGc81XvdQt7GES3cqxRM4QOcj5j0Fbc7my5zqV5K+r8l+SRJf3cFlbST3MixxoMkk4z6Ae56Vh69d63MkaaNp6tBIredLLIoYAjjYA33gT34qDxhc2lzbfZFQzzriRRkqqk5AJbjPGflH6daxtNv7zSre3tre6Zt6ZjhkhU7nBKsgCY2LlQR/eDccg51px0T6nfhsJaCqWTl2d7fhr+huaTqUselJbWVi0j2iCOYMwTa4HIA6k/ln1p2meLNPu7WPz2eO7K/NCIZDk/wCz8vP4ZxWXcWlpdx22o67pTQ3Fw+TbQW5fawGN8jAZ3YHDHoOKhuNNSfRLjVLFL60ZYiYI+kqAHqDnO3uAeTT5YPf+vzNnQoVL86abe679r6316pdDQ1qO41W9tLiymgmsIVbzrdywYydgRjr7H8qpaNb2kGnQazIblXkJmaIRkiM/dxsA3DHp2rNtbK4XGqSStLZ3MQeafS5SjySdP3gXBPvtG4GtXw/qsQs7S1kjmBlYoJlC7HkJJKnB3A+7DPqambsrJ/1qayhKFLlpu6Wmnzuv6XYdr+gQXqyXERltbuIBt9vzkKwf7mcFjgjPXrXO3fii/ItIYzGI5w4a5VCxQ9gw6c+vFdpfWy3cHkvJJE+5ZFeJhuUg5B546jkEEfhXA+INONtfpDE6+Q7bg77csvUxspHA68nAPHNFNqWkjTAOE1yVNWtVf8SnbRBIUgd0d4j98NkSFusZ5yMnkHkCpJ31Gyv45rL5Y7e4ElxiUp5abTuwgyGx6d6pNMgjW3hWN4Fba0QkHlEZyrKOx9/m9qtPf3Rtjb3P2cSFCp3s0hjOPlCkqBJ9QVNbNNnp1IOSaXU3fD/jhL+0mlW4tr5OiyIhtgjDtIH5Geo47VbfWL67jjPm2Ekb8u0TgJnPA3B8bhxxmuYOoWlha2guJ7t2jO1Qm9mVyOSQM5GPXd+FX7e70w3lnNfXUkcLAspk/wBcDjggNkgEHtgcnis+S2tjjWGjB35dfT8lfQuSXHkMWmllnklcZ3qudpJBO0knbnucCq0wupNOmazMXnmRVRWlMe1i2eSOenpgZrV1pnjtRd6fJBIu1RtDNmZRnDRkZIYcgjB6/hVC2MXnM08csSbFDJnplcszYAB7Y6nPXB4pxlpzFwkpR5v60/r+tjTXxJNprJJqUlxLao6RSRuEDJuIAfIAyMnrxXckMQ+QuwY2kHO4Ec5ryeKePVTaLZW8LP8Aaltma6RkQKMEsuQPm6YPIJr1V2+YrwScDnj8+KzqKKSaPIzCnCLi4LV3uYPjRnGgyqDiFnVZMHacE9veqPgwxo0yRuRG4VfI8wYRlHPHXcR3GQa3tVs0v7OWAkK5GUZhwjj7rfhXJy6bq0ELvb2ha8iXaHR1IJ7HG4N68c5pQaasa4ZwqYd0W7O/+R1N/f8A2R3RLG9udsZkZrZVbA9MEgk1NY3KXlus0auM8NHKhjZT6MD0Nc9aeJL+2jMeraRqZljTLywW5fJ74CgAj6Vs6XqVvqcSz23mBD94yRlHB9CpGfx/Kk4OO6OWrh5U46x+ad0SygbtpGedoAB9M8n0469O1MIBIznGOwqWUk4OMHOeuMflmoC2SQxII65qWiYgADyeR1yPX0oK4O7vnOB/SmMeRvYDpyTgfnRgDgrjjj2/CpRdh/UE4ySeuamU/MNwOMgn5feoQcoR796lU4IK8Drk9T/jRYmQ9AM8EH1wQfenyK/lsIpAjYO19u7B9cU2NsAt0PUkjH5//XrnNY8QK8O2wdpEUMJJVyjD0CMRx7kD6VSi5aIdKjOtO0UZd/b65b6gNPMv2r7YyEuYyqJg5ZQ3QAj9eKuX2oaQbe+truWWRJHx5EULgxEf3SADn3rD8Pab5t5BbwMlqJFLk/Mzk55IJYkk/wC1XcWGm2dmyyQxBrhAUFxId0mP948/lxW0+WLt+Wn9bHqYmVOi0pu78tNe/Xt0OLvkt7HS7ZoZLoStKZIYLggyoGUqC0YO4oST2OM5OMcZX9lWP/Pa5/Jv8K9Ivo4rmD597OAwVkxuGQVOCeMnOK43+xrj/oFP/wB9j/4qlCfd2+Z04PF3Tblyv1X6np5b+EHB9D1+tNBJPA5Pf1rA8QeKLTTHQJC96GBLGF1wgBwdxJ7c1c0TXdP1mG3awnWSSdDIqdCoBwc+4PH61yqE7XtofOPC1YwVRx0ZqqDg4IwOuD+grH8U3Rt7BIUwWuH2bFQNkYPPPA+uK2YcSx7grFeQQy4Jx7GuE1iZr/Ui0YMLuFDB/wCCIdVBHG4/yrahT5ndmuBpe0q3lsivpkJvZIra0WdJ5mMkrzfOUIB+Z8cDJXoPauy0rRY9LZWhKM7bvtEzp+8lJx3HQA4wPSp/Dlk1lpirJIsrysZSwXAweg/AYFaO0kcZGP1rSpP7K2DGY11JOEfh/MxdY0WDVXjknuLyLbg7Y5SquB2Ze9XNvlKFjUIEwAB0AHYe1WmjVhlkyQOM9aiZVIYFcAflmsG3szl9rKUVFvRHP6fGNNa7tHkiHmzNPbKODtbkj6g54qta6Hp1rrd1rCW6nUZ+shJwgIwdo7ZA5NbksIdeVGM7gSO/Y1WdCfvD0y1Nzd9DtVXmbd9XuMDZbI45x6fiKhnSO4iMUyLJESPlYcHHrT5AT047E4zj3qMDJwCMcjB7D/CpLjpqiIWVibNbb7DbLbr8yxLEAqkdwKzz4a0wW11bRxNHa3fMkW8ugYj7wU5Cn6VrBsKTtJwMgk9KTzGA6soPU461SclszSM5rZnFXGimC9trOaTy0hIRbtCIgVx8q4B+YEcHOasav4VXVdHnt5rOBbO5i3YYBHG0/d3DnGKu6pZ3qXGp3969tc2saqbRY02yWwAwzFj1J/SsrRIbmyaZLfUrqWIyCeNpx/q0c4EbHr8pOSPTFbKTktzvjN1afMml303+7bp/W75VOn2VuEcpLbRxRIxO5GOQFfntjrmqd5YHU2S3j1CW0uY51eWPqWTnMZPQhvUVpeIIp7eBbi5eQo5Do2MtkLg717HncAM+lUNfE2oX7iIQgG3iBJbd80fzKflxjLfzxWltP68jZa0/d8/wtoS6Bo1n4e1N53hupYSvnJaLMXWGNcEIgJ5C8t+NeowzJPAksbLLFIoZXHIYHvXkZsvPeGO4ludKlnQS27RMGe2nU72hD5wVbP3emeldz4WvksdL/s67eOCSyUAFDlZUblWX1J5Uj1yKiaul1PLxlFyimlt+T/4P5nR7CGYc5x82O9QyEJGWIVVHGX4x/wDWrHuJNX1CF7m122EIG9YbgEySbe7AH5Rj+GsXTNF1W7nuNQ1HURI9wMRyGPayr6BOij681moLds54YdWvOaX9f13LXj3Xp9K022+wMxuLiVUWVEMjRA/xbe/+FM8Ly+dpBGiQFZ5WLXdxd7lxLz1XrznIA4FbMenQJp8drKvmEDDSHqT65PQ1NbW8NpEI7VAkZYsUB+8fUn8KFJKPKjf2tKNH2cVrffv6/ovmZ11p97cQDzdXmiYKMtHGEy3cj29jWHqt7r2hENJci5tCQsJki3HO7HOPUdKmkh1y1u9VeacyWU0oaOTd5jCEqdyxx/8APRTn8PWp9RZRpsaXJAjSHzCQC7F+2B3xgc1SdnrZo2oO9oySlH0X4dSzba5Y7hHMTboV3CQsDGR/vdvxp7+IdJibZ9tDAqW3IpZQvc5rkPISTTrqZ185403PpykL5wzncQepX24rnbTWNTn1hrG1sDbmBVd5LiPy22v92LAJG6n7ON2kbywlJytdnrEWt6RLD58OowyxlSw2EktjuB/Ssa78TNfCODT/ADbWORlj86aP523f3F7DHVu2QKpRkeQsjQrFECB+7Ay5I5PqMdM0moWhaGa9EqQz25860Uje8crcJuHU8gse3FJQitxQwtODu9X5kmozvaX9pomoa1599ex+ZArMDGu3qW6ZB7A9SDUeoxNBE0Us6vMxADxnzCGPYjt/KuPXQ3hP27V8a1ryTbg8QVHjUD5UBJ2oMDJ68k10sOszfaprm1sQsu1Uik8vcImx8zF/48e9aRi7WOijCotl59v+B919NS9o979hmN/f2lxDJjy4lK8EdCwA6D0rRfUtSvrlfsJt7SFwRGlzGXmkx1IwduPaqMs2ozWm+6vDfkKN+PlxnplRx+VRi6uI7Jre3uBpr7cLJLExVPovTn1qWru5M6Kn79k5bdWvut+hKt/qomlSS8jC9WCxgszZ/h/D9axN2of89rr/AL/GrAtJ1miaSdQu0mZicOzYwuOypnBI6kgDgZpPsVr/AHn/AO/tVFxV7r8DqouEW7L8Du9a0/S9P0z7PHDBbiR1VQIg4yTgbh6Z6n/GuOTTbyDUIjaXaWcUPzNuj+fd0JH4cd60by70sXttBa/adc1iGB0EsmSdhOWGOAxJIGOgAGSMVc0mxubnUHtpre5gu4wJmvCwdYyQCIyD1P0yBTpQcN/x/q55VGUqFN+0b111/Oz1t6/cVrS51adpI5r66kiEv2YRwEDYOoZnIyTjrTbic380kFmYolZvLUDPLZxknsDzWp4gv4/DEX2zW54YLQ/uxcgMVOezKMnPfNYcGoWV1aW5t9Ss7iN5Fdp4Hxgj7rOTyoBI4OK2i/IujJTfPGPpbb8vL1PT41EcaoOigAUp69qyPDyapAk0GprGyqd0cyzFy+SSRgjgDjFa9ck1qfOVIck3G9/NDTjPIxmoZDkEnr29vepWJA7+lQu5Cg9eOtY3CJXkBCnJDHvVaQZBG7cp7+hqxIcIxIwe2R09arlgR8rcNycd6nzOmBxuvePdB0HxPBoer3jafdzxrLDNcRskD5JG0SYxkY57cjnPFdKGDorRFSGxgjkYqtrel6frdnJY6zp8N7ZOOY5kDr+HcEc89q80fwP4j8FO0/w41Xz9OBy+g6q5eLHpFJ1T8TjPUnpWyjCStez/AK+7+tTW8o9Lo9P5GfbI+vvSAFcblOf73rXz78RfjnqOlabBYWGiXWjeJRIDdR30YZY0HPyH+MN03YHAPqDXpnw18f2fjzw79q09ltdSRfLuLbO5oHI+97qeoPfp1Bpzw9SEOeS0NIVoTlyJ6nZfaooJVhlmhWQYZoWPIBPBI9Peqs10zyWZfJhkfy0myN0jMTjAA5GOPwFYOleF/wCyJ9RvU1Bb3VryMxR3F0uwIT17kn6Ust08As40vnV7XMRIhzyR94jsw+Zht9QOtRGKep6EaMXL3Hfzs+3376FXXp0uJHt5P3EFspRXD7yiscHaP+ehztArJjNpBqL3CAANKtrFExC+R3YH3GAT9cVHcT26X6xE3cMSbpYyYD+6Zv4icfeJxwe5q5ptrHZpcy3MpW6uY/OLzDd5bn0XjJyOa642UT0WlCHLE1YIYiWtJ4ZMqgkHmYYbuqn2PtV/wekc2rJKGnZvLaaVZip8ttx2hccHB3YPp71iXolsdMto7a9kuJois0jyksZgeWzjp/Kuq8BadcWWkzTalbwwXd1KZDHHj5U/hHsO+Pes5u0Wzkxc+Wk5N7nTvlBx68k/pUMkmzLEkPnJB708OQST6HIJ61BMRzlfQYzXPpc8OK11ITIzgM2Bu6+g9aR5cDZx/npVeSTEhC9fSonfqTuDduO9Dep1qnctKQz84zkMAe+O9VftYe/e1a0nKeQzm4ZcRY6Fc+vfFBl2BWk2KcjG44HPbPvWFqertdRy2tiSsTrteY9Sc/cRfcZy3QURV2a06MpvQreQ95qEc8DrEBGUWQxEusY6EE+v0qlbI0qwzWjJaHBheNm3pjd8xPfd6HtU073UM1u9gshBIhli3qAqdfMOeu3pgVIq/aPMbAjOeYmYZ3Z9ux64611K3U9OK1a6Fg7rGOd2hN0AS+4HDbM/dPYfXvUGoXNuZkYyK09wHdI2OWSIL047AEjJ6g+9aFu4WGWCEFbu442SghZAPY+vTmskpbpqMVxcrFbTkRoUdvlZAQBtYdU7nGelEbXu/wCv6/qwQV3fr+fyEUMIUChZ5DuJWUbRkfw8dhwSfeplae2RYo3f5QCdiADJ5IA6cdqt22iXV80jwJE7CLyi8isgk3DJIB/hJ4B5ziodSsZLNJcSQTIuxljjchVYcMpb/CnzR2KVaEpct7+RJokUV9NN57tAVY7cAsZBjk/SqMlzp95ZyxSRXMWn3LDck7vBK5B2j5Ac4PY9xVuGQNKyM26DaWaKIjKccKcdvrWJaaFuv5dTu5CNRYARHO7YPUH6dKlq8nd6DVNSk5TlZW2NJdPV7eG2YXNzAz53PhguDwp6cDjg9cVb8hv73/jpqnaR7VaFGIjY8TGT5TzlhtH3iAvBP+Nbu6H/AJ4wfkaJWiRUk4OyOl0m7hlvkg0y0it4UQtcB49kkbfLhdvBO4H7wyPkPXIrUk1SxSN3+1wsEOCEcMc+mB39q8+tWv4rdiyXt7bTfdD26v5O4dYnxyq4yAc53VY8m5isb2C0S5h8zO66e1EUsSseAp798ntWnsUeNUwEZS1l/XW7/r5jfFMsepSg3QE7Bd0dvMpj28/dKnjPv+VdN4T8P6Xp9tNd2cNrJNekSSTRwqu4dl9cD3rntQsgkoad7gx3K4QplySo+6R13d81c0zW7Xw7CDqs8dtp07YiYjo/fgdAf51o1eNkbYiE6mHjToN+i6+np/w521NbOOOaqW+q2Fz5Yt723lMgBTZIDuHtVzHynFccotbnguMou0lYhY8Y+9xj/wDXUT525PCseT6VMwOevPT8KgcgEgHJ9xkVja2pcSpKSXUHB65yefr71CT+ecHP0qaTHzcYPfB/zioHIVhyeB1zSsdcTOubxYdWtbL7zzxPLkNjZs9uvOetTMSHJBYHt0yR/SsHxRqOnRyLbTtc/bIiGQ20LNLEW4BXAPOT3/GiyvdaWH/TdIiSPonlz8t7kHp/jWjg+W53Klon37nnfxK+Clt418R3OsvrtzaTyqiLEbcSIgVccDIOM89e5rlfDvwV8VeDNeg1fwx4j06SaPgrcxPGkyd0cLu4PH06jkCvYL7xFd210YLvT4opvJDoguQxZzwFAH/66p3HiqaGC38+xSOeVMhHcqWbHIAAPT610Rq1+VR6fIlZepvmtr6lkq11q009+qRHToQ6sQWhincZdlkIBYqOBxWBf6gmoCOV7uS9tI/l+zkgK5LZVG28s/GTnA5FJqmr/wBv7raKS5jkTAW0VSokY9N/PK9s9qLCGL7NMPObfOTMdhwwHTaGP8IZeDUxjZanq0abTXMT3EKT3q24ZvLTmfb0PqD1xjjGOppmsB20+6mtIrg3DQ+TFIrbXQbvc4BHfjOCat2NuFhWIGVkICSSNgM7f3mYcE9s0kkUkSyW0IRpYl8wqp+XkZBJ9fT1NU1fS5u4qSfMyKWa2kn0q2jsPNSXyoibSbyiFBGTkZYru3cYAwOtepE7MoAG9MDJA/LpXm3w9sH0u/SB4o1gjt5JyWYvLkncXY9hjjHtXYnXtNjujDLMyMYRckbD9w/+zYGcelZ1E20rbHkYu83GCWqXr/X6mvDvMSlyQSMnjGD/ACps0eEba3zDkBu3+Fc3YvazXgvr3UruO5WQzCFHKxsnZSvQjHaqWszR3l1a30ks0IVsW6JIx34PUgcFeRk0lD3iFhZc9r6en9XN24UiXEjAAZyBwPxrH1jXbfSZIkNtdXdxISVgtArPgDkncwGMVmwzajbWEdnc3YnnR/3rs3JyST83sCABVZ4orWNGhgbbE+9RDgGRj1yO+T1JqHTV9WdkMM2veY2K8vWuFi1RLi8W6d2KBQLeGIH5VLYUliDtI578jve0uNUkt5LYQxkKeY1OB1zggckjr71i3WpF7i4Rbbz7SFD5rKcsjjBKqDwRgnJ7YqSwjtLqaC5tfMSKF2CoCSs25QMtnnjkj3PtVqL2N4x5U4o2JFEMqom4xzbnB6EEH0yc59KLiASaiRDCS20LjOTuxzxjP5VZbc8m5twUAKr79o/GoGcgebhJXkKqqyybN3PIB6k47Vqi1O2oklus1tseV/Mhc4dcgwf3Tu/pUclyskDWGrRLLAsL+S/3ZI5D33dFyfTj14FTXbzo4aymjjm3jJniL5T0wDiotRAvJYp5pnWWJhKr7MA4YZJA4IOPu+hpavQSbb1X/D+RbsLi3sdNMb6nGunktGrRXA/cKcAqwPbnr1BHvTJPDk2myrLatZ3trnKLz5p9MqTtb6/pWRHNFFMPLgRbUNuknKhRI5xnC+57Vota+YlxLaoYYoU3yupw6j2z/MVTTXW39fmEoTpyvzWvvpv6+ZXeOW3uFju4jaTOdzovygntz0fPr26VG0Qk1PdbQIBx5lxNM+Bjt5Yzn69a0vDtxd6qb0rCbmC1+7C8myOSQcjr6/lU2maRNqtoNRtJb+yaXeDZXce2RGDcjPYD+E46VMpJP3hVMTGlPkq6P+v6109TEt7m9uNb8m10qWHS40Znv7lgjSkDgJF97H+03XFT+Zcf9BbU/wDvmH/43V65E1rO1vqDKh8tmVF+Zj1w2evXFZX9oah/z7Rf9+loUblUqbmrt3/r0PUpNBVLlZrC8urLaAPKjbMRxnqh479sVS1j+0LZDcXdpbXyRg/PDI0ToMjGF5zz710tV4po76zZ7d0kjkBVT2PUc/jWkZa/1+Z8pTxM01Kaul/W61/E4OGeNIpr6JreJHuGCGOYttOOck8Z9asXESm6jhNikkTogBddy5xywPRgfrxVR76BpHR4ZIBbStbNvUMJJBjcUIzwc8Ej8K3NK0GWdd1+skEB6QxttJH+0R/TB9a3asrs9mpUjTjzzdv6/QyL+ztLWxMMEMUZY5G3CDHqP89aq6ffiLUhc6jdXVkSgmW3tnHlyKEAcYPRd3I9j25rsdV0YSQKLLMTp91RjGcdTn6fnz61w1xpd7Y3SjV4pYtOO4vcRzKsispJX5R1UqQpAwSR09cotNahh8RTrQab1f3neafq1nqkKSWdwjblDbCw3AH2qZy/zbQfp71l+H9P0+2tIrnT1b/SUDbycFlPIOOw5z0+tZ/iHUJpdOaQWUggEqtBMvzAsrZBdQc7Ce1csoXlZHnKjGdTlpbeZsy4EYVm6cH2/wAa5zxFqK6dA39q6pBpUdw4ii8pC03JxndyAMcH5cD1q1o+pxeIdLnkkUxuXa3nSN8FHxzg/TkGodJht7Jm054bcXccJLFIlXz4d20OffkAj15qOXldpdP6/rc3hDkbUt1/X9aFyKJLVI4YlwVGN2cs3qSepz61R1fUINMg+0XLFTI2yJByztjgAVgWfn3unlk1O6g02G4aG1XIXfGvygbsB8ghhgk5wOCMVS1fw29hZyS6RBeeZbyrNn7R8s8f8ZYZDZU4OM4PpVKnG/vM6404rWUv6/r1KlvqdithLf310rO5S5u7sR8ZOQrKcfewOmOMcirKXtg0Un7mR5Xj2xSyZLFD6fXqSK5xrpLa2la0ASwsyZvMMjt5a4yQQeC24/72D2rX0uyvtUsYr63mim+08vISEB+g67R79a2lFHdFxjpKxRs47NZXaGCKObJO+SQsoA42nnG0dPqa0bAp9okS6SFiMxnz4mTyR7dMg4GD0rSfQLOzsrc3N/BbtFuKsIEjUf3tig8H35x6VTt9EupD59jepe25IaMmQsVGOAVJAJz3Ynr26UuaLW41Vjb+vzJoI5JjEiIxkbIeJuM+it6ZxTLG5k1EWl/5VukDrIY0DFSw6Kx9BweCOCKoSrcT3T2tx59vYwIwvopR5csoH3TG69l55HXjrTohfPd6XcWr28OkPG8l5Eyfvd/8OzjPAxkH3zTd9/6/r/gA6zb20/z+exZu4L2NxHLeTxRh9gjjOCc8nJHLZ9DWi0d9cQQTzo0TkI2xUw2eAcnnAIHIIqtbXEZhSVpUkViUQo5XOTwcYznr7YqRJ7ezMbhzDGn7wzXDiSJSTgBVxkt3Gc9aGnfzNJpvW2pbl2WkUr3U9rbI+RExlAaUg9EVvyGM9aV5YntAYQFmYhWjnbbsPoRx27cVof2Ebu8snCvb2EK53zAefNnnaAPujP8Aez9K2ZdOtXtJInto3STkttG88YJBP3fwqLnBLFRT119Dh4/KIYXUptbhZMCBW3I+OB2G4HvWbeSb4XktbdZ7hCRFumKAdRwwBx09KtaraXVlJc2t4sUi5DWs8IPCZ43L1Rh6qcfQVWunIhjWWYMoQknZhWBPU0NeZ30mpxvFlWe/t4pmEiscQyyeVGSyzBUXcv8AvZwB9as6TdQXcEV3a71QLuCSnYpVsE7s9MDnHvVWaWG7j8hisUhQgtGSuzJGQjDBB6dO/wBKsR3UX2ML5Zmj5UrMeT757n3o1RpaVzc8pJZy7kXEQXARVzHjsSc8H3FSiSB4AZpkMiEIwHGG9Bntjv1rElubuHyY7FLYRheWkc49hwOfbkVYh1VrV0e+G14v3hdd0inccdcHP0PSritCZxdrt7G9aWYvY/8AQJBKkhZC7/LsA4bnuR2rQtPC9jAxeW4vLkkch3+UcY4A6etYvh/U5oU+1XNrLFauZD5bg71G7G4L6d8966V9Ws0thc+ZvVvlRF+87AE4A9eD1qJOd7RPNrzrJ/u27PqiaLR9PEcaPZRzNG4lBfruzwfwzgCtB4lkSTfGoVgBnHIH+e1cjqWtaq8hTT0S3BA5YAlcn15HT0HWqkOozwySb7+/KQcb2kzyevXgj0zml7OUluZ/Uq1Rc0pa+rZ3aJtO2NFUHnCgD6Vn61JbLps6X94bCOUY81ZNjg+qnrmuPbWUk1Bbc391JcKm8guQpz2AUYJ+uT7UqXFvufczK6sUlaXcrrkcDkfrij2Uk0yoZfJNOT+5f1+Rc8Q3tlfxZt7ZJrlUCJcuxTA6kEgdOO/fisb7Pbf8+kX/AIFSVpT23kaT581rcJp6pv6cEZ+8cnPP51S/4STTv+e9l+Yq4p2tG7PQorkhy0k2l5/5fkdPeeIfEMayzWUNncWdqz/aWYMJlwoO3aOMqTg+2CKlfUtWZ2NxNDbquCsaqArggevJ/Ct2bw5ayXhukmuY7ggglZOGyADuXo2cdxUTaRYaTYPNdXdx5EG6TzJX3GMH0OOgrovF2SR4UcRhtox1flr/AF/mc/p1q+na3NeS3DvaXjBZ0kbLxN0Bjx91K7C2vJvtklvc26xR/wDLGXzQwlHpjrmuNDyJqdwl9bXFpbsNsV5cKHhdT0O5T8pPuK1JPD8sMgvY/L1GVE2wh32Mg9n5omtLsrEQpztzvVrT/h729b9De1HVrPT033M6gblTavzNknHQc1zfi3UrK7tJLVYZ5JFO5JET7jDO1h/eGeCPSqvh6xR7xorHfGPLYSXSKzYGfuh3HJPbHTBrfv8Aw1p95MJZvtG9HEgKzN1B4rD3YSVzNQoYSouZu6/rb/gmLDq8V1pkNhDaXS3l1GqPH5ZRY933sE9AOeOorZuFhsLAMgjhigj2xk/w8YGKzLvQn0q7tL/QrZbiWEMs0MsxLSoR1VifvD3rH1C5ke/H/CQLqUKOnmx2trB5kcA/uyOMhnOM4HAqJRUvg2/roaKNOrJezem/n6W9P66FTwzYae9lMNTuiLiJmkZTcGP5Sc7j03Y9a1Y7B1v47+e7NxHaQsloEXBZWHJds/PxjH59azP7DX7JFJcTumo6jP5iW0iq22E9VZT228n34rQ8QwPZeF72LSEIKjMUZQsCOnlgdgRx7ZqZyu9HudFSanK6k9Xt/X9Mq6y1zqbW4sUDeWYroSEoVZc/MvP3WA6N659Kge91JUhvcC40+QsXWGLDpk/KMdwB1PSsTT5dVsrKW100RT3Fw6RW8yxZSNNuViQE4fau5mOQAQepxVzVvDU9wvz6le3LyOgYRny9qgjJABAAGOgp8qi7NqxcVFOz2MzxDdraTSiO3e2Q5lSJyFUhhlZBgZyD+HapvC99plpdtY27GDzwrG4JLSTTnkg5ztU84FX77w5szMNXkWGONgTeIJdmTktuPQf7PSuYu5ni0pdRtONk/MqWxJkYHBZhgHHQ56YqopTXKv67G8eWatc7XUtCsNQnaa5hPnEBS6scnHSls9As7a9guU8xpoRhTI2RjHRgOtSzarZ2SxfbrqMyugLyRIxjJIzkY6fStKHY4DQMj9OVOQf8iseaaS7GLnJK3QpaxpMOrKizTTROvyh4mwdvXHtzUVl4fntonEepsZGAAkMCkgjrnOcg9a2wuTxgk9OKkTPzEZwMduv4U1J2sZOrJKyZz1v4VXBM9+7K/M2yMDzPoP4a29P0mx00Ys7SKNs53kbm9uT/ACq4ozk4wTyeelOAzztIyOcnvTc2zOpXnPST0FIAcctkHJz60OGwRwSen/16kA/2QDjke1RXkgt7a4nbayxKXIz1wM4pLVmCd3Y4fxs4OoRw7coieYozyWHJOB144x3NcxJ5dzFBdWkbtaKAIVZcEsO+09eveununeaWeTPmPdjYkn8KKTyw9OK568smFzZWtrcRraorSBed0aA4Bb3bGa2Vkj36a5IKH9XK8OySc/ZUzIzhdikZZ+v5jv6CiGO9uZ/M06GJhJuV3J4BHAC54AHf3rIjlC6gsbJK0Eko8opxsLEbjkc9jn1xXd2kMNtEltbjiMZA9iev4mpk3Auc5R6FODQbmaZJ5LmO3kjG2EhS4B9WXoa2NC0IpEZNZkjubhmJIhUomM8H1JPcdKfBIqYHCMxO0M3zN6gVqWhwc85I4x0FSqjZyVqk31K+s2QcT3UUYsVttriRZMLcD+JWXtgdDVBmt1txdyu0alPMSNh99dwyVHsen1960fEsrTQJp0cMkjXHzySbTshjXlmLevoOtZE+qahr5dLGGP7BtVkxlX6EH5u5zyAOhFXG7SuTQ53BX279l/wf66EURmWC2BX7RO+VDQozqQM4bA4GRzz0zWoNKmExnNjfNKygbC4aNcDstaFqurvFHFa3un2OwFNsURZ9gA6Z4yPyrpY9yxBGkZ3AAZ+hc+vHGaJTsY18ZKDSVvx/4CPPnsp7VC0VhdgKNw8knOfXaKFs7kv5kMGpRzDpI6kgH0OTyK9ALEEKmA3cgfofekYsx28lT0pe1dyP7Sn/ACnH2UmtXkJ8uSUn+ITwhEPbPPU4BFN/srVP+few/wC/Sf4V1kgVyhYElGLLj1wQf5mqu6X/AJ6L+tZudnpFAsU27xhH7jrOmazvEVqb3Q762BAMkLAHHtWHouqTaZb6rHq0t9O9rtk3TQgDBUfKrjOecnnB574zWvN/aGoWAFu9tbCVQfPRjLhT6AgDOO9diTi1Y8j2E6NRSvomtenf1Lemsk+lWpAzG8S8MOvA7Vl3GhTWsMo8P3YsjISxhlXzIST1wM5X8DW5BGsMMcSfcRQoz7U7HFLma2MVWlCT5Xo+hm6FZT6bpMNrd3X2qWPI8wJs4ycAD2HFW3+XcSOvpUjehI96jYArnqD39fSsJPmd2Dk5ycpdStM4A5GD2FVpX+Q7c4wPpU8wyPm4YHHPeqsikNhSc52kDqT6YrOVkdFNIyFtZotTvLw3SkzhcfuhvVR/AD0xnmql/Y215cp9snnn2sHWFptqZHIJVcZH1qLU/EMdvHeyC0u5BayGNpAgMY4+8WzgDP4+1NsdOs1WC+MUE95IokN2PmLZ54P930xxRZrVnpRjJJSenQdJAs2tfaZgyta2+yHso8w/NgeoCKMf7VWwRnIzk9cfyokIYD+LtnNNQHDZIHOBnv71L1KWxk+Jld9Cu0iRJi6YPmNtQDPJJ9BXJ6WLaTVUtbp5VifLoUuiUiK427m6YPPHSvQCoePDLkN8vI49wf8ACud1DwdYS3ourOR7B2wrog3q6j+HDcYI4xWtOSSszeFRJNFaG7FuzRW58gXK/u0uHVDtDYKkHpnk5pkD3fnNdwahb2sSOWdHUYlTp06/X8DW9caHpK2rvc2Nt5UQLM8qhjEAOuT09gOK4jS4beRlkjazuYhdGZpI4XmcKBj50XJ3fdzkAAdauPK02aQmpp3PQ9E1MX7zwXMP2a7gbBjHIcHo6n+IY/KthSFHAHSuGFjmOO5juIrC6kDSQXDsSvXkgk4GR1A4roNK1Jzp8k2pFE8uUQwyRjf5wIzwByT+XriplFbo5a1Hl95M2QQMDj1BPr71IASpBDEGuZ1DWLllRLSS1s0wJHa4DNJs/vAKCAD6nNZgvLm6mkU3sot2wVkWYOhVs7eAfcdqSg2KOEk93Y6+51WytEZri7iXaM7VPJ+grNfxHp8nnRvFPIhQjds+SYEdFPfIrAgt0jBs4TK7vGYzchVIKtyTnOD9AD9Kbbx5h/0e0jS1tflE0jr8gx125G3n2q1TVzphg6SvzX++xcaLT0sore1liso1CwrBdsW2qG3bRjqc9j2rmbmW/wA6kJtO81WYBXtgSGBJBXPqOvpgir11fS3FlEbbzoJmYF1RhL3xjqQA3Yjmsq6gvbGN0UT2nmKRG0bsHJzkryME98EH607O+p0xg4LV6mShls7WeSGC4hcgny54wCxGQAP9ojJ/GuhM13eaWsE9vFEZV8p2eXYAO3I6N049apnUrz7M/wBtWDUTG4DrKnlmM8YJPTP61BPNZxxvNHNeaXcXPzGMMJY1Y/8ALUg9j0yPWlJcz/r/AIf8DR3fxLUVYPtflS+fcSvvKBlnEfk7RgcY6+/eui0DVLxJo2lMlxZuNr78b0AOC4x79q5azmdJgjXEV7uAWQWuVYf7RVgD/MVbtzNhd9wikOJCbddwAByGBBPYYJ5qlBPfYc4KUWmesZ27uSVB55yB7msceJrWO9MMcMskCHabhEHk8EZx9MdvSsyz1Xw7d6kNUFwq3kibBmZlLoR18vOGXrzj8aoWSqLie00p0uoixeMwFZTEhx8+0c57dO/vWUaer5kedQw8ZcyqLb5GhdajJbxxXVrFJZwwl0RJQXkkOcDao5Kknv6Zrd0LxIt1AhvlVHJZfMXJQkHBBHY5rDWw1S6ukIhljiOQyM+0MDgjOfmVBk5A5JNaq6DdyogudQXbn95EgJRQOgU8ED65NVNRa1KrKg1y1GvXr+v4nUDEgUhlMbDjB4/Oo3GWJYkr6g4NcpZSXfhtXFx5stiGLFcfIuTwQ3QfQmugg1KxnhEiXEa7/u72Ckn0wf51nKNnpqefVw0qbvHWPRonZSB1OD12n/PvVf8Ae/3v1qUMkib4XVlYY3A54HX+tV/n/vR/991KJgu5SuLbXXaR59SmsxsYNELbz2OWOzocEfe7A9K6Twv9tGi266kgSZRtX5ssVHQsMAA47DP1pkmt28wnjs4ri7MfyyeQnCnHTPrjB/EVkRy32nmGW3F4ltGNs0V0pddoH393UH2rtbb0tb5f1+JE1OvBwlFRfTS3/B++52FIeh9axNH8RWd6FEl1brJLueKPJUlB3Oe9bKOki5RlYf7JzUTutGedUpTpu0kB6HPWoMKQDjYSBkEcj/JqVh6fL3zUHUbjjkeucVzt3HEhkYEDgEc88Yz6YqhqUUktnPDbyiCZ42RJSNwUnocEdPwq3IWRCzNsUAlySAMep9K56+1lriJY/D0a308knlGRf9RB6s5P3seg61KTb0OylFt3Rlw6bINOsGsLu5tzbAwz2rN8k/rjPCEnoyjBBxis608R2NjNb2KmP7IXlRSpw9qVGfLlj6jBONy5HI4FdPDAbW0jhkmaeRCfMmYcyN3OOw9B2rNvdJ0+S5a9FihvAd4eMlGLAccgjJ7c0+ZO/Md6abdyeK8tp4BPBdRSRcjckg+UjqCemR3HbvWQniW3ubmP+z7a6vbVpvIa6gQeXv7hckM2OpKjaPWppNB0grsFivlB2YqXYqWbqSucEn1NLrFk+oWUNvE7WssEitDJCdhiAGCFwOMqcY70e6i7LdGo2AM5Xb0GO/1qK7vLeyCyXM8cW77m9sEn0A6n6Vxd/e6vpk0Sy6sGWbeYUypmkAO0cYIOf4RU2k6NrGp3kl3rlzLDACBHbDBkZO+9gOAT2HSq9nZXb0L5EtWw1q5bWNaFtbfaJUgCFY03IE3fxleMkdt+V9qNL8Ly2eqSanqSwJGZmdFNw3mgkAAs3Cgtj5scEAYGeR2EVqkLloYVBA+WQ5JDdMH2x361k6rdzWbQxSPDc6ndMfslow/dbh/G3GcDr+VNSvZILqVlHoWL2JJHEN0ivIFbyZU+ZISeFJUnJOehx+I6VRk0+SIZuIHl8oeYE2sI5HOB5sgHJOR9zHOOTitrSdO+zBLi6l869cbpJB03YwcZ6VoqiKxbgSNzuPWjmtohe25dEZEsF1dTLdvC73RQJsjcHzzj7xJ2jgdhj05ql/Y8ltCXnkECsSuz5VZgRkgEHB5+YAenfnPUOodWBGFxtx2+ntTJ4BNEqqEPl8qXAbkd8Hv70ue2hMcS46LRHHXP2i7sZYE+zQxRk7mVthfnJ3pyF3DBIzye1LZWV1aWUkTTbHwoKnhIl9UUDaTn8Kr6tCLbUpLGFl8qSI4n37mVwMsMdMrwRjisy8ltkeyvLeeeS+CmHfLMchCOWI7nPORzWt29Fszvi24+7szSvPtgv2kjvrWKSIKke9QpZscliTzu44ABA/OqOoiaRQ0/2qaeH96rRyYRz/Ft2oQAO2Tn1JqlcywQ25jYssnlfeXkvjnepPVvr61V+W9VWCuzKcPGwxz1BXHGf5VJfLbcI5PMSKNVi2gcLDwdpJJ+ZTx0J9aZIPM271WSAE4kQ/MB6c556880sk7PC32aGN5JflBiQLJwOc44zx1qeGNJTEUTcshfa8hIXcDjYPXJGeegAqr2LvqWdF0Rru1863RtjsQDcSgFhn+IouT7V1egaMLEia5lW5uFOIwFIjtx0wgOTn1JNY3heRk1CKOJx9mlB3xlON/cqfUGu2jyFXBK8454yKicmro5MROcXy9CtqGlWWpBGvrZZZo1KK/3WQHsrDkfTOKy7vwpEWt5bGa9jeCTesasu9zgDAcjjjj0x2roMg4ycEjJyOtSr84ZQoIPykE5zntUKbWxxqpOGzI9ES8itj9ukBlLnAyCVX0yAAfX8a1QRuHTBwAfU1XV1yMD2x/dOM/l/jS+byQDsU9SP5+9TJ31Oapecr2HXAjniMEsaSwt8rJIuQw+nTFQeRb24cpFEuRgZUdP0zinHBYDknPX1prEBScA4PKmpuEU1omARVjXau1QAMKuMfXt71XyPRPz/wDr027m8hA8u8KMjI5A5GPzqHfH/wA9jQ5WN4Qdrm1Lqllp1rbmzQS3V1CvkwRt/rAOh/8AHuT9PSq8mna5eSGd9Ta1UfPHFEo7r9059DV7R/DmnaTs+yxuTHwnmuXK9Txn6n862BXY5pP3fxPNeIjTd6Su31av/mc7b6RqDWEa3F7DdSbRn7ZaqSp79MVial4Xvo7hruzhiiuyQRNYOYWOP4WBJBFdza3C3MXmIrqpJADrgnHfFPc4B2nn86OdxKhjatOT0Xpb/I5C31fXk3R3ekyiXau1gAyZxyCR3/Cgah4mmOwaJbWr7iC8kwdVHqMdSa6iST52XOAADxVaTIXg4B6Z796z5o/y/mVGtFu/s1+P+ZzQ8OlpoJdZvpb+Tb86bdqSHORuHcCrl3PaWFoxkeO1tkx0GFUnpgDqavOSBnOCR/nFcx4lkiXUNAe6j863luWtirLkBiMqxH171GsnZnRGUqjXM/68kSx3l7eMxt7IW8KEfvr0kF/UiMdvTNTsWwocoZD3HAJ9celWJmxuD8Y4bPU47Vm38NtdwNDcwiWJuTyVI9wRyDWb9DaOpK6t8rDj6fXr71QubsR2rPAr3MpZgiRtgsyjOM9Ae1VLLQNM0+9N3arctcZJV5bhnCZGOAeOn61ob8LyBjHJ2/rVtJFx7nL6PYXV1qM9y9p9jBAcSFOY5COEQHsvr681vvpZngtxcajeNPF0mR9rMf8Aax1qdJozcbWdmnCAkZzgdvxqfPKjftYH06j0NNzbL53e5nQ6HdQMhXV719gKgyHccH1Hc1TvraxXWxPf3DWW0jafmJkPAJz0A7YHvXRrJgEMOcfjTTa282oQ3ThmnQYjVjlBnr8p4B96pTe7BVGty8MKMlSUyTg+npTZp44ImluHVIk+87HgCovMLRseRnOPqKz9W1q309DHNC8sh4UeWWRj7npUxTMowcnZaiXviS3REa0KyR4yXKn5hnt71z+t6jeXzMUOzym2qOFMingsSOgwTx3rGuLq8uNWF3LcExEgC0SUG3GMjLYGc889s0WtxIYGcStM5dlV9mGB9h3UetbciiehSpRhrbX7yWJVGrx2xuvOupSjxiE+XHhcjBz/AAnvjrWze2tvFp011qiCMqnmOF/hI52qe/tWFNcozoDdBHxhHYDJx0NULzbHBsN1O7vg/v5dxLHgEegzSs21Yqz6MnuNSi1CGIW2nyWyIu9NrAhg3PT19aozxMWgdFleMIWRnbaWyckED06Zq8imKLymGWjfMhUgHp0I7A+lRmwvJ1be8drHLk72kCtgcgD0HXNUrX0HfTcbbsJrq2l8qFLZlKfKNp3A/Nu9/etEwwQRjz52kdpzsYglAmMhQOx6CqEcttI8CLIwEgHl7CMpzgbs9z19xWpLYxNLJJBDLMsZ8sqWOCerH69eaOW25rFpaMk0SUnWCPMYM5DKjHkD1A7V2qzqwDI5Knoa47SNCvYLq1uJpB5cWfmJy3XjHqMcYrqTKn8PBPTPc1NS3Q5sQ4ylo7lwydQeAP1qVJwwVSc5BOBx6Z/mPzFZ+8YyF5J49PenJICMBgAeB7ZrL0OVwTRrRXAYEtjJIz6cipUuMucbAQdp9qyopT/XGOBUkbAAsvzDtUNqxlKijVUr1PJJ70xzlj5hyR0IPH4VSWbO1jywOBgfpTnmD8FsjHUGptqZ+zaY+YhgQVH0PQiqWyT/AJ+pP++RUzyYALjmqeV/vPUSv0OinHQ0oNeubG+sPtkq3Gm3eY/Px80c3GxRjqrjJGefrXXK4YKwwVIzmvNdK1Cb+3NUtWWNoWuQrBl3Zyu/ODwOfSugglnsbO0nt53EUjlDbFVMYzySON2f+BV3uPNscWJwqk7x0f8AX9eZ1e4HHamsTuHpWTr2oSWdgJI0ifKtlXBIOFJ6ZrC8J67feIU/0h1tiYlfNuvc/wC/uFQk5K6OKlh5VFdHWSMfQeg9v88VjX2s2doJfOkJaLmQJGzeXwpJbA4GGB59RUF1pyySSG5ur6Y5/wCfp4x+SFR+lY89hZSeQk1qJljuVRfOlkkxknJ+Zjk9uc8cdABQuVaM64UIRdpN/d/wS/Br9hf311b6WzX0tsoL+UMIMjI+c/LyOeCayxZ3V7qSTajdQOtpIX+zW/SKTH3XJ5Yj1wPbNWdbne1ito7XEEJcARxAIq89gPXv2q35zSMgOAMhePSk1bWPU3jHlSceoyZzzng9WLDJ/WqrttPOMjkc/rVS+v5U8SaNYBUMN4Jy55yuxcjbzj65Bq2w4BGBuJJ49qixaKqSEiTBbKSFQJEKY9gD94c/e6E59KX5QQMnIOBVTxNPJp+jX91bn97BGWTdyOgNZWh3t9qJuy97JEI7dZAI448Fj1zlT+lWoOSujSMHJXOgQIHdspukIOR1GBgCpht3feHYHNecaN4z1G81HTYZYrYLcna5VW45I4+bHau6MrHaf9vbwSO9KUOXQbVi5PdRW9tPcSvtSPg4HzH6Dqc9sda5GbxLcXhkESx2lo3SQthie+ScYPHaovH9w0ZhGFYKSQD0ByBnA6HmuosrCGw/0eANhSPnY5Zs88mrioqPM0awUYR5mr3OZHiPVJnKW0r3J3CPEFsz/PnGNwGOOtJd2ut3N0I7tbxlLFvMYhUXHGNoPH/AsA9q68yv8y7zjkdcVSuXJDA44xVc6+ygdV3ukkckNJ1KCQeVGkYZdpEjKMc8HCkjnr1qzZaEVIknuWVUHEcXzE/Vj/LFbY+eNXPBJIwOBTc5AB6ccenWpc2wdRmUmiWEaOSJ33/xSN39vSsm70u/hnkisbZ5LQMPJAlB2DuTnnNdT/A556EVCp2tgdAM4PNEZO4Kck7nOSaNcI9reyxhPJb96gbPmEnaqqAffJ6mqs+p6RaSXscuopdXNo5SSO1hLgMDzuYDgD2zXV61pNrqemO10rloFMiFWK846H1B9K474eXIk1PW4Rb26faJY97xptbhMcY6cdQK2hqnJ9P8/mU5zeq2Og0DS7WfxPd3im1ns1iR4ArBvvAH5h1yAOM4IrtFVRyFA9gM596aqJCqiFFjA7KAAenJx1NKWKlxnIDgc+4zWMpXInNyYyRlaMNnCnlQflJ/Drn2qBjkAjn69f8A6xqo1nBqE7T3kayyRNtQkY2gfT+tPSVmvLmM42xRqw+pOKFCwSVi38wdgDxnimqWIJI4PXvnHb3odv3jL/dxg/jSAAyDPc4rNxsJPoWYmY5IIPr+NTp85O7ls4UqO3eqqDhOSdwzyenSrioNiDJG45ODioY2V5ovNJ3Fxxg7HK8ZqxF5m5ti789EHU+wzwKWQbGOMdM8il2BFZhnPTk0raibuhCSpG44z0ycH3FZv+n/APPG0/77b/CtOJiQfTeUx7Cue8+X+8P++F/wrKbsaU1e5//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph illustrates a relatively acellular fibrosing interstitial pneumonia in a patient with asbestosis. Alveolar septa are thickened by dense collagen deposition (arrow) resembling that seen in usual intersititial pneumonia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Asbestos-related small airway disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    H&amp;E-stained section showing junction of terminal (membranous) bronchiole with a respiratory bronchiole from a person with asbestosis who was an ex-smoker. The walls of the bronchioles are thickened by collagen and show mild smooth muscle hyperplasia. There is a mild chronic inflammatory cell infiltrate in the wall. These features are consistent with asbestos-related small airway disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grade III asbestosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph showing predominantly Grade III asbestosis, partially defined by diffuse interstitial fibrosis extending from acinus to acinus The respiratory bronchiole at bottom left (*) could be classified as a Grade I lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Am J Respir Crit Care Med 2004; 170:692; www.atsjournals.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    H&amp;E-stained section of lung showing Grade IV asbestosis with honeycombing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 307px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEzAYUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD578A+Fv8AhLdVurP7YbQQWxuN4i8zOHRMY3D+/nPtXYS/CNY5vL/tqQ4GSfsXH/oyqnwFsrm/8TatDZWNxfTf2azCOCQo6/v4fmyD29K9j1zw7NofiizsdSmuZ4p7YS2srLtMgPLI46ZU1vSgpbnoYWnRnG01r6nid/8ADWWwcC6v5FjPIcW2QR6/fr0jwZ+zjp3i3SBqGleOS0YbY6nSeUfuD++rc16cwaXeWcpMgWJtis2795ngqOw6V698OZfC3gv4fRTxarbtBL+8uZycFpSOVC9cjpjFVWjTULpWYsTh4wS5FufPfjb9n7SvCFsr6l45Z7iUHybaLSd0kh9h53A9zXG6f8KJLmAS3Gqm3B5wbbcQPf5xivZPEt7H4j8W3+sQm58m6VUtDKuGEajBAA6DOfer0NrDBG/nyIkeMZP05NSqcYx97Vv8DehgYtXmeS2fwSiuGcN4k8sIeW+wgjB6H/WVbj+A8LeUZPFDRpJnDf2fnp9Ja9x8E6JZ3+nvq2s35s9KV/LhVZAjTAZG5m64PbHPHWtK9bwK5SGy06eck8lJZE4xnILHk/zqHFJ2CVPD3tGDf3/5nz1J8Bts4jTxMki8/vFsxtH/AJEp3/ChAZ3hXxL+8ThgbHHbP/PSvoKTw/4UcrHa6jq6PcEKYo8OY89CwKnjp61x9hbRXHiO00+8uWNuL9rdrtCUEio3XHuVx/8AWoUL7FQp4Z3vB6ev+Z5fb/ACS6uUt7bxFvmclQpscYPv+84H+FWdX/Z7gsCTD4wjuII1JmnFhtjQjrg+ad3pX0R4sMdhLdW+lWX2aCPEc00S8sxAIBPXpVXwZ4dGtSW817FKmkWjCSOJxtE8gPGR3Qdfc1KS3exMqWH5PbWsu1z52uP2f7yzht5tQ1W5gguADHIunbxg8jdiT5T7Gm2H7P2pX92YrXUbgxbgBPJYFEC55JJk4+nOa+4B7VDe2kd9aS21yu6GVSjr0yDUqS7HAqlPbk/Fnxz4n/ZsutCjEo1+W5gwN0qabwpJxjiQnj1xXMN8HER4Gl18rbuVLuLPLIhOC23zOcemRX2bP4S023tZHtormSZYnEYe6kOTt443da+e7XVxb2ULeJNPvJNWguQQJIWhjVM4xIxwG6Dnr71rShz+Z14eGHqR5Wtf68xyfslbhkeNeO3/ABKv/t1L/wAMkf8AU6/+Un/7dXYaV8VdT03UEk1O6ttXsLmUqIbWLbND3JTHDqvcZzitjW/iDrWmxxw2kmm3sk9q19DcBTtZC+EXaCOcdT2qfZTTsc/1OpzcvU83H7I+f+Z2/wDKT/8AbqzvEP7LMmk6TcXsXit7tohnyk0vBI7/APLb8a+ivA/jW21/wPDrt0YoGjVlvFU/LE6/eH07/Q1r6zottrsUJlu7yKMA82s5jEinqGx1BqWnGVpdDGmoqSc9j5Q1T9mh7Lw5Dq0fin7SJAjGOPTvuqw6583p07VmaV8BLW7u7aC88WNY+euUeXTeN2Adv+tHODX2kun266etkIwbZY/KCH+7jGK808V+GJ9PtLf7GJp7SEFSETc2SeCyjrgcZpqzO3CQw9ZunPRvZnj1n+yvHczzwHxqFngbDp/ZR6HoQTMMgj0q4P2SMn/kdv8Aylf/AG6vZtGutQaxQeVIdWsIg8W5TGbiEkZjYEdQMfjiu6sL2C8gWS2kR1IyQDyvsfQ1OxzYig6T02/r8z5g/wCGRv8Aqdv/ACk//bqQ/sj4H/I7f+Un/wC3V9VBsmmSypGpZyAo6k9qDnPjuD9mSc+IP7NufFAiRw5hnWwDiTb1GPNGDz0reH7I+Rn/AITb/wApP/26vcPEV5b28uha2scEjrM3+qIIKMMM4OOTgCuu0q/t9Rs1ubSQSRMeCP5UHTWpWhGpGNk/zPmH/hkb/qdv/KT/APbqP+GRv+p2/wDKT/8Abq+qqKDmPlX/AIZG/wCp2/8AKT/9uo/4ZG/6nb/yk/8A26vqqigD5V/4ZG/6nb/yk/8A26j/AIZG/wCp2/8AKT/9ur6qooA+Vf8Ahkb/AKnb/wApP/26j/hkb/qdv/KT/wDbq+qqKAPlX/hkb/qdv/KT/wDbqqat+yjNZWMk9v4sa6kQZ8pdLwT9P3xr61oIzQOLSd2rnxLpXwBtNRu7GGPxisP2ncAJtPCuGA5UL5pyc8ckVn3PwHu7KK9k1HWDaJabRJvs+dxbGB8/IxzkV9hax4SsJrxtSsYLe21blxcGINlsdSD36HPtXOeKLy5uPCc+n3qkalA8ZJ2f64K45GeOeDT0uehRhQqSVo3Wl9Xpr+R4D4f/AGZptXc7vEstvFgbXbSyc5GeQZRgdK2pv2TlhieSTxuFRAWYnSugHf8A11fTPh+RRpsFvvDywxokh9CVBx+taLxrIjK4BVhggjrUXOSty875VZf13PlGz/ZTW7QSR+MnEbKGVm0jbu/AzZqx/wAMkf8AU7f+Un/7dX1QihFCqMKBgAUtK7MnbofK3/DJH/U7f+Un/wC3Uf8ADJH/AFOv/lK/+3V9TyHajEAkgE4HevPNH8f+ZrPk6wlta2cwzBKGI2nGdrZ6ngg46GmuZmkKUqibitjxpv2SSBkeNQT76V/9urJu/wBlu9trUu3iMyzg/wCri07cpGezGQc456V9dwzRzxpJC6SRuMq6HII9QakIzS5iYtJ6q5+X3iHTW0bX9T0t3MjWV1LbFyu0sUcrnGTjp0yaK2viv/yVLxj/ANhm8/8AR70VZL3PVf2Khn4p6p/2Bpf/AEfBX1r4u8K6Z4ntoItUWXdBJ5kUsT7HQ9wD6EcGvkv9in/kqeq/9gWX/wBHwV9m3nmfZpPIIEpU7CwyN2OM0JtaoItp3R4h4gu9Hs9ZbSNa0wyzQ/uRIrhnRDym2TGSfZgeK5qGzhtpbq5SN4rItmBZNkjFAM7twH16VpWOuRSa3O/jPTJLueKZUklJ8sqQcfdAy3HbPSu0uNO8M+ILsHR9Xt4DOCWgbjZ2+VCRj6V0XcNGe63Gi1GSe2+6+R57r9lfaasLznyri5USQW6YZmRujMRwi/mfaqLafe3PkQMIZbhZVwM/uyx6DH9TXp3xK8JXrz2usWcstylsixyW6RBmVAPvL6juRXm0tzAl+YYtSswSMqoY5I+o/lTU3ZOOprg3TxEXzSsz2eP+zvDaR2A0mLy7iNZJH3Lh5OhyW4OMda57xjqdx4h0u5t/DURjWCTbKnyxmZh1AbGOAOx5zWD4b1W/vND1s6VcTOunRI4coHXOSHCkj5TgZIFdD4Tvxq8LWmryWz3Mqb47iEbGcrg4cDgnjgisuVxd2cao+zk5b8u7/WxT+GDarFcSt4iRzslIhmaNUbB4IYL3GBXReCfASeH9Wubye9W9iV2NkuzBhDkliT3POPp9adZ2N5qEqraAQxjO6YkEr6ZHc9eK6VPD9oIUUvc/KQeJmAJHsKUpt3tpcyxM0nZStc4jxZ4tg8OeMoYws8txeMIls4juNx8uN3ooBx+VZ8Ooa7q5kvdZv/s8cZPl2dmxjSJgcDe3Vz+lMbwzav451m9uZjPPCUigaTloV2hj7c7vyqxe3H9oazJpSKFSOHzpw6YDqThRn06/lTskl3OmlSgrO3RfkbFl4ovY5RG86SO6DZEy/N359/8A61Pv/G2o6TcQPfacl3ZzusKi0yJlY99pOGHB6EYql9jgeVmhZlAOJFQ4DEqB+HGOmKx7i3efVIHulaeysl+RHOXlmYYzwOQFz+JqeVFvDUp3909Dj8W6Q5Xzbg2wYKQZ0Kjk469OtaLLp2t2U0TeRfWjMY3UgSISOo9OK4vS/C39vaXONZDtYTyEpAVwxTPTPXB/Pmu606yttMsorSxgSC2jGEjQYAqWrbHl4iFKnLlpvU4f4o+DxqXg02ugWdpFeWRE1qqoE2AHLBCOhIH414vpcFxq72raTayXN40bS5gl8l4iDhyeeOTz+eK9n+InxIs/DLxWllCuoahMCBGj8IPcjPPtXkejaZdQwx3Nzvs9R3tOktuwDJubPPqOxHTmuqlJqF5fI7MGqig7/I6XTNXHhzSb+wvbiK9dkkivIYhsgjBByTLjDyjIBIHP4VseAPFGqaYFi1HTBbaAyAQ3LRyqsbYBx82SQRnkADNc9H4Xh1fTreLVp782fnecUtin71i2W3scbSc549a9B1fUknsoLWyhuEjUJELZxyRjAUcnJI9frUTcfVsudNS9y177s6bT/E+n3sk0aXEPmRAsQrbgVAzkHGDx2rMi8Z6feTw/ZzMLUuA11sHlKT/Cx7fWiXRLmW4j097YTaMsQJ891yrYIAjKgEY45PrXQw6fbvpq2k1tEISgV4cbl6dPf61hocD9hHo3fz2/4JxOqa3LqF9YafpMhfUBIwF0v+rXjO3fjkYxnFYK22rQXlwj7otRtZd7PbvuDgrk7s4JHuOleqWej2FjIZbS2jifYIwV7KOij0HsK5PxnLaWepG8SaaK5hj3TlANojwepI647CmnbY7cNiU5eypx0/r8B+neLLtFWS9hjlidsZi4K/mcGofEMw1WNGnurqKzhBaaEKVE5JwI17k1y+hWJ8VIZHhWLR4G3o7grwO7Hv64/E1uSS2dvqdlqEJe90yIHD9vMHVlz6Z4/Gi1mbVKFKFS0F73b9PUtahpctxpen2k9vOzmGZfIUZWNmGVBI44GRUnw0FrZWM9gJXjnVwBbygh1UDAOD1/CuwsLiG+tYrq3bfDKgZD7VxXjcLc6/ZQ2lqFvY1843RbZtUZ7+39cUX6HNRqyrweFnot/S1/67nYpq1sLFrqdxDEjtG289CGK/zFXIZ45o1khdXjbkMp4NcHGZ7jTbqO+tFlju1Upc2rjEjZyCSMqG9ziuemtNc0kvcWa3lvDGeGAJVs9yASpOO/Si1yIYKM7x50n+B7EDkUV5Tb+N/EEKRrNb25J+750bKzD3wcflV218d6rPbtK9jZQ7fl273k3uOoGAP1os0EsqxEeifzR6TRXnEHjrVljaS6020Kk/IscpDEevf3qyvjTVbu1BsNFCuOZJriYCNB7Y5Y+wosyJZdXjul96/zO9LAdaqX91FZx+fNIVRSFxxgkkCvPJtZ17VuftDW1sw+7aqAx/EgkfhzWRe2d9PO8LXJis0A2rEGdmyedzMefWixpHLpJ++/uPQ9Y8X6VpcPmSzGb5tu2EBjn8/at21nW4t4pkDBZFDgMMHBGeR2NeK6XaX+kvcNbXUTSAFoZpLUO8f0ySB+Aq5H4i8Y2jN5N5b3IzkJdwDJHbDLt60+Xsy6mWya/d/iz2FuSOeK4vxZr2nRzNZ39pcOsb4EysEKtjORzyOe/HWuJufE/jS4m23dzBbBSS0FhBufb7sc49OKZF4d1nVtWt4ZYJRHNFud7iRi23PLNuOTngUcvcujl3snz15JL1Ou+Hl61zq92haQhYhhmGN4yME8YJxivQQOKwfDOhJo0G3zHkl27eTkAdhW8OlSzgxdSFSq3DYp3uo2diYxeXMMBkYIgkYDcT0AqwkqOm5GVlPcdKx/Efhyy1wRtdB1lj+5Ihwy/T8z+dQ6X4WtdMngltJ7pWjUKwMpIl7fMD1pWRHLT5L83veh0B5U1y3iLwfpmoo1wA1pdK4m86PsR146DPfGDXVGqmp2lvfWUtpdgNDMNpUnGaIuxNObhJNOx5wo1Twpdx/2ZLBNZ3LBjCCPL3H0Ufcz6gfnzXdeGtcj1y0lkWCS3mgkMM0TkEqwAPBHBBBBBrktZs4PDCWrLsdZQbcMeGc9gfbk/Ss+0v73Q4bubRJ7OUyPGHhnU7DIAEIVgcjoOuabjzHo1KKrQ5ob99rnxZ8WP+Sp+Mv+wzef+j3oqr8QbiS78feJbmdBHNNqdzI6LyFYysSB+NFB5bVnZnsH7FP/ACVPVf8AsCy/+j4K+1DzXxX+xT/yVPVf+wLL/wCj4K+1KBGDrnhPRdbl83UtPimlOMvkqxx0yR1rz74k+CvCWjeH7jUFghs7tMNDulYiRgQdoXPXHpXrU0gjQsc4AJ4GTx7V5fa6FdeNPGf9tavFPHo1jIFtbW6QjzTjk7ewzzk9eB2q4Sae+h24WpNPmlJ8sf6sbvwquNQuvD3m3yTR27tm2Wbrs9s87fTP8q4P4w6NB/wk9r/ZWmR2l0yC4e+Viu45xgL0J45PB5FewaxqUWk20bvDLIzuI444lySxzx6AcdTXOyPpvjfTzpupF7a5jkEpihm2v8pyCpxkjseKUZWlzIqjWcav1hx93yMH4U6iLbz/AA/PFG0ZRrlZAoG8nG9T/ePfNbek+ENOS9a4sIPK098kKXYsxzn5f7q8dOtcX4a0XUrjxdeDTbKe2tNOuHh33TlCUbcuUbBzxz+Veq6hrmkaRFsvb+3h8sAFS+WH4Dmibs/UvEy5Kj9j9rojB8b6reeHbOyj0aCKBJnYSTGPcsQGO2Ryc9T6Gm/D/wAU3Wsmez1XyPtcfzxyQ8LMnQnHYjv9a8/8U+OG8Wtf2NpbyR6RBIqpMyfvJW5+YDsP8mrnwq86PxSkJYNbRwSbHPG44Ucf57Gm4OKtJanRHBxeDdSa95anceIfC9zeaz9psTbJFdBUuvMznCkcgDrleMH2q0ng3T4r2W5t3nieVVRvnzwuduM9MZNX9V8Q6Rpl3FbX+q2drcPyIpZVVmH41yHiT4kor3Nj4TtH1a9gXMk4IFvD9W7n2FTHmlscEJ152jE17rwvc2kc0mmypLJIdxjf5cn13c/rVTS/D+p3FwF1G3itLJDztlDSSc9Pl4ANeWyeN/iEl+1uZLfzSof+HaoJ9entW34U+IviG1ublPFEkAhaItbymFijN25UHj1rZ0ZpX0fzO3lxKi0mn957W8sFnbBpHSCJFxlmAVQPc15Z8QPiVby6fe6b4SmkutRbERuIk3RpnhtrdMj16V5pq+ty6ndyXvjaeS+sWf8AcfZ5GWEA5+4hAzjvnmtm30SbSvDMOtpaRafpdxdrEkDk+bLFI+AxB6euO4pxoqDTlr+RnTwkKbTqvUg8M+H7bQ7db298m61FVDLHkkoSM/Njp6+/0qvNd6jrWorY6VCWu+c3BIWK2XPJY/0+laWtX0WlQTvp0Ec9yvyyPgIi+m9vT0rQ+HFvFceHDBYXsd/fiR57yKFCChc/KeQCw4xn3q7tp1Ja/wBfkd82otRvv1J9S+GfiSz0KK40fXftWqiRWzkJEkWOdoPBPSqfgnWmvLSRL9kkVJ/JaTczKzAZ3qetew+EEm/sUQ3cUyGN3jAmB3FQfft1x7V4GLabw54v1vRPlwkxnhVOAI2GQBux/s1EX7SMk90cuHqt1JU5u57X4V1mX7a+nahLukYb7csfnZe4PqRnr9a7EDFeRaf5t3o1hcPJIJVcESR8FSrfKc1uxeLdVgmjjuLW3uVxhmjJRiRjLdwAawsYYjBylO9M9ArK1nSLC+hke8tlc7fmYD5iB29/pVfRfEVrqc6W+JLe8KF/IlxuwOpGODjituT7tI4Wp0ZdmcRp8kulXVjp92Ym0+9zthdP3iluisOmOgrom0LTfInhitUiSdcSeX8ufT8q8+vWudPvrqbUIpo5UlUxSohZyxJ+b0KdPpXa+HvEdvqczWsuIrxRnaGBV/dD37ce9No7sTSmkqkNe7X5ho+k3+j33k29ys2kMCfLl4kib2I6g981gawk+l67fvqRlOk6ipX7REjM0DYG3p0AIP6V6AmMcCmyIG4IBBGDnvSuc0MVJScpK99/8/U8k0O11mKH5ZbTW9LkYrMkTACI5yCehBxz0Oc813Wkalb29nFbPa3sTIgJhdDI0YPY7c8DpXMa5psPh/VJHiCLp80gumhhk8uVH6HaO6n0/l1qe2ebWnvXsS2yDeYmgHlOsjncMg4yR+RpvU7q0FXXtH8L67ff0v8AJGjqn9gxYljgRrm6QqIij+YVP91eqc+wrHj07yHeG6tlt5OAqbsjHb616PFGDFEZQryKB8xHf1rN1vRINVj+YmKZVKrIvUZ9R3oTsc2HxSpvlexI+k2U1jHbTW0ckaIFXI5H0Ncfe6LDBqfkL5jvHh1LEkbT7eoq9ZWviq2SSAXNnLCBhJZCdyjHbjk/XpR/wjWouYrmXUI2uSQ0pKkgEdApGPfn9KFoa0Z+xk+aomn6mTqV95cE6wxh4YcblYfxEZLNjqOwq42kyjRm1AahBDGyCT98AIwO+4jgD3qvqVr/AGdNv1NpoGJxHNCu6NyegOBx+NY1w7TLDHBIW4yyxzFUYg9dmfWg7Yxc0lSdu73JL3yWS3la4tZQ43eZbNuVl9jgd60Nat7V20+e2eMW7RqJEzjDf3jWc0LyRqxtmZEBwM+nXipr9DYW6SXRRbbqFyODjhce+elB0Wty+9qrnoD6VANP2aescEoxJHLGOj9m960LeBUUsyASPy5znJridD1bVBaukTWQt4YR5UcobzMg4AYAk4x3xWzpuu3lz9lafTJLeOYfMXkCtGRnJKnBx0/OkeDWo1Itpu9vM6TAoAAGO1ctqHiuO0vzaJaTz5UMs0bKUIPoc81iab4u1SG6uP7SjhlieQLCq/u2HH5HnHGSeaLXFHCVWuax6ERQVHHHSuQg8WzcmfTpOGKfJIMk9SQCBwB/Kmal40gCiLTkllumZVCsnIJ7AZ5Ocd+9KzF9Uqp2sdbcTrCAXztPVuy8dz2rhPEPi68le7i0B4I4rbbuurlThySQVjXHzHoew+tYmoReLPFVzbWd5CbGFdzOhBjViMAbvXGc8ZFdzpnh600+1V78QzyouGdlwgA9j/M1VlHc0UKdHWbu+yOMg0+9kP2/Wbt54YoGeNTKQ8x3YBC9Bk9xjjtULwz3W+O1aEPG4dvn2KzdSOR056j0rvNd08a1aQSWEkTYI2vu+UpnnBGfSpNC0GHT4D9p2XV05LSTOue+dq56KOwpc2h0rGqMb9e3Y/Ov4jxmL4h+KIyclNUulyO+Jmoqf4rKF+KPjBVACjWbwAAcD9+9FB5bd3c9W/Yq/wCSp6r/ANgWX/0fBX2Pquo22l2Ul1fTLDAnJZj+gHc+1fFH7JOpxaR4+1u+uFLRxaLKSBjn9/B619BTavaa3qcWsa15q21su63sQrFc4+8zEAdT/ShRubUaEqmvQ6TxDrmm6a8etwQ3VxqFxbhYRKW2Qo3Qlf4c/ma5661vWtUjQSX00Ik+6lsPKLenq3X3qnJN9r1CaZ52kB/vZJ3Hkgew447Yrc0C1ECf2rc70JOLaORQVJH/AC09cD+dO1lqe1CjSw8OaSvLz/IhsdO1S30ptG/tO6uNYv5Vmna6cyLbL1Cj3xgmqevahcQXs2l+HIlgn3+RNqWMzSPxvCH+HnA/Ou5hkg0jTNQ1zUWlXbGZH3jnavoPf/CvIPPa78y1htnnnlkaRYosszO3JA9snk1UbyZz4dKrKTlsvuv/AMAu6NPc6ZqU/wBm1ye9uiGSedJGdNxHTkYJGOo6fjVTU7SG42zuHkkR9obox4xgt/jXQ6f8PPEcFssxu9NDOSrWIBEap2w4Gd3XPGKu2Pw81S7uF/tq6t4rVTkx27s7MPTJAH481TaTumdEMXh4xu3r6HK6f4Ym1YNY6VHcNGGyZ2fCxjry3+TXc6N4K0rwtJb61rV+811agBZGOxFZhjgDlickDP5V3en2VvptmlvZxrFBGuAo/mfU+9ZHimeG5s0gUxuhO9sckAd//r1Dm3ocU8ZPEy9nHSD/ACPMdb8Lzi71GZ9M/tiwvG8yOeNPPL5/vfxKfp/9aoNC0DVLa3mh0/TLbR7SQhWkvZPlQE44QfMSSQOa6aILNE/lFvLKhC8SsMZGeuO/FM0u31G9kvjp+llQygwXbAoHPQgk88Hnir5pWsdjm0tWvW3/AATltd0kaVeXkGpX1xNHAi4mih2lznkKM8KuRySOtbuieFzr1mfsGtmFrYKjLNp+JIiRxzv547/nXQeF/CurWmgw6fqz2rPFuRpUy/nKSTkg9Dz3rp9B0l9NeVpJ/MLgAALtAGf51LnY5quLtD3Z6nJaZ8O9MstSspNVa71q5Qlo2mQCCAjnJUcEntnNdlr2kWet6e9lf20NxASG8uUZGRyDwRg1qZrJ8VXtzYaDe3NhH5tzHHmNQpbnOM4HJxnP4VDnJvc85znVmm3qeBLI58STWmr2MNmIGMVtZJgwx+5IyCxGOTzWloeoanbeI7y98PvbhPJ+zSSzqXQEMSF2qRkjI74FQw6JNo9lNJqU9usPzyLa3S77meRgedv8C5IO5ueKdoebPTxDaTSeQnLvjDMx6kfl1ronJW0PdpxVX3LXRryeK/Hlv832vSJ48HAaExscg4/AVnyza/ruoR3PiBrSQRrtWOzhCjBHO4nJb88U5Lu5EpLSl/RZDvyPf/61T2FlLqLD7ZdNJaAHdEq7UUZH3yOo/nmsVWT0SVzp/s6FF+0taxqaNfxfZFjgJljQmPeRtVse56j3FS+Ire/uJxLYsscbqBuiXhfUYJ4+vNXtSTw89zBAkUtxa7BuiUBVOPc1oPcWeoQXiLEbM20XKKwywxx9PqKLnPKpyyU1Fr1/yMPTjKjKVvIYNXhXKykYGB1HOcg554reg8bTwXKw32m3EmY1ZZbYhlc98A+/vWDaRxeba28Pm3W/Ef8ArFVtvpubqefxxXQXljp9nqItJdM1SREVGjuoWc5xk8kEYwf5njFLR7nLi/ZuVpK7NKHxhYXjiJLS+3tkjzLZgvHX5uRx61JJ/YF6BNLFbxuvzZdPKcHHXsc9Kxr4W8Oh3WoWE+pS/Zjs+yeaRliwxnA9+3Wp7Pws9ysU9/fEXC5YRbQ6qcejd+aRzclKK51JxMMa7qpu4dJ024eKH7SI0uXAMhRjgcE9Ac/pXo84uorTFtsluAoA85toY+pIH8hWFpPg6xsdVGoSyzXU68xibG2M/wB4DsfeuqFD8jLF1ac5L2a0X4s4XxHpOq6i8V1qEmmQRW6nkM/cjOSRgjpxQLWTw7ayXNpeQPNIh3I6E+YRkgKAck12s0ayABlDYIIBGea5XUPBVvIzTafdXNtPksFZvMjJPXg8j8CKPUuli7xVOo7R7WNrw7dXF5pkdxdtAXckgwZ2lc8deaZreoXdhEj2elz3+c7hDIqlfwPX8K5zw3ry6OU0nXVazuNx8ppM7CM/dB9PT2ruIpEkjV0dWUjgqcg0GNan7Ko243XTs18jnIPFtkPLF/Dc2MrfwTR4x+IrUsdY0++IFreQSZwQA2Dz7GrlxbxTqBNGjgdAyg/zrI1DRNHkePz4YIZGb5SrCMsfQYxmgX7mXRr8TT1KJZ9Nuoz914mBx16dq87l0uBPD0t7bCH7SGWOQyZUBgQOPUkGt678NXEFyG0yYrEAPlaQhsj+dUHuG/s240zVLUCEgqoi+Rs4ySc8dec+1M68OuSP7qV9U+zOV07V7XCQkZmkzjKnBOcYz0rQu5IJYQGQoE+Yn7w+o/Cs4aTFDBOI7i2csMLFsJkYEjlTnORxnIrQ8iBBELhHBQEZcDqeOnbpVOx6qlFu63NPQtYh07TtQvEi2zDYpadSu4ckYx26gd8moIPFN7fSXSXUVqiODiA5LpgckZ6jp2GKkhJuNAutONuLfzyB9okBAceikjngY/OsOSDDeaj/ALuNFUfuAyLIM4JIGTkY70tDkp0ITnJyWty8CL6WJbZZ5Z2XCoEzlRj34AzyasXlnf2sMa3sRjgbueV+nB4NdHp1pcw6LbT2SQQXLW4aZ5B827qfmPQdT+FcydV1NLgw3Gsx3cR+e5+z2rSbFz/CcYPTA6Ut9iFiZSlaCul95XFw0VzvkhkC7lUkY+ZR/LjNat/qL2d3FeaYbT+y48F0jj/eJ2DMCC3tkcCqesXNnJLaPYO5MZZ55pUEeVYcLjA54/Cs9n8u3Wa1nJWQZXy2IZV77T79KEayh7ZKVreRZu/GN6ZzPpEmmTSlfLkM8kgDYHyiNehY8/8A165211qDUY1ute06+1jUXkIkYz+TBbL02xqDjIBHJ7nrmnppcesXr29pODdZz80vzKTxkntx9TRqXgHUtLuU+w33mWPlhriKGYQqJA3Qk5JJJHpWkeW1jGdKFN2e52HgbxToNvJDolhNqT7pCqPdAEK39zcPx+p716LXjek6NqcNozW0ItCWVlJAMkpycfPjO5SeuMEYIrqtG8R6tYxBfEWnyoqnBmA9ucY+99eKynHqjkrUOZ3gfCXxY/5Kn4y/7DN5/wCj3opvxRkWX4meLpEztfV7thkYODM/aig4Tqv2eli/4SzVXmQOE0xnCnuwmhxXvN9LdKT56+aI1WZ5NwWNR2A3EZPHQc14N+z1Cs/izVEZtv8AxLW554/fw19B3jxfZjIV3FcqhHJAz19quLtqz3svg50OWPc2PD4+3TrJdw7NOgjaeVy2OAMAYHPX+tdXokcWramPMMeVKyOI2yCExtwv8Izjj2rH8HRQ22jNMXBmuH2Od+dgTqD6ZJFdH4TtjDqt1LEHMMiBT0CoQfzJOTyaJdTHEzbUpdtDO+N08i+B57S3DtPeSpCqpnJGdzfhgVV+COmabbeFoporSOPV43eC8kK/PuznGfTaV6VJ8WNQtD/Z9ikpbUll81Y15CptIJf0B7e9c14V1WTw9r63LSbdPvdkd0pYEBjhUk9iCQD6j6UR+Dl7k06Ep4J8u97ntSnIzTqavShmCjk1ieSczqXiTdqN3pmmxxSXNso86SVsRxlui4HJOK5WGw1vUnt7Y3unXMZclnijZDHg5yOTnHTFamy0Ou6rcW7L5s0oDpja4woHI684zV7RxDa6x5rHy0kG3tgscc/pWisloerTj7KneC1sdNYW32W0ji4LKOSO57n86sg4FGR60jEYxkj6Vnc8ttt3ZleJ9YGh6WbxrW4ulVwpSBckZ7n0HvXDJ8WIJJmSPSJCByD545H/AHzXSeLfGum+H90MjG4uxj9yhA256F2PT9T7Vw/he1g8b+JNXkktYbO1tQiyC2G3e7ZPf2Bycc1pGKau0ehhqVNQc60dO9/0NH/hZPnxSn+xpwjet1jB9sLx0qjc+Psxi003TWt76VfJjYT+Yyqx6qnBJz+tdnc+AdAnRfMtHZ1XClp5MfiAwrZ03StO0mBfs9raWwjABdIwn45/+vReC6ClWw6X7uD+88B1vRrvw/rNhYas+Xv4WkWVizbXz9xm/ibp+dUDcNDcyYCRyRZy7Hv0OBXsvxHuPCWp6PdabrmpWkc8YMseJQJYpAOCPQ14HPJLqGjwXSyb7gkh5AuN2M4J/AV1UrVEmzpo15yjfZnffDy3TxJqE1j5oDwR+a7MM8ZxgD8as3qy2etXunQefFbKSpyflYg85x39K5/4UwX2k6rda3GQUmhNpGp53tlSW/Dj6k11LM0k87TfM8jls/XrWVaEYTtHY7sJOvVu6nw9BvksU2EZXPAJqpqDXVihmtp5Fnd1VBF97JIzjPHQGtmNA0cmMgLghj3zWHCw1bxCYYypjsTgvnG2Uj19gag6rpps0dI1G1u2aDWEEUjHclxAuD7bx0b6jFPvLrXNKuTZJe3TabGgaGWN8DGckhupHPT8KL+1hjRQ6bwrHDYxn6UunahNBGbXUoFurTdkMeHjzSWhzVaMZe9FX8v8je0nW4NSuoYdQM/2jAhDxSFfmzwSgGCf9ocVa1ye/wDDM+n3XnxTaerNDKJF+Z93IwRyCMde+OfbnvEWj28c8V7pWbiYuPnWUpImRjBAP/1q3LLXryMJb3dobyMDg3BAYEHHUDBH60tN0cE6D0nBXi+n9bHQaD4kXUbpra5gNrMU82Lc2VlTJAKnv06V0G9eBkc1yq+JrNmAe0uI5gpwQquBxkYIOSK88i0nWdZ1SC4g1Bb+9fieWS6Krb8nA8pV4HXn9aEr+Rx/VuZuUvdX3nt25fUUtcboUeo6bp0lhHfwajqcTmRo5JT9w/XJXn1JroJNXs7UrHfXMUE4QOyFun496RzypNO0dR2saTZ6vZva6hCJoWIODwQQcggjkH6VS0Pw5Z6LJI9k1z867SskpZQPYdK21dWUMpBB5BHelyKLkqpNRcE9H0AkAcmuY8ZLpk0cAv7uOCdcmEMTyT06cjnvW9fRtcW0kUcrws6kCRMZX3Ga47xJppgs7WK4WW7k3kteSLkqNxIU+3OKEb4SKdRa2M3wnrmpWVo8LpFPaRvmMuzmVQTyDnt6d8Va1LxSL+xkjMFt82QH3bse4PY5qHw9aNa6/YAFZFLsZDjqSnGOwwf516ELeAnIhjye+wU3Y68ROlSqX5L9dzzXw9plzfGK3j84oqh5Ltx94f3R6j+tdrp3hnT7KTzBGZpODvnYu3HTrW0qhenAp1DZy1sZUqvTRETRgjBGR6YrBvfC1tNI7wSSQb23FFGVB9h2ro6KWxzwqSpu8XY46+8LXo0kW9nqdxJ5edtvPgRuOynAyB781zlx4GzYySapc3KgRbTHE2wM5I5Lc5A7D3r1MmmFQSaXO0dFPGVYJxT3PGtL0BrU5cpdSqflLTq7xjoAME579uxq39iZppEmuYoUAw6TAoWOOmGwe/UZr1dYIkOUjRW9VUA0k9tDOMTxRygdA6hsfnRz6m7zGb3R5xoN2sN9DC2npdmVlThMlePvKScHGOa7abw7pM2fNsYmy28jkZPqcda0o4I4+URVPqoAqWpcuxy1q7qS5loYx8PWGAI0mjVRhVSVgq+4XOKzj4deBGj86aa3zlFTG5T68/411VFHMyY1px2Z+aHxJXZ8RfFK5LY1W6GSME/vm7dqKn+LH/JUvGP/AGGbz/0e9FWZN3dzr/2bzjxlqvXnS3HH/XaGvfLtRHYncDH1OAMhvrxxXgP7OMgh8YarJs8wjS2wvr+/hr6MkUSHB58w9OoHHSjyPpMqbVC67/5Gx4UuLK50lLS9lksbpJC0U2cpJufdz6c8c1veI/E8XhrRo1tXtbnUJWKoEb5V/wBt+STj8ya87gsltpHiW5mbzMsRKSxx6A9gKfPAkcL/ALvcIx8ueePQVUrXG8vjUnzSvbe3/BKlul3Ne3N/f3LSXE5CtI4Af8x09hUi2V14r1ePRtLTfEsqNe3O35IEUhsbu7Hpgc1s6N4K1rxHCk13OdJ0uQqVjwTcMoJzjptzx17V6xouk2OiadFY6bbpBbR9FXue5J7k+tW5qGvU58Xj4RTp0f8Ahi+owoHpWF4lvBarBCZzFLcuUjK/e45O33xW6G9jVe6tortCk6B09D1H0PasEeJTkoyTZwoSGe7MN1H50jAshcbnIHX3FWjpVz5Jt7e2kEn3onkOUjPY5Pp6Vv7tG0hp5XktbeRFBlkdwGAPTJPODV6G+trhENtIsyMcBo+QD7+lU5HbPFy3itDzXxP4r1Gy1mTS7G9azSwVEkLqhab5Qd43A8HpxVDUvG+r6xpj2lrLBbiU7De27ZcDuoHYn1HSvTWsbXVFMuraVb7kOFNwqSHH1xxXk+uJp9t4t1KLR7iOeB3825QIFjhcqMKrA8ngHGOPWqjZ7dDqwk6NVqnKnqupnW1ukNoBHGzhOAGOct1OSe9Wfhv4lXw3DrL31lfy3d1OpjhiVfL2qCAd5OMnJzVG8lsbRme41BY07GSQYYj2/HtSW88eqXNvNFNFPEnJEIVgD0+bOfy+lWtnfqehiKSrJU5HYXPxA16+iI0/SbawUg/vriUzFfooAGfqa5PVbO91gltb1G5vvMGfKmlKRrj0ReBV6/sHnjxBMN+c5dyCw7jFVXha1jkF1cpnG5WJBGcfXmlFpax0IpYSlT0SMSXw9CrSbbSCSZU75ckduvJ6VZstHuJki+bybdCAse3aOO2K22u3tUjeSOfcQHH7piMe3qapvrgknczq8cjAN+8AXr046/Sr55s19nTTOqtUt4dCtrGAIbszNKm1vuKcDBzjk46Vnus0VxOlwjh2P3G7f4VoR+B9XeNr6yvLWUTRrJEkqvG4BGduDkDPv0rC1PVNQ0tMa/oWpPGgIMkcZLR+28ZDA/iPpWdm9jKjXpttQd/wKXiXXW06NLLTkE+rXHywRe399vYVa0LR10zS1QTZlfMtxNjJZj97PtWNp+vabe3Ut1pOkyeSSVa+vmDPKQPugA4VR0GOprcOrWFyrxKCnHOxzggjnjH8jVWaWxsqiY/Ukmht0hMiuSOVTvn/ADms65+0pFCLeTe4ADRlsiT8z2FXbCexv7mW2gnxcZwElXa3pgHOO/rTru1mtJG/dCORPkO5Thf8/rSvbdGkHGTsnqXdI1VvL8p4VJBwivgspz2Yc4rpYro21r+9vXimbkoen6//AFq4/S7ZLeSMbpfMJ80kjc39OK3/ABHoUr2EN/bypJAR95RjaD6g+9QY1oUnOMZO1/zLRhhSUzlo5ppPlyc49ePTvUbadazsWzcRyyHbJtIy454zx6D8q5+z1Ca3XyZMlCeB346cGtO41BzFIyPsSIjc46E9h+NMiph5U+vzIrrRRpii1n1TU1hKA+UGKqV564bp2xSfYYba3RzDfPEPulZFHTsDg9+cVJfy3F6LZ7gyGUDZkr/DngNTDatbxNHdSlJg2UQ5AAPY4/wouyKdNW1epc02/Fsl3HaSTCB12tBIwK8jkggZDVBY3EFtbXEWpCa4ik/1CQSMm0nsQfXjJ/Sqf7yHDKp2g7tkbjBHqCO9aFrLZEuLj7SZSpC5IOT747fhSG6UEnZPXsXdL8WrHpkMF1DdWohIaKWL96pA/gYfePp0p0XiB9ZjbT9PWe9V280yFdjbM5+6edue9Zz2mn7xLHdrHJg5Hlv19zj1qtEXMu62lkjusfu5EBUpz1yCMj8qLIxeFg25QWvnc1ZIL62kAZQhU73fBIUZ6flkYrtdD1qDUkQDdDMcnyn6keo9q4r/AITW502SCK+it5rfJSVgMOxA5J5xk8Vesbaw1S6a+0K6e3uIl+a3k48vjkrkHA+mRQ13OXEQc1+9VvNbfM78MKUHNcNbfECyuYm8i2lZ422v5jCPgY+bB5PUcAHrW3pXiWxvLNp5JUhdQWeNnGQBnJ9xxQ01uee8PUirtG9SE1DZ3cN5bpcW0iyQuoZXU8EVT13WbLRLJ7rUZhHHwqjqznsFHc1O5lytu3U0Milry/VvG2qxNELKNWEj5P7rJReSOPYYzXVeG/FEWpyfZrlUiugCflbKuB3Hp9DScXY6qmCq0488lodNRTUZXAKkEeoNLmoOYWkFFBOBmgQtFZ15rWn2Yfzrhdy9VQbj9MDvVaw8TaXfXbW0E580c4dSufzqy1Sm1dJ2Pzx+LH/JU/GX/YZvP/R70UvxXOfil4xPrrN5/wCj3oqjM639m8n/AITLVAOCdMcZx0/fw19IKwSFdzcKBk183/s3MF8a6iT0/s1/w/fQ19FSqXZDLk5PIB+U/X1FNH0eVfwPmTgjIUkkjoagmjVnKqNshGdxXjn2qYMpxhl75AHJA61G6h5gdhJGcNjp7Uz000z1fwzqkep6ZCxCRzqu14gwJUjjOPQ9qwfH3ih9KmttOsi8d5cDeZggZUUdjngE1w7+ZFPBPalllJwZEfYyAf8A1+Ki1q+uZy092ftd6wWONMf6wk4Cj8T/ADqVG7PIjlsKdX2jd472KMmt6hPdtHBrGovcANnEj7VOfXoa7v4Z6nr2oaLqf20SSeSNlpPKMNK2Dke4Bxz707SfhyvnrNq98ZlK829upjTPoSSTj6Yrv4IEgiSOIbUQBVA6AU21sRmGPw9Sn7KjBetvyPHdOS9urqfS1Yf2ltYTy3r8qQASw45GWb8q9K8Px2FpbpHaXkc8k4Emd4O/CgEgDtwK02sLZrkXLQxm4VDGJNvzBT1GfQ1xQsv7Iv5IotsUoy1u27LOnoM9B2NDfMcjq/WlyXtboct41TxFfavcxXdvfXUZlKWljCpEDrnClmHXjkljgelL4d+GOszOJNXv7bTbdny1pYoGYp/dLnAH4Cuq0m81mxvw9zO1zpxQmSF8PIrE5+VhjI9iK1v+EihN4SrXDRg/dWMYXAAIJ78nNVzuKskazqV4pQppJLsGm+A/DWnzNNBpFs8x6vODMfwLk4rlfHHw6t4Un1rwpD9j1VQXkt4BiO6HdSvQH3Feh2d890I2itpFiJILyfLj8OpqxdxGeBoxI8ZYEbkOCOKlTmnuefGrOE+ZvU8e8N6TqWpyM92sltF2lvEKf98r1PHPtXfaF4YsbCDz5BFqV2CWScoBjjgKOQPr71wlj4a1HUtcuovMmQRyFTNcRs/mKDjIzx/jXpvhfQ4NB0sWcDtINxdmbuT/AE7US8j08wqtKyqb9EjQtmM0CM6eW2BujODsOOmelRzaZZT3EdxPa28s8f3JHjBZfoe1Wo1CIFUAAdgKdSPHv2G7eMZrO1HRrbVLFbTVEW6jDb/mGOecHj61p0UApOLuji9T0Xwt4W0SS4l0u1W3iRvlI3Oe5ALH6968u8Z3XhiXSZ5tHi1uxu/KzCyjdA7dgxJJA9+K9Z8U39taX1tFrltC+kXatB9pkIIjdgflI7Agda+fhpt7pHiC9tH8640a0vTE9mWDzGMfMo/3WHp2rpoK+rf/AAT0sNFz1k236lO7W7bJjRkdwOSQGBwOfc56V614Fvv+Eo8MLbsw/t2yHlXEcrHMqDIST347+1edaudJmtvtGnTX9rZoSWi1IBREOwRup54wai+Hd/cWPjK01JJTFYxZWSeRW2sjdQBjLZ7e9b1Epwd9GjWakmpQ3Ou1Hz7IH7Ms7lZQGTOWIx2z2ya6C7lneykeJ3+xlFlaJCTsfABBA7A8iq/iXUv7W1T7TEpiijy0QC7WOOpPuR61P4dmT7a8N3MRZXKbSzH7pPT8Aa4uh6UlJwVRrXe39dTKlVbkBtxydpBxtwD1FXCsCIIrhX8kgqI85BPYnNX/ABF4cutLs0uUeOWCPJK5wCT0J/zisI3cdxIrQ/vTtB4OQv40vM0jUjWiuV3Rea5k2sUABPKrjBJ6YJokvrqYu5UykL8xOCR/9aoSGddqqVkz8wwefTms26nne/ks7W28yVY1klaa4S3jUdAAzEHnnpmmk2x1HCnG7CXxTZWUhgbUYxNn/VqBITz0ACmnL4jt0XZFb3rKc7U/s9mO4/Vf85ra+Fl3oHhvSFsdZvtEi1hZpGUrOkrhCcgGQcZ/Gta48c2r3BhtYJtcuN3zGF1S2jPJADk4LY9M1copOyVzyXiZyk0onnT+IbqBpjel4c5wk1gUP0HFJZ6hf6tLAul2mpXF6MZFtbtHGc/3icAfWuq1bU7/AFyZE1IQ2Onx8tY285aRz1G9sZwODgfjVnSPGN/olxPbSRXmqWnk+dDGihpYgGAIJ7qdw56jFVddFqbS9qocyWvqYdx4d8cXIjWLRvJKsd7y3URDA/e45z+dZ9hc3mmOsOnXkaXsbeWrQ58yAk/MjoQR2PHT0r3LRNW/tiwinNndWnmqSFlXBAzjrXJ+ONB0ux0gxwaax+03Cu8kUpiIYc7mcAkk+9Qql9Gjno4qc5+yqLV6GXfSahrumwW91p7jUrQm4MrW/wDrIwMcNwA/OcdxVHRdOvNQ1W2trO3mMcRSd7m7iKqMAkcdznjFbC+P57G1CS6ahjiTC7JDgAdAc8k11PhnxVZ67aRurLBcMM/Z2cF2HTcB3XOeai9lexVWWIw8GuSyfzOF8Q6lf6FrUtkLicPKgZXt12gkgdF6YByOn41l/wCmXl15mozeY6t5QfzA2AOh55HXBFd/4kii8QLqFpp1u41exUASSxFFIY52q54OQK5e28P6tHaySDTDDOrHB2qxYcZJwec009DXDV6bSc7JmJbQXEDxWjSJdM+4tK7mPavqeeeewqFwnnJIbg204BDFQTnPr9OK02jaUbI4J96jBXy2T3xgj+VU1nSR7iO9iRBEACG4bPf8qTud8ZU5Ozehe0We+ix9lv1t5lOGMEo2OP8AdYVvQeONR03fHrGnvclAWaSEbNoGPXg+o9a4p30tldjEhwQCSc8ngDFby61YNaLaLbQlYAWMkm47enOTx+FK3kctahTqP4br7jobrx9FexpDocY+3ORuN0dkUSYyWLjIOPQcmsRdS8Z30erS6Xd6bcWYufKEiI2Y02AllORx15x1rKhEFvEsu6KPSlcK8m4Jt3cAJwctz0/pWpDq0zW6ab4YBSwVGMs9xFtM53YPXHGKaVtkc0qFOk+Wmrvz2KkNtcxZlKqG25diThQP4sY7+mc8VVmWYSeYk8ZySoU5BZfc4znPTArYmd0jWNVTYAEM0imRhkc7QflX8BWbf6nBpsZkgUxysQx2Hy89txIFNK+x1KrUteVkj43+IRY+PvExcEMdTucg9QfNbrRUfjuUz+OPEMrEkyajcMSTnrKxoqD52fxM7v8AZwGfGOqjnnS3HAyf9dDXuep6zY6bGscxbI6BuD9MDr1rwj9na5S18YanJJ9z+zWUk9v30NfXXwt0uxubC5vbqG3uLoy7R5kas0SgDAyRnnr+NXGy1ex6+GrqhhedK7ucXosGseIX/wCJZo832UptFxcjyosfj8x9OBU91Y+IbLfHNoclxGn3prSYSdPQDBr3AxjZtHAxjjtXIXtjLplym13MR+7KeoPuR0p86b0RNLH1KknrY8wg1Lz5Zmj3AqQHRo8FO2COoPv0q7Y6heaVq9tqH2GC6SKJsRySldrHqwODyBkfjXWa3o1vrhZ1f7LqqjbFfRjn/df+8p964yyZp3uILgtDd27eXPbsfmQgYPHdT2NDSeqPQpVY14ulUVj0rR/iFoN3YLNdXS6fKG2PBcnDA+2Oo9xRrPj/AEmxgRrGQajI+SEgYYUDqWPavO5Y7eOMgiIlVx8xxjHFQPYl1G8LFlduFxtPv9aiyM6eUUua8m7dj2nQdXg1vSob+0z5Uo4DdQehB+lJr1vZPZNcX5SOO2BlEzAfusDlge3Ga574VW11a+HZftKKsUlw7wEMSzR4ABbPQ5Brs2UMCGGRUy0dkeFVSpVWobJnic+ratPeNaWEGoixPzwzR2mJJM8hhv4CYPc5+ldr4TQPc4vtMmtyQPKaadZNxGTkgHhuTXRaxp89yga0kWOZAQAwyrex9KwzY6hHczAwSFHGQQ27B6cc9Kq6aO9Vo1oWvZnYr6ilYZFc3p1xrlraot5Yxy7AQPLkGcDpnPety0vILvd5M0chX76qwJU+hx0qTzp03Dz9DhfE/iTxJousyiHTI7nTwy+V5cTM7pgZGR0bOccdq7+3k82FH2su4A4YYIz2NPCgUAY6Ux1KkZpJRs1+ItFFFBkFFFJkUAUNY0iz1e2WC/i8xEcSLzgqw6EfnXD/ABX8OWn9lT6/ajyNTtI13SDO2WMMARIByQAcgjkYr0jtXmXxj11V0w6DbSBZ7vb9pY9I4M88+rYx+dXC/MkdWFVSdSMYf13PKJdMkuJ7y+1e4TURYssUcTLtUzOcqqIOnGTubPTtW7DBDNcwPbFGjWUqQSBz3JPQ/Stvwbo9vqGjaw+s2VzFavMlzDJESrsIkJZt3XbkkD1ycVzHgpLWaznuEhVDJMLiOJWJEQLEDn1AxkH15rd/C7dP1PXpzTqOKXU6MI4lZVVMBQTzk/5NRxea9vF+5+zkYYgKCAM9P0/lW1o6st4bgwh4oRk5XcA54Bx+OaZq3lsZ50byHUDBAG2QZ6jtnk5rG52Op7/KR33ifUZPDCQSRxSywug+QklwDwD9eK56PXY59a+xR2TXDNMUeK1iZ0L4+ZQV756mq2uT3ENhcTwllnfaCq8be3HHPT9a9j+HGhtoPhK0tJ+bpy1xcH/po53EfhnH4U7KMbs4cTWjhEvZrc8z1WfUbHUIku9GvLKKU/I+zzF69Plyc+1LNol3q6reT6Hcy2sILM11CEf0+ReuMc9K9y2jPFNIA+tTz22OL+05tWcUeEDTtKkgEFraxOjEDYIkdQOvTjbT0t7K31Oxiv7eWHTFj+/ZxF/nzwCAfl47gHpXdeKIY9XkuU060t2uYnCfaTMY2z3wVBzj3zWBJ4e1XcIl1CIsR8zXADBfTlAMfiKfM+rO2NaE4+8uU6/TvDPh3UIbe9jiN5HgmNpZGYc9cr0z7EVqW2l6NoKzXFvBa2IYAPKAF47An+lQ+ENI/sbSfIedJ5pJDNI6cLuOOFHYcCjxJYSXElpcqx8q23llHUkgAH+f51nfpc8lyc6nK5OxseZGu0mRfm5GTjNR3FzaLEzTTReWBlssMY964qWcXGtWKQMJIVglkd1O4BgVUAnt1ao9eVV00wuArXMscKNjj5mGfyGafKaxwi0uzev4dDLeYLC2uJcEr+6GOfwqjCfKlWaCNIHIwRGoGB6DjpS/JEzhH+6MBF5IFSq+MbtuT+FBvGCirb+pYttUe0gZXCyuxJBaQjLEnA56elPN5rMmrWSxWlsbGWMNPl/nhPP5+n61QYKIj5qhiDv+6SfwFTW081s++AgKeXUjOeKLGcqEdXFa+Z57450u7stelbznjaVhMkyMVMq5xtJzwe1O03w9f67M8scsU1uWXE0jEbcds9SQf5V3V7O2rukUkEcxU7gqpuxjuCa47xVd6lZ6q1hpwgj8pEZmZM7WPIUdjVxbasdkJSlFRsuY0J/hgrwJt1WPz1bc2YfkYfTPGfUVzkngy/Sa5Zri3u2ib/lgxXduPHynGQBjueldd4dvhqdnFLJAiTYKSbGztdScj9Mj2IrWkXIJbywgHG4Z/GlzyTsYKU0/elf5HnKeG9QB3jRppdj5DHjkqQSAx61rWnhPXrhopUXyXC4TzMJGinnkcljx2wOetdgitKQMI8I5yev4UxppECLDJL5SDDL5hCgf5zRzNlupUtaLsYg8OXVqJba71CKZVwzJHGQDn1bPUYJxiuc8T6bBYRTtN5jRcKJJflIPvj17HpXoURbaF+XAJYfT+tc549Rf7BuP3aMZCEIbAJ3HOB/3zVQfvIlSl1dz4X8Yusvi7XJEGFe+nYD0Bkaim+LF2eKtZTGNt7MMf8DNFZy3PJluzsfga4TxLqRMSyn+zzhW6Z86E5NfSnhrxr/wi9wtxdwTXGn3UZWQWybmEg+6FGcc5NfOHwDz/wAJTqYCB92nMMH/AK7Q817dbRssbyDfKwYpsKkAnnjAHv1rSKTWp7eBpqphnCWzZ7R4I+IGk+LZ7i3tFuLa7h5NvcqFcr/eArrZokmjZJBuRhgivmkWVy8tpNYXDQahbfMJAf3ijttb9Mciuss/GXi5yYpLy3QJhVfyFZiR1LdsfTFKcI3vFmNTK6l709j1c6HCXyksqenIOKzvEPgzTtavFvWae01FE8tbm3fa230IPBFcNH4u8STRTwC+t/tSAZYQKoGffnj8KqaV4q1+3nD/ANpG9mBZHt50+Q/QjHI9uKSTT0YfUcX8V9h3jPwWNBh025OsXV1un8hopUUBtwJ4AHsTXPS6mPtEtvAWuZ4zlILcZ28dyeBz6mtbxXrereKLe2sNTt7e1sxJ5xlhJDEqCApJORnPUUlnpdvFaxLHA1sI8DanGPr6/jVSbaXMengY1YRftdzuvhxr9suj6fpF9KY9TiiAIkORKeT8rdz7da70c14JdxRykiVN7rj5QTkd62dK8YaroP2a2MP27TlzuLuTJEOu0OTz+I9s1Fr6o4MXlkrudLU9hwDQVBOcVl6Frlhrdsk1hOsm4Asm4b0Pow7GtXvWfkeNKLi7PcaVB6iqN1YlTLcaf5MF64AMhTO8DoG/OtCiqBNxd0ZmlXssiLFexPFdBeckFX7Egjj8OtaYpjxqy7SoxWfeJfwoTYywueSVnBP0AIP86CtJPTQ06ZI4UZPAHU+lc+mu3ySeXd6VLHIoJbY+5SM4BU4/Ss+5S/1u+81Fkjto12iJj8uSO+Dyf8RRY1jh2/idkWNb8UxRO1rp2Z7kox3DhVwPX19O1c0NR8RwRpfLdNPEDtZlhZ1VV+8Co+8cdxg574rqJJdO0LT0jW1M0pHEOFZ+nQ+gFc3qviDXW8xdPSOCNCoCIq9Dz9455HPaqR10ad4+5DTu+p29xqbs3k2Fu81wUDjf8iKD3JP8hk0iWC3IibVrWynlAHSPcA3fBbtmuO0HxnNaXj2niW4iaJiBDd7QAD3V8cemDgVa8W+EzqN4+s6bcXLzOikxpMSDt6GPkAE/rStZ6mDoOnNQm+XzOp8SWk134e1G3sHEVzLbvHEwGcMVOOK8H+H0fl+HYoSB5wVw6er7uQffNdU+ueKtC0+a6kMiIRsjg1TktJ2CYO4/mR3rlNGs72fV5bx5Y4XuwZZYoxhAzHkoByBnmtoq0HE78DQlTm9U13R1VneTWLMIG3iTHmxEZWUD26/iKSa4W8jHlWzWoX5iud20ntTjD5Tb1GZCuwEntnvVeCKR2uJRIylTt2g449QD359Kg9K0b83Uytft4UgST5drvsd2UH7zDJH05Ne9wACMbenY+teD+IJIm0eS5DkAAEliFb0yfTrXtGkalbXmmW063MLb4kdisg4JXnv9aUtkeTmsXeLNSub8WXd5DLZQ2kyxRTM6y5XLMNvGD2610EMqSxh42DoehU5B/GqOr6TbaoiR3ZlCo+9fLcoemMZHbmoR5lKUYTTnsc7ZoUEzjagA4AXgYpyyl2bf5wMbKCSmA5PQjHXrWsuh+WNkVy4hAxtYBj+dINDOAftUgI6YAximdrr0273Mc/bLeb7Rpts1xLu27UOAen3iTjHv2rq9Pa4ls42vYUhuGALxo+8KfTdgZqLTbWS1jkSWRZFZ8phcYGBwavgAdKTOWtVU3ovmVG0+zCnFtCuWLnCgZJ6k/WqB0O2ZEWWSaSSN2kR3bJQnPT2AJFbR6c1zV5bzWOsz3kZKw3AXcwJPzAYwfwA/WgVJyk7J2GzaY9mqygiZAuC3VsepNVWkBj3xsoBPRjnPrip4Lma1lfyljaGXLsM9G9h2B6mpNGsrSd5BLFtlik3iNThBnngd+/Wnc61KUI3mVRunEZiV2DdF2Z/P0p8ulyPMFe9htZZFwFLAufQhe5/PpXU7VVSAoAxxgV4Z49aWXx1MbRXkuYZk2tjoflIUNjjGe1OK5nYrDSeIk4p8tl6nstnZR2R3xsQpX95wPnP94+9eb+Nkii8Qm/8APWSC+jj8penIO3ufbNeokefZkSgxmRfmGeVz1GfavJ/GEF1da8E1OK2SK3jzaRqu/epbqD0zxz6Uob6kYBt1r31M8zXmmX8baekcIkXbLlcrKvbOPQ554PNeg2YS58PR6nFG8TlN0kZbdjHBAOOnFeaiR7OZYdx8iVhtYndsyRk5/En04r1q4W28OeHUt4CAiDyoy5LbmbufXuacnsdmPtCUeX4mzOPMbKxbByflGMCmuUDAbtu4j2zms+61O2tYPMuXw6rlQP4iRwAM+9Zlv4pnSB3Wz09Q6tgksz88gE5/lQkQoTl8CudEXW2jeRgY1AJ5P8Xp/n1rg/Gd15ttFZTfNdPIZfLSQsYxtwu70PJJA9qnn1HWNYh+y2u21G0NtVjuC9yzdiPTPNMtfCUUl5FdzXvmRhWEqqpyW7KTnpnr3PHNXG0Xdj5GnqfF3jDd/wAJbre8/N9unz9fMairXxEj8n4geJogMBNUulxj0lais3qePLdnY/s9AHxbqikkE6Y4BHb99DXv0cG51MMu+JgRn0z7/wBa+efgPEZfFWoIoBY2DEDOM4miyPyzX0FZm5WNom2sCQEyOU78+3SrS0ue/lcv3NvMs2enrZuCpYqU58zkDnt71eXYNyiSHcDnsCB71iTedbalv1QPdW7KMRRyeWF/EfzNP8P6FqWvalO9pbuyREMrSSBkQ/wqWPX6VfJfVs6JYlU9GrJGlHdKIpZjuWFGEbsikKzHgKT7+lNt5bae7VLVA11tLMEQnPvwK2Na8JLa2ZuvEGo6fp9vuBLvIzfNjsvAJ+ldb4XufD2kafHHp8vzH7zyRMJXPvkZ/AcCobjbQwnj2taa5vS/4nCRiWVZC9tNI69fLgcgfmKZHe3se3LKYuSdvKqccZB5Ndrf67qGoSbYJHsbYvtXZguw9SccfSuT1rTbiGWTUEkmndADOB1mXp5hA6svfHUc9RykaQxEpfxo2X9bmeZbxIpZJJYHmU7gig4C+/vyKmiaO4tixP77GcbcN/3z+FUdHt2gu7nfOJI8AqS2WPUnNSSQXcryS2KC4kVgihmAVSc5x79elOybsdXO4x5mTxwrHcCa33wTZyXiyhPTuPpXQW3xA1GxnRL22N9bt/FGAkij+R/HFYMKai2nPNc24dmYkwiUK6++SBx9TVSC5VGaSS1mEQADOjrMEP8AtbGYgfUUcrv3Mav1eurVD1+x8V6NeJGU1CGJ3APlTMEcH0IPetu3ninQPBKkinnKMGH6V4C/9kiXzbZ4DM7MWKMG3HHOAemKsWWn/ZmmSO/MAkADFSyHGOhKkDB5walxscDyqnL4J/qe9kgckikyCM8Yr54vNKgWKWGa6kMAUkhZnyT15GcE8dTmuY09p0eCyTVtQgsriY+XC8zhSmM4xkdT/k1ShfqJ5NLpNH0vrmv6bo0KyX10iljhI1ILufRR3rjtS8T6hqAl+yKthZogJdmyxz6noMe1cZY6HBb6pBKhDuAS7uu4k44I54rZnt/nt/PaW4t4iMQ7sZJ53PnqB6ClZGlLA06LTlqxYrgQ58lriTK4MxUnJPcZGSc9+lI1xeSt9kSOe5v5VBWKBQCecbiewHcnArRsbW51m9mgtgyqAA8hOFjB6D16dhWhcRWuk2t5pWnmSa7ID3VxvCt0zgHtgdAOn40XRpUqqD5I6y/IPB3h3TXupL27lhvdQiJRljBMUZHGNpGC1RJ4X1HwxeJNoEt3d2kkrSPE82SmSSF2ngp245FZcZk0KdL6HUpA804VYwmFlBH3Sp+8QDnI6c16XYXT3UbLLC0ZwOc7lbPof50NtHBXqVacudu6fc8v8YXsmqapbSSSrEPJ+SBGDNEQ3zBiPU479KzY/wB6d0UcsUwHyrwGxk8knt1r0LWfA9ldO82mt/Z9y3BZEyjfVcj9KxU+H2oTEG91aGNhhTJb253so5x8xIH5U00ddDG4eFNRvt5GNDM0qFdmUJxnd9f/AK1MghVZpkjO91xuGeg/xrXn8A6xaSO2l6lbTqWz/pERjkx6FlyD+QrNudG1608ySfSZuDnEDCYMfXA5x9RRp0Oini6M/hl95n6zpou9PntlUK74cbgCScj1+laWnaXpWsulnbN9g1cpvkBTfDcbeDg9Rxz+NZ8mqNArQXcUlvJjHnSxMg59Miuci1p7TxFG2iSRfabZGa7niUSeSh42Y6F2/Smk3oXWi5xvB69DptW0rVbLOiXEZltp8PZtBcSBw5GCM5Ab7ucdfzrp/CviefS7aOy8QLcLsAWOWQEuFwPv9zz3qHU/DGs6hY2d9JqDzzxJ5iRucPHnn5SAOcfjx1rN0XVmu7yDT/Ebre2E7+XHNJxLbtgkZkGCQcY55Bqd0ck2q1J3Slbe26fdGtdfFnRIdRe2htNTuI4zhp4rY7B+eCfyrZ0jx/4b1W4S3t9SWO6f7sNwpiY/TcKx/Engqa2tUuPCiq1wpBe2uJSVmX/ZY52n0zxXC6jd2E7fY/EenTafen5Qt1HsHphXHBH41ajGS0X9ehyww2GrL3JNM9P+IPjW28H6XHcNF9ruZHEaQI4Bz6n2rlNJ+M9mzBdb024sMjO9RuH5dfxrndO0rQrS4N3AsUrdPNmmDEN0wNx/CrFxf2ayN509qiN8hLOqkd+M9QcU0oJWtc6IZfTUbSPVNH8Z+HtYkjj0/VrSWZuke8Bvpg1vTRrLEyOAVbgivn06TYa3uisbEy+YQVlt4iCvP8Lgc9Oua9W8Mz32ieG7e1125NzqK7tiu26TYOm8jqQO9ZzilscWIwipNezlc0DpEqsE3oy/3un6VlX95HpGtxQ6pm1spEVYL8PhXk7q/ofT6VqJqd3u80rG0R5CBecfWnX0el659mt9RjUyqS8cLMQcgc4x161PqJSnF/vNvIqP4o0TR7EJJqiXDRrgZfe7kdsjjPNePiQa14nk8yWSFJXFxezRuQsMQYncWBGAegwa9Wk8B+HraOaV1mW32kujSnbj+f61wS2GkNq17dabZ/ZoJE2orAfKq8dD0zjP41pBxV7HVg1B83sr3e7Z6BqXjDSFtZobSWW5fZtHkr1yOxbg9PevMtb1xtT1Nr29hUIy/ZYoMkLHt5Iz3POTx3qgZorOYPvaUF8LllGR1Hao42ke8klntDNG6tFHFEBlcnP55796pU7amlKjTotcurJ7uQzWsUYZFSMckdM+lQx+NdZjtobaeVLm2VwyeeoYqV6Y79veqviK6uNPlm00yLMgYZAbIU9+nGazdGg+038YLwgD+/yVOOv4VvCmuXmktAqzjVkktTdtGvb+Xe8nm4+Y7xyD2z7deBxVgpqtwjHScRRO5yZQAqKB07k9+wqzptjcQWjGeUyrNIGUbtgcg8E4Ge54xXYWMEbkSXTBfKJVVAwenX0rnlOz0NVG0dSLTopGVI7m5eVEXJwu1TkY/HHp6Vedd8JCbWWPnKnAVh0x/Wmx2iXcoEkgXB5UYwV9ajaLTn1QxpKyf2ccMhY4BdTy3rwazJbjF6bnwx8Rg4+IXigSndJ/al1uOc5Pmtnmil+JKhfiJ4pUMrAardDcvQ/vm5FFSeFL4meifsraHH4g8d6vZSSyQt/ZEkkcidVYTwYPuP8AGvoafwjrmkRFWthdQKSTNA+Xb8MZzXiP7Ff/ACVPVf8AsCy/+j4K+1OtNTa0OjD4upQ0jseDalHdw2U73+lXVqjgZeWA7WB9T26VueAPFEdh4bvo4LMvdteMtrFu2+cSoOd390dz+FerXk0VtbSzXDBYY0Lux5AUDJNedpMl3cnUUaJ/tBzA0aj93DxhB9ep9zVKV1ax3Rr/AFuPLOOw2XTzf3EN/roiu9QTlSw/dwZ/hjH6Z6mrBgWJ1bDsVyw3Hn0xT4ZhcRhvKOM9G9j1/Sp7f5suJGcEnrxjnoBQb/DoiHaEdgFXJ5x09utJdWQngkjLOu4YDqxDD3z65q0eflIzjqSe1SAg7SCMUEuTPLbJTBeXhk2RzLIyXcaqR5bg/fT/AKZvkH/ZOR0xXQeGfEdhZatBo1yUuYZVklSONd7IQM/Jjnk1Xk1sX2panb6OizXTXJiFyw/dwAKFJJHU5Bwo6/StLw/4bstFgaVWMl9M2+e6kwJZTnv6D2FU2nuaTj7nI/8AgoeNOl1LUbi5mkm/s5QBDp7nknuZG4z/ALuSOKu32n2yW8zxRtBJtCkQYVj6BTx3qcL5s6lZnVUfzGAHDjGMfSr8cscYUHkHqT1qSG2tDn5vD9tfOs2o6ZZ3czLzKQY3PpnHfHtTZPDmkeQpt9GSN1G0+TcSAt7HBGeP1roQ7kttf5cZQleevNTaRaDUbzLHK25UuVbgnOduB7gfhQ5vuZuSgubt6m3p+g6XaBTb6dbRkAYPlgsPxPNW7/TbO/tmgvbaK4hb+CRcgfT0/CrYpag8dzk3dvU831nwpeaW5l0qOa+tGfLRbx50X+6T94exOfrWWuTI64khliwNkx2kE889+K9abk89K5Xx3ZQtpU1+BGt5ajfG5ON/+yfXIzj3qk7npYbHybUKmvmVPD0rxeGbhoVQ3KyObkxZy3+0O/TH4Cq7PZ2MLyPEh3gykYAaUnAPHU56VJ4HUtq98wz5ZiUOuOAc/L9eM1p31slteF3jEjHmIEfKvt04/wDrUnoxzap1ZQ76/wDAMLQ7KRNQ+26k0Uuo+UTFFGSRaxk/cQeuDyfy4rUs7yTTNWUhSbG7lEZHTZKT976H+lS2zvLMdzJuAywjU7eexJ696zdd12xtJEs2WS+1B+VsbYZdh057AfUinuNp1HytXO9Bpa5XwdqGpzQiDVrCK0AZvJ2XAl+QdFb/AGh+PSuqqdjzKkHCXKwooooII5oxIhV1DqeoIzmvE/iVZWPhbxbbamNOlg0idUa4a2j2xGTcQwbHAJXFe3kgdTVa9tre8t5ILqGOeBxh45FDKw9waqEuV6m+HruhPnWpxWnfEzQrrEaR3sQAJy0GRgD2JNedWa75b2M3FxNG7tJDFImxtm7I4Hfp1piaW+heL9U02WbZCs3mQQhT/qn5XZjjGcj8K1HZYI/JErokhLyKpI59ffpWkkoPQ9/C4aEFz0epe0jxReeHmVpJJ5dMjUbraZslY+7Rt/s+hJ49OK9XuLex1SxEdzFBd20ihtsih1YHvzXhGqaUNS3ygC4RlU+QQASQfXv+NTaXqGs6Fevf6bdW1tbzBV/swp+6kcDk4BwrHj7uB7UOCaunqcWKwUpyvBWZ6x/wg3hZQ+NB0/5uSPKGM1kQ+HtB0tJph4d0syx5ZQsfp/vfz/St7wt4jttesiVRre9j+We1k+/G3f6r6EVpT2SSTiVCVJGHGAd351nzS2bPOU5Qk41LmWl3dqiqPKgXaCscS5Cj0yarSsIXmllYHC7i7enqTWsdNZyvmzlk9FUDP/1qF0exEokkiMj8/fYkc9eOlSWqtOOxhPcnesVmGmk2l9kY3ccd/Tmta3sHQI12sARPmJBxjHf2qprXijRdAV4xIjTKCTBbgFhgfxdl6d6871fxdf8AiKMCOJ1smOVRSUT0+ZurfQcUzqo4etil7itHuzV8b6/c6oZ4dOQtZwj5SDzM3qB6CuKkaWytprdDuuGQSybThmznj+lW4Irq2DSCWSTAwG3ZUeoAz17U2C1u7py3nyOykBiV/Lp6dM1cEr8zPVaVCl9XpfeYum6LNNLHd6kkySKwaGF+ccZznsOadd3k1mzbXkjlBKDY5BTjnp/Ougkt5EUoTvn27csc8+nHaubvIhNNIH3b+eAfSuiM+eV5bHNVhyQSW5n6dAlzctNdzGONVZ1G0kyNngD09z7VuaHo7kg2WxWZss+04GBjg57iqul6VNPeD7MyRnYQ27ktxwQPrXY6Xpdxa2DuIwloke1zzuLDAz19ckkeopVqjvZPQKEIKHvbt6F62jmkg8sZRycbUPzMPRcdD0NWZVki+SeORHyflYndg9/xFSeHrqCyuVuLgO4RNsSKOjcCnz3cl7cSXbNvaQ7R2AHt7YNcpq3JVLNaEugWsz3W3exjVGlLuOFB42nPt2qW+skk1IvvRYWVJJQCu+UY6Ee3AqnqFzHbJDbRXG2SULHGvd3HP/fPqafYyxLqLreMBKihQ6x8sAegPcZz+dLUxldyc19x8N/EpUX4jeKhErJGNVuwqt1A85sA0U74nsG+JXixgCAdXuzg9v3z0UHgS3Z6z+xX/wAlT1X/ALAsv/o+CvtSviv9iv8A5Knqv/YFl/8AR8FfagqXuIZMqujK43KRgg9xXkmtaHJ4fvRFZ+cLbCldrkKVyTtVTwDkgHHavXTmopYI5V2Sojr6MMinGXKb0K7ovyZ5NHqF5LdfZUikaZR5iFwFV0BHXB+9149ua1oLt2BW5ESEHICnIIxnrXUan4Ws7sK9v/o86cxkDcinGPu+ntWVc6PrEL/ubexuuNu7z2i/Ndp/nV8yZ6EcXTl5FSScFlRvl6lWxnn/ACa53xFqlzqGoDw7osnlyMga9uwcm3jPYf7bdvTrV3XtM8WwQt9g0+1urp1JVklxFBxgnLcu2OwAqt4a0p9BsGZyZruc+be3L8vvxyCMZ4qla1zeEoSV07mxpemWWk6clrp1v5UMfVRyWPct6n3qRiUxImPmHUDtn/P5UrPJKH2DO0chW59x6g4xUYImibywqybcEbvm2nuD2/H0pBcoPNONQvY0RJ2MMc8ETtsOMkNz9QDVvTreazhMc9w11uI+aRRuGfcda1dN0eDVTFfrMySQhog6EESKeoPHTIB4qje2smlyOt9OgVlxH1H0Ge59TSv0JjWjJuF9R76hHaWs011KsUMRLGRxtVFHrWd4G8QXOqavcXlrEkWj7NkJlJElx83L47KOQPrWTc6bL4kkRJNraDGQRGVYC7kHJz32L+prsIoHbyRbWrGFQAoRcbcdOv0p6WHUUFFp9TtYZFljV0OVIyDT6y9BW7S1cXyqjbsoobJC4HX8c1pE4xWdzxJrlk0hJGCqSTgAZJryHxJrjajqbXMSmWNJVjgHAAXOM/icnPYV2/jDXo7S3ezhb/SZ12b8jEYPHPv1xXm9tpwNibVyA0bZDA4wpPTP0q49z18tw9k6sl6Hr2gacbCyAkC+dITJLt/vHt9BVfXdPWWSK8SJBPF8rSZO4R9SPpXNaJ49t4bvS9F1CG7e+lcW/niP92/HDZ9+47V3+Aw5ApNNbnn1VUpVOae55xdyXt9cmz065NrbEgyXMYDvk9QmeAPf16CtjSNJtNLjcWkKLk4aXO6SQ9yzdTzWhLodulzI8d1JbvM27CsAMegHT8etUPE2oaZoNsn9o6m8Tsw2RKA8kmewUc/jRvojpddTtGPU1LSFmvomjCiNCWf6kdq2s4HrXlq+O5rLcYNNebJI3zz4dh2IUDAHX/69Y2u/EXXxcyRpELW1WEOZYoixDHIK9+nrinytjnl9eb2svM9plmjhQvK6xoOrMcD86VZEZNyspXGcg8V82ag8OuzRPPJPLZMcTBrh9wbHXB9OvTvVzzp49CgtW1i5m0aMERoJCvyk8FgOX9Menar9npvqV/Zb6SPVfEnxC0bSjIkHn6jcxg5jtV3KD/tP90fnXOeEfidqGralG2s6Euk6LPlYbyWfG5gMjG4DcD6iuPk8EeLtWZBp9mtjaMylJp5VX5B2KAZwfQ44rb8SfC3xNq3iK2vT4jingRQoWVCvkjGCEUcY/KtIwppWk1+P6EVaOGptRUr9/wCvITxpf2OreJjPYXpvSkbHzBGVW2jAwdrfxZIPOMdearm4S9jRQ2SB/rMYDfQ96n1r4YavFaGGxSwvIiuxgsrwyFeuMnI/WueurLxDpKyp/ZF5AqWzRL51ss0akEbWDAEDHPPBxS5IzVkz0MPiadKNqbvb5HQWEIguHMkoZiAERvlwe59/WqmtGeC2eWRAbZSGchiWAJAIX04zVbRLuAw5eVPPxlpN4ZfwOcn5q7ODw1d3Uds+sz29vZMwkkt+fNcA5C9cDPGe4qFFQepviMRFLmk9WdU+jWGiOLvRrCFLraVChiGcddoJz7VmQ+OjKJtumTMU+5tkHXod393H4mrer3kMT211qiiXy5S0EcQyd2COmew6muf0aHUtXuNThtruK2+0y7pZljDmGPoEXPfrzUJX3PIp0k4OVVXt1uDfEXUfPkjXSrfC9G81iGPP+z7VlXGq+INZL41CZWwN1tboAF4yRkcnj1rspfDmlabFE4sDdNbp80k0h59yOhJJ/Wqfi15LXS5IbV106S8VUXYAp4HzEAc8DFPTojalUoXXsqer7nMWPh2+uIQtjpuUdwHMhCAc8kk5zj271r3emJptuRqDB5dpVLeM/KPRmPXHf9KxluL2whEUNzMEH3mRiqj1JGaqwSmGNdzySiR3YSFtxI7c5z69RxiizZ2z9rJ2nL3fJEttBGGiWTJhRVRpSPvHt+HH60+4nDRlLdwqg7AFXJJGcjjp9ah8yWSZIPNBij4eVkI3P7ds+lXtM09o4ZJJHmlLMGy5wxwOhHYU7GjlrZELWrJhW3KAwOSc5x14qCy0GGS5ZpgpDjaHAwR16j2459q6m4tGt9PSaRlh87lFYZxz1P1qqXijLyIT5qgbM8jPTOKSdjPmVRaamVFp8lvcguUlKgBdq7cYAHPqc5/Cr1u8hxHBMknzlCM5XcRyD6cVKJo1+8GaUjd0yOSR/jUMFnEiySkbHlJbaoC5PAz9cd6Rd1azNGXSZNO0u382UvPOGXAxxn09aqqv2eKNVR2EEagEjG7jgY/zmpHvnndbZ51QuQsRmYqAcdPx56ViWmmeJm1V/NubKK0R8FGJdSuex9cevrSM4J6upJXL9nbNPMt9JCWnZRGBI2WUZ59h7+tbsEMV4J3kEf2lfmWRuNqgY4P41Snd5p1t4l2qhyFU/KPxq4sItyEbau4ZY46460MzqvmXY+C/iUNvxG8VDOcardDPr++aij4lHd8RvFRz11W7P/kZqKR4MviZ63+xX/yVPVf+wLL/AOj4K+084r4g/ZB1Oz0n4k6ncahOsEJ0iRN79ATPBjP5V9lT6tpdzaOF1S0CMh+dLhcqMdQc8UmmCi2apbHXH51H58Wxn8yMqucncMCvnrU4HikvVi1ebUbS2lKrO0pJcceh55OMj0o0bwxr17Jm20u7a3O3iVhGmep5btn2Na+x8zveBjGKlKdrnt154q0SzDGfU7YbfvBW3Eflmm6f4s0XUJlitdQhMr/cR8oW+m7Gfwrx/XdJ1Hw+E/tfT1MDE7WizKpOMgcck8dxWrong6wvbSM6trK2yBQscMB5GefmLDqPb86XJHe5csJQjDm52/TU9mHIBBFcf4nX7JqqSqEEdwNpZs43DP8A9bium02WE20UNvcLcLEoQvvDMcDqcdzVogNkcfjWSdjhpVHRnc4iATSsfKhaY46xjg1p23hxZzHLqJI4O+2Rvkb0yepx+VaGqakunYjWPc7LuBPCDnufWuR8W+KdVjiEWlpFCSMvNjeyDtgHp9apXex2c1asvcVkegQxJDEkcSqkaDCqowAPQU9lyOa8DtPFviCVZ4JtUnV0OSQ6jb6fMeo9qIdV1a+leW51O9CgnEa3OB/vAD2z/Sm6TW7HHLZy+0j3oheMgVUvtSsbEbry5hhGM/O4z+VeNW32iaPy4dQu/s7MWOHYZz1HJqK/821YrBbyXII5keQt9MVLjY3p5Q5Ss5f18z1CTxzoipIySzybCQQsDDp6ZAzXN6745N+RaWMclqrD5mkI3sPQYPH1rhjqt8jqZrdEX/aSn2+o3WQsFmhOc/dP8zQnE9KnkkaT5t7d2izrVu15A8YdSrOpJA6Ackn1rZ8NNpctw0euz3MLBwI12/uZIwOMkZI5z1I7VAcG3ieRFjlddzR45Q+5qKFFVJJ8l1QYOB/L/CtL9CqlJVIaNr0O1tvDPhXU/tEMdx9sZxgqLslkHsAQRXSaPpq6TFJFHd3txGzZUXMvmeWPQE84+ua8ejtLYqtwIwQCWR8EOPfnmrqfES50TUkt53kvLWNB5qygblHYqw5z9QaOVy91HlYnA1eXm5+ZeZ6Pq2lHVYZBJFGo3g7JTuD4xg5HK81y3i/4ar4gljupLvZeRRGNZ0ykmOwLc5/Gqt14xvri1R0ntYS2GGEIZMj7uSe/risPRtXvtO8Rabdre3q21xcrFcxTyNJG6MSNwyeDnHSnBST0diFhq9OF7rTpuF98P9Z021iaHWX84AD/AEuMTRHA6blG5epwcVn6idX0C3265YqIX+5dWpMkDDHdv4T9RXqOra5qVmZFKwA4YgFGJyOnfp0qPw9DdXNxLNKJFhdVklhTARnxyu09M9cVXtG17yKhXrU487eh5YbaNrpb+0jiYOSVmQ5y+3aecdMV0PgV9Gh8QTy6sY7drZR9lWRP3QJxuYE9GB9eg6da2dZ0vwbpeqyPDpKyX6nc0cTMsSsfUA7QfYCuKlDTpIv7yF3kIlSL5wR/d56Y4/Kk5J9Tspt4ym42av17nq8Pjvw85k334iVRkNLGyK49VJHzD6VPYeNfDl9M0Vtq9o0q5+R38s/gGxmvKZdL2LneXA+VVJ4xnnjPJ/wpzaXDuWK+tzcwSZMF6QHSUf3g3VT2weeKOSJxSy6nFpOVrnpXiXxnaaLdRWyQNczzQ+cm11CkE4GCTzk+lee6r8SvEVxJ9k06HTbWSRcNvZ2ddzbQVHHI64rN1Wf5dG0q0+zzQWAaSEtHudPQFh2+Y1JYaZpV3dXFzq91JbQKmxRBHuZjnOUJBxnJ96uMYx1ZccJTpx95Xa+Zm+GbHWIL/SWnjtZTa3yyC4EJYumTuGTxnn+ueK9TvdftZ5JltppSikjYEHXGPvH35zXM+KL3TbnTIrEROLCBFhiMnUAEHgD6DJNVpbTbHZeXEGj/ANaoDsAy49AefxqZy53dnQsN7S1SasJJdwwtFKsv2tpgXL/eZfUY6j8K7jRL5bHTIILPTrt7mcb3IjEeWJ5GW64H14rhdMgFrcSTJckXW3CtH+7IXOSDjjr6+tbEHiPWZ7NVV5DChWNpBH9wHGCX565qZK+wsTTlNKGlvU6/VL4aZYhpx519IdwRumfU+w/WuC1L7VfX8t/NI80wyE67Y/bHpUkLRGed52Z59+XbJ5x0z61PDEJr5ikjESDaQThI17sfSktB0MPGguZ6vuZX2C4vZGigtxOLtlzgnt3JzgL+VabpbwSHTrCYJbbv31ztBMzL94+yjsO9Wp7uHT7VltkeVrmTyon3cAKDuYgduePUkelVdNhXyQip5YVASZCOPb8KfQG3WnzPZE5iitpits8skQADO56++O3NWWmYJDMMMFXBGMgt2NRBkW3BlJAHDIQM4qS0tbm8xFaxZwpJLcDFTsaOyV5bIs3yXd7YNqdztWPAA5wOuPlWs1UzFgIWB6gGntcStAsIncQnBaMkYBHt2pbKRC85gbOUIOWztyfb2oQQvTi0/kIpQbBtAOcFe+Peq+lXUl9bGW4szbM7t8knDBVOB9M4qRAyTiTJ3YIJIGAPan2yJ9pIAJCAEg9DmgqVlqWbG3Cxs/mGRi+4Kw5Xvj2FXZrr7RbKkUJXZkAR5Jlz/I8Gq9ujfvo1A3OMscY4rP1vVLbSrO3uL58lpMRLGMnceARjqaRi4OpKy1fQm0DVE1S1+3eQ1tFnBikHzgg//WNaCN5lw7lsRhSjBsrj3H5059PJtj5UShoQGlAGPMY981BEpKSiVszFxtXbtIGMkH19aRDcZNuJ8J/EgAfEPxQFztGq3QH085qKPiQNvxE8Ug441W6HH/XZqKDwp/Ezsv2comm8aagiLuzpzZ+bGB58Oa+iI9MCEstqm5sHn+L2/CvAf2Y8f8JxqmR/zC3x/wB/4a+j1R4p4vJdY4SzNIAu4ux6HPaqTaPcy9Xo6d2anw70Oxn13UbryyRaMgjU/dLkElse3b8TXp+K8VstRvdA1+HUY3knhlBjuIjwGUenoRyRXqGh+JNM1qNTZ3S+aRkwyYWRfqv9RxSmnucGOhP2jlLYk13S31BIngl8q4iJ2kjgg9R/Ln2rCutKvY45QLeSSQA7CjAhzj17c+tdkM9+lZ99remafII77ULaGQ/wu4B/KoT6IxpV6lPSOpx/2S5RraREuYLpRl0QEGTIwVbHUZx+Vdd4fs7iy09I7q4lnlYl28w52Z52g+g7VZsL60v4vMsriOePOC0bZFTTu8cDtGu9lUlV/vHHAobvoFavKpo1Y5rxbd/KY7a2NxdwlWxvCgg9s1R0/SDqFut9cT/ZeCioxB2+pPOM1WlGtT6kLjVba3tIpI+I0fc2QeMkcdDWL4ws/Nt45nLtFED8oJGD6/rVW6HfSg/ZqMHb8TmvEdhaPPcR2xa5tlm2hgMcYwf+A5zUVnZm2nmwqRnhUB+Y59sf0rW8P2H9q6lBZ2xkCuSXJHyqAOTj2/ma9X0jw9pulqpt7ZDMOTM43OT65PT8KpysrM6KuJjhkluzx2zS5uZ7mK2srpJgwVhLEVXdjPQ1orY32THDPZyyK2JBHJkxn0OBgfQnNbvxA1JdBvLgwROLu7UC3wh2Fz1Yt0464pdNtYLayFlCiBUGG5+Z2/ic+5zmi91c0jiZzipI5JoNdvpX/sxbT7MgYNc3BymR2UDrz3+tbWi6Bq7gCbU9NWcDAZYiiuCf5gdqn1S5t7jU7TRUkRppD50yxnBSJOecerYH51q74SwbcCAdoz2PoPfpT6BKrUa3NjR/CNtZ3MU8073DrztIAQnHXH/166I2Vs0ZQwRbSckbBg1zGi6nex6lbWQVZLaUktvb5ogFJwMe+OvrXXDpWTutzxcTKrz/ALyV2cN4p8GedC82juY5FG7yG5Vu/wAvoTyOeK84sWfT/FhuUsRPI8bGVLnjGBtIAPQ44r399oBLHAHOa8enu7W8v7q9hQYklZoz0yCf69auE2j0MBVnWjKnU1SJl0vTNRsQ1k/2NI2B82KMSFG/55uvpz1GKdp2g6k09vHPDYGETJI063WQNrA52MAQT6frWXFHJp939osWEUrZyo+62eTkdDk/Wts+I1Nn5cumr5qkn91LtWQZ6HPI/Cr5jepRqx0hdpnVam3m6hK8FsJ3X7hTDHp1+vbFc1rPieSCyubTSyYpZSoe5HBBIAIA7Y6Z5qlca5d3AJVY4CBt/dfe9/m79KzB5jxhm2K3bjPB9alDoYLRKp93+ZVvReyIq28ocoQXc/N83fd7dT796aJLtboRqoxvzxnD+hOe9WHE4jByyv3CnluetLCY1ZF3SPhemeOvQ/Tih6o9CPuS2vc0HcAMcYbv7Vt+CZILS0vYdTjVRI5e3DKxj2EDOOwBbJ+uaydLtTf39vbIQnmPjPUADmun1dri2v3LqWtRgxxR8EADHy+/Tii/Q8/HNStS67nEajaRTTsjyRQyxHISKNYwoJ9PfpzzUm63EyTPGIYFwomYEhATyQOuM+groofDukyJ50wvhFK28Kt11bOccDPP1rX0zSLBMuunRRo+AEkzIxHo27NU5GSxUYRtymPHo+lwxCSbWIWZ12rsKhR+BNY+qWyWeoImmytewvGRIWBLo3GAp6EYz0710baFHIVYO8L7ydhAKjn36fXmrunpDptstvaxMNq5MnBLjJ/iPP8ATpU3sT9YktVJv8DB0HwnPJvub+Dy44kytuNu+Z8fxlTxz296rRWmq30xto7cLbrhjHGnlop78HH0ycmuone2aOUvNhjtYlWALY7jvzUD3ImnmTTYWmvJFLGV+BF6Bj247U7kKrO7lLX16FO10W3hmWTUJ2LKCVihOQ31f19qTV7KxhYw3V1HDvCvFZQ5d1xjr9Rnk+tZ+oa/dWj+VpnlT3hQpc3KndGCD0iXuf8Aa9u+KxIEeS7TzQ2/buMu87y2OpJOSSDT5XuyoQqVXdvQuSSHUNQkmZim44EG0YUbuAMen6k5qUpKb3czbLfGSvG52/wxVnlbUCOQCcjBZxk+5z60um2/nzwW8cwVehaVhn369TUs742hHyRQe6mn1iO2+zyG3RS7Sk4XGDwPU5xWpa3M32aSMXEyqT91HK5+tUZ2lDyFScqThDwMjoD6fWpAWe0RpIkSfrhGLD88Cgqai7JoldImgk84BWI2mPOcr6VHxbklMom0AKvAwKfC2A28YYHv2qtqVza2dtcyXkvlW8OckjJbHGB9e1K4ktbDxcxfbv7PVz9ojjEzrjopPHP05q6o2SLtYKPl6c5NYGipLdzXOqXCCK9vXV2hDZ8qMAbE/BQK223wvEVXKyHBfIAQe9ANaf1uXzN+6njTIkAOee2aqXFva3VnbfaBv+zyfugE4UgYJqe1EaFnjZslsHd9OlTCZxHkL84JJBUdfb86Dm1i9BdyokZBmfHOxXK5ParkyPr9zHawCS0MaCSeVeSF6BVPYnB57DNZjJ5RZ5nbCLkt6dzkfpXVeFrKS1s3luAVnuW8xlPVRjCqffH6mokcmJkoLmW5+eHxQhSD4l+LYYV2xx6vdoq+gEzgCin/ABY/5Kl4x/7DN5/6PeiqPJO1/ZjQP441UFymNKcgjqf30PFfRzKNimVXKK2VC8k5H8+a+bP2ayw8bajtOD/ZrDpn/lvDX0ZdXgZ7gymbZHJ8vy8AY6/4VSR7uXP9zbzJJZEkk8lid+3dtrNubANzBtVieRjr9D2rqbHwtqDWxu2V8EFvLY/ORjsPpWQ+z5hHISpPBxyD9D0PtRez0O+FWnWbitSjM2oeXDGmoXUEYOD5lw54AJ5APSqRtrQ71TL+YQfMVssB659yOtavybljY7S2ThhnNVRaQecziMBmG3JPBH0qlPuT7BQ1gdF8I5LWO+1GZ7+FbiULF9l8wBiV6sQe/wD9evUs5HtXgn9nQESSbR9oYYz6Edzj+daWjaxrOiJBDBd+dvBV0OXjUj+Lnpj2qZwUndM8vEYKpOXP1Z6D4jEsGpJI5leKVcIoXIBHUex781zXim7js9PZQQZH+UKWwcHOSM9cc1nv408SGQQNJao+CSRb7gR69eo9Peub125vdbktZriaF7mIlRMqbDt4yMdMdacafdl0oVIJRktjR8JeIBpHibT0uY3Ebjynkx8qqw659uDXuKMrorIQykZBHINfODW00IKzBDuY/vQcE9vTFbPhzxPrOjMxhmFxYgHEMh3Ac9P9nA/CnOlzaxIxVH2r5lue4X1lbX9u0F5BHPC3VZFyKz4vDmlwvI8Ft5TyY3lXbLY6d65K0+J9kQv2qzmQk7cod3rzg444rVtfiF4fuCSLqVVAyXaJgorHkmlscap1oaK/yNiPw9pcQbyrKFJWzmVR85Jxk7jz2H5VUXw63mur3biLjaVA3Z9+MUybxvoMbIq3TzOxxtiiZyPrxWRqvxIsbe8a2srG6vHQZduEA+meTQlN9CoLEJaX1Oq0jR4NNLyKzzTsNplkIJx6DGABV+aeOCNpJpFjjXqzkAD8TXmM2s+LPEt5HFplvPplmygibHKt/tZHI+mKjvPAohlF1r3ieTDMGdZ8NvwOcZ6evFUofzMHRu71Ja/eWvFvxAiuo7jTfD0cs8jgxSXW35EUjkoOrHGQD0rmzHGlpDHGoCRqBtQd/f2FSaglk1wy6c00tsVGHlwC2O4wBgD3pkCRrEisu8LgZHX8ad0lZHt4TDRpRvbfuRxrKyFZm2SEk4QdfY1btbG6nMu2ISBey5O3FTWhVrqCC5UCN3C4zgBT79qvWojv1w/mv5R5iXKqhBOBtPGRxRY0rYpwfLAyXjkRijq0Tg4KyqUJH40nzJKoPVjgfkev5VqatbSqotnklmtiQ0SyMZWWQc9TyA3I9jiueWd4rZ0maOSVZM4BKgYPA9cjoadhUcVKekjQOSmSvI/GqrtKr23lRNukJBBGVwB19qadQAvJI2hZ4gQAycg5FXPNJjmQjGD8uD147+n0pbam/PzaRJYrW7MBvdOulhkjO0yFsENjk8A446ZqWx8RamBH9onZ2AxtuFWTfjvjHXn1qrpNtBfzXJa8aGZEDrFHEGeVD1I57elXoNGkvFkbTJHmeI/vYZLdo2I/2WJK56cU2cc50eeSq6202/U2YvElm4C6rALZgMi5gAIQ8Dle315rRe+tlieSz1KynSMktiZQVGO+a8r1G9Eeqy2Ygka4AxtwCV9j2rMfS7WC8ub5zsmkChY8hlGcVap93Y5qlCDd6T0PQrjxTaP5ccJa7uXHmSBmIhRugG4c5Htx71TfxbqGmqVtILfe7beIjJgAd8nJAP6VzumLNEiLLJFHIyNtB5GM8HP4fzraS3TKKUcDqHB4Pc4/Kh2i+5rDDKUdUXI/FuqyRD7Tp2kpAW2giFzuOT2J9eahu72/vg6SpCkMgBZLaERhwQeGwckZA4zzTIoQ85KklewYdKW7heWIxJI0WSCZB1xnOBipbXRGkMJTjrYghsmhKbnVZNu3eibTnOe/atBY0igUIrcH77EnP51EZfLjUvKgRcLuc4yas2Cx3bbZJsIuWd85AXvgetJs6OWMFdkMTrJlVk4xu28Z+v50xGDzPGgcGFsElSOevB79etWbxoTK32RG8roFJ+Yj1pucswVJFC9cjg/Q0mUpdSWSSWW5Mkjl5TjLdSTj/CkSREjbep5JI9f881ErlJo13L8xy2Tk49v0pJ5UF3HCzI0rjcEB5IHcigiyvYmR9x4zkjNYV5Jb3Xib7LfeagRA1uhP7uU46+59jXQoigZ6HHFZ+sW1pfWzx3ALSyHERRirow6EEelCBNJ3NC3jCRIsSKrBuSOMk+tWTJyjBFIxht3cdTmq8TyJbRx4c7VALY+9602KJbhAEIISQt97Jz3H/wBakZPXcs2xlWR3dgI3AwoH3AAfzzU0WDcIuDtZNzMx4z2/xpAvmKi5x83zcfdHpWrplil1csuN1tH99j0b0X/GkYVaiim2S6BYS3Mi3Fwu23Q5VSOZW7N9PSupQYpqAADHSpBUPU8WrUdR3Z+bHxY/5Kn4y/7DN5/6Peij4sf8lT8Zf9hm8/8AR70VoYnXfs4AnxhqrA4CaYxJ/wC28A/rX074KtZdR8QWvmhWt7ZTLKpOQxxhT74Pr6V8tfs+qX8V6ouHYf2achTgn9/DX1p4Avba01a9lu3jgSSBQjuwAODk/wA/0qtonp0JyWGkokuv69qW+4hu2NrHE5RhD958ngA/TvWDaJHcWrTJwBk5Y5yc9R61HdQDUrq4eO6Z2eZgGJ+U5PXn0H5U4p9nlhsdPzcMzeWpJC+Y/oM9BnvQkraHoU4qlHTQmhndLiR4n2fuwhVtoBz7GiS1URK1zFKVyNrLhVUeucV2PhrwzFZ2jSarBbz30rl2JG8IOgUE+wrZbS7BgQ9pAwJyQUByahySZyvHJSdkeXzxWihkdz5ZJ2OGHzdzStbQH921zDggERhgDnNeoLplipytnbrzniMDmqr+HdJeV5Gsoy7dTk/pzx+FJTQf2i+x5lDbErLN5i7CSFYN+tIbFUiXPCsD8xORz7elenr4f0pN+2yjBcAMeSTj8aydR8FWcyMLK4mtmbsTvX6Y60c6ZrDMIPSSOKJKxbLlY3jZcMAP8O1VY5T5xSNTGw5VUXGCe9amraJqGjREeQzWq5JaIFwf6rWVaW999pjj2SzO67kj2BWIP8+hq1rqjpWIpy1J4bq6EWx7wNCo2qksav8AzH1qGa3jnlQy29mGRs/JDsz9R0xV99N1IQGaTS7uNVJ3ZQE/Xr7VkWurQTXJjJlV4uQJFYcH/P4U03ugiqDatYmuonSDZCu/JA3BtpUeo9celO0iW9063VYJ4vOZcPIyKd2Oh55zU6wpMuYCxGOPLf8AnzUUkTBfLyynOSTyR/Opv0Oh0oSXct3epa1eKoutWm2bdrJH8gJzweKqJZRuySSSSSykgFmJJP4mnkW4ixMZjzwyMF3GkWbAw6L5ZP3WfJH0o1JjClD4VYe5T+4wjxgk8EfT65pAGWQIATvBAbdwPw70yZFyjs77Bg4GcMPf8alikUxACNihGcjOR+A60F+bYxn83A3btysMFev51M2pJbqBcTSpKF2LNER5hXHCup4kAHA5B+tEiRTwnDEhlzyMYqtMkb4RlZ24AAIz0xxTTtuZ1aCqK5vQy3N7bSJos8N7I0eVCvskT/ejYgj2IJrm/F0sNj4jurYt8qFWbJwWfYpOcdycn86o3sSWrR84K/dKscr9D1/Wubvmle6eR5ZJHJ3bmbc/1JPNb04KTPOkpUpXZ0dpdW9nCREm1W+cxKMBT16Y9utaFvJHHFJMij5yWIbucdM9OlcWs7TyqJ32qoxuB6f41eE2cxDeBtLKu7hjjv8A405ULG8MWl0NuUfaJ1mSQQTFQwxklT6gjGMD0pLQX+oubaW9v5Il+80ty/l4xxgfn1zUOny8AlNsqjKnGQPr1/yK1vNNkJXDYIP3GBC9OOfTNZtuOhfJGo+dofYaOLaUNFsIY7QqJjdk8A461K9nFbuy8MHYbQ3PJ/DNaMKqLWIyBkAUSAqxyD7Y5H4VEznqudu45LHO3/Gobb1ZrCKWi2KFzpsYnQSK1uoXahyfmGenoR1rQhjQTLgfKFwAOgA64p0biSNDLgjtt6MartdmGVopVAJb93tT74/u/WlqytI7mlbaVe3SF7W3kKdNxAAP5nmqjpLDKy3KkbGw4PUelTzzSnaPMlKqu1VZjx9KrkE7TIpDA4DMePakVDm3k1YrzwJMATErAfdDZPvUsaFWCk7VzggAAYx/KrBVo0LZxIMDaePwpSirsZlwx6UFJq1kgcGOHfGi7x3OTx36Uu/92cnaSOCaQE7kAYsTxnGM00jbvLdF5+hpk27jkKuVwAW9e31FY0Fg7eJp7+ckRooSH3HT/GtOW8gtAokYEyHCoByfpU8Y8whnTaSMAdce1Go1JK8RRKTgH5VxkOTx7isfw38mo6ldoN9rKy7CxIA79Kt6kWl/0OAgNIpLNn7q9zVuyhS2tVt4BhV5HvQLaLXcsl2yQ7h1bPK8A1YsrdIVby40RZHLtjoSep+tQ2qNumVoiFVVYPu+8TnPHtgfnV7SLa4u7oRKnkoWPXkhR1b05oOWpOMYtlqytJri52wqM/xMeAo/qfSuus7aO1gWGFdqL0Hr7060tYrWIRwrhRzzySfUmrGKh6nh1q7qPyGL1p1LilpGDdz81vix/wAlT8Zf9hm8/wDR70UfFj/kqfjL/sNXv/o96KsR1n7OcXmeKtakDKvk6U0nzDg4uIBj9a+hJ4wsyPMF8uQDCgcKQORn0zXzv+zwR/wl2pqxIV9NZSAM5Hnw8fpX0YYkkilluovK0/ZsxL3+b734kcCtI7HrYB8sbs17VEsUtJWEL3Mx2QQnnL9ifbkHHeo/AunXEvjjUJNVlV5rEKURX3AMcr24HfI9TWhpGmyXl2dUv4THp+nx+ZZwuMKzhf8AWFu9M+GDRNe37iXzbiRQ7bVJHLHJLdMk9qT0TCpV5lKx6PmkyBTRkDmk61zHFYWWQIjNgkKCcAZJ+lU9F1NdV0+O7WGaAOSPLlXDDBxSajqVpp6brqZU4JCnqfoK5w+Nrd5d1va3ctuMgssfU+n1FUo3WiLjTlJaI7LPvRn3rmJfEztZtPp+m3F9kfJ5JGCfRv7p/Oti0ubmWK1ae0MLyLmRd4PlH096lxaE4NasvMfSofs8BuEnaJDMo2rIV+YD0zUlBqbiH5HrVW5sLK5YG4tYJSDuBdAeaxJ766j8ZwQFpEsXhK4YYRnxkYPc/wD166LNVa2o5RcTjfHJsbE2kZskkS43r5UYEQyMHcXHII7DvXCLeS20yQSec0m/KDbksDnA9+Mc13fxEgWSG2eecCFSdsAHzMe5H4Gub8L2uo2N7JHYaX5moRkxrd3ZJWMDgdsemcVvTa5dTsoycIcyKd0JbfzHuYHhKnpIh578A8nr2pIWikZQxUFfVh3Paurl8Na1qs6DXtRikjUZLwphgfQAjgVf07/hHbS7tdJhWG+nYFwPLWVwQTl2b05x7VLa6G315paq7ONjTdLkOgzwRnmpYopll4kTn5QwwB1+vWrd7omjrfXc15rEVo0chYRKwcxr1GMYAJ9D0qOVfDaTRzRXN/5BbIRDFlGx0IJz+GKe5t9cW6TIJQyTsGnTecfwnH+fxp01usm18q+3kZBX65PTmptVk8L6cssFvNeXU0v3XS5RQjD3OB+eayIbm5tJg0YujHxgXEQPy88Ejr0/HtTUW9UOGKXZo0NR8LPqdu1xpWZ5FGJLJiA6e4P8Q9OlcBqGl3VjciO5hlWct8yuCCBXoseoxrtliuRp93EVzGw2kA+3p+dap1SK7RF1e2iliP8Ay2TkDtkHqtXCrKBhODk7rVfj/wAE8altkDvsGCOcY/nWnY27Zh8uOOQtu5wTt46g/nXomreFLNLMXNnduQ0mFR1B38ngkdvwrHiimsXBRYokHy+W45TntWksRzIKVGM9Ysr6akun/wCuMZLKRyAc8dq0rN1luSvks6P1kyCuBjtVcWbXFjl4vs8rg5UgNg5ycZ9eKn0qTfAdo27OApHbOCc/0rBvqdkdPdQ+5S6GqGWMg2eAAoYhge5/T8qsCPrulLljkk9FHoAO1NlZUC72GcEqo4L4GeKch3oCSVwoOM+vYn8aLlxil1HgxrZ5EnmSEgRqBgAepPemPElxG0UrD5gd2B0HrSBShPBPpjpTsum8xlif4sDoKCuXTcbHCASMkxhMg5ySaqiaPT7GOfUp1Ds3IzgZ64H0FXxlojtUBz6jIA+lSbIWiCzRLKAc4cZwfp2poluzKtpe2125S2uI3b720NyPenyny8SySIkJHJk7Enimx2sNu26G3iVPukqMcHmnSRrPhXjDR8cN0pD32JRAYsj5cnkbarOwll8tQxYcnb6U53Mp8pV2r/ExPX6VahsQ6IFl2EEOexPsfb/CgJPkWu5lWM8Oowyu8Dny22lSO2eoPY1emdQUSMlT12gZyP6dqt/ZRGu2BVCuSxCjvUXlbDgD5gfmGOlArxbuiuIAZ1kOFcKUJ9VODj8xV1I+gZQFUBgT654qC3W5aeVp2CxDAAIGAB3z71pWVtJqLiC1Xo3zP2/GmZ1JJJtvQLKG5uZo7aFd0+3Lf3V9yfSu20iwFhaiM7WkJy7gY3Gn6bYx2NuEjGSeWY9Wq7U3ueDicT7V2jsAGKKKKDlCiiikwPzW+LH/ACVPxl/2Gr3/ANHvRR8WP+Sp+Mv+w1e/+j3opgdj+zPCZ/HOoxjbzprfeHbz4c/pX1PoOlLrurSXMvzaZbFVAz8srj0H90cV8v8A7LdvNd+P9QtoEJabTHRmBxsXz4dzflmvrXxBPB4e0KHS9NZYS6lEycsqd29zTvZabndRm+RQjuzE1e7vfFGrpaaeH+xQybJUD4XAPLMR+grudL0+20y1S3s4UjjUY4HJ9ye5qt4Y086botvA4QSYLttHckn+tamMVEpfZQTkm+WOyCgUtJWbIMLXvDsWsXkU007xIiFCIxhmz79q1NNs4dPsYrS3XEcYwM9T7k9zVnNIabk7WKbbVmc/qHhuNrs3ulTNp98WBZ4/uPjsy9+prehDrGnmlWkAG4gcE06lpOTejE23uLSHpRmgmpsI5zxuXj06CeB/KnjlBSXGdtTaT4gtpdIjutQnihfd5T5OAW9s+o5q34gaMaLdmVQQI2IB7nHH45rgNe0+3037PIkjB2gWSWKQ5CHGPTjPNaRSkrM6aajUgovc9BmfTruCO9l8iaGDLpKcMF9SDUmmahbanai5snLwlioYgjkV5lo+k3d5pc8lwkk9gjM6W1u5DSuxGM85CjHP6V1HhnWxaodP1C0SxaH/AFcMSsdq4LEt1x06miVOy0InSstHexo6oW1pJbSC4uLBYZgssrx7fM4PCnvziq194ST+yzbaPcGyuHIV7nBaQx5yyA9QD7UH+z/GKRyRPcJFaTDIIwH6H8unNdQvCik5OOxLk4qyOOs/h/p8PnfaLu8uPMG3BcKF47YH881YfwHojkt5MyuTksJScn8a6uil7SXcbr1G7uTOHv8A4eWU+4wXk8ZPOHAcZrm7rwd4ltJH8qdrmBR8nk3Lhsd/lJAr1w0AVUaskUsTU+1r6njlxqN5E0VlqU0lqWCxRI8A+Ue+4Hj8fxpTHcWc/lJqVqXKAlJmEXP+zkYYfQ/lXrV7ZW19F5V5bxTx5yFkXODVWbQdKmt4YJbCBooSTGpX7nPOPSrVVdUP6wlqlY89spZI5HjlCxXGfvI/y8g4bcvHNSt8z72kMz8rukOTx/OofE9tZWHiWb7PFLBDkCaMYMfIBVlA+7z1HvTY7qCBIUkDFT87PnJTP9M8VTV9UejQq3XNIswowkLtudpMdenHQfrUkqyxycRxlOuMd+5p0cbgSxFV8tE3K2fmHPT9aFDbd5BBJ3EN1zUnSmm9ChqDTrqtiYMmMggqBkD1OK6LVFsW0y0urK1EczuVfcfvbRyapmSOSNSjYwpBz2qBZJH06wjkwJQHfaOwJ6fpTZk1zuLWlv8AgkZiZ0IEm2ViNrdcYwcY75pRC22EXEknmRnKt93ecY5A61YiUYjXGWPtUkyeU+TtbGcex9KaZUrXISrbWwuSBxyRkUkZeBd0hL7up759hUhBIDIpUd8c1XcyOjEDcQOBTHa+rLlwkCWyh2LXMhy4U/LEvYe5NZ8Ui3Z2QliEPbIB/wAanto2aU+aGAU7dh4x/jVmNDtLQr8ucfWglS5epHFFFAYwxGDk4xwMCoNSvfLSKOJgLon5FPRjwBn25zVJ9QSTVhbGQLbxnD8/6xh1GewHepZ7f7ZcLJcFhGh/dRBj1ByNxpimnze96luyM8AQyuryAHzCBtHJz07CnrLIrSNIy4LblC+n17moII3JZ3Y+Ycl9v3cZ6YP1rb0LSn1XExcpp4yNy8NMf9kjovvUt2IqThSjzSIdKs5tTuhFboUtw2XkyNo/xPtXdafYwWMPlwIFycse7H1NSWsMVrAkMEaxxIMKqjAFSE1Dlc8SviJVnbZD88Uu4VHmkzSuc9iXcKNwqPNAPNO4WJM0Z4pu6jOaVxWPzZ+LH/JU/GX/AGGbz/0e9FJ8WP8AkqfjL/sM3n/o96KsR6b+xy8afE/UjK6oP7IlALHGT50PFe9+LLx7jxUzniKALGRxlCpDHB96+YP2d72zsfGWoTahqVnp8P8AZzAPdTpCHPnRHarOQN2AT64U175feM/D9zqEskmu6ArSujb11GF/urjJJbv1xVRSvc7cLZa3Pco3WSNJEIKuAQfalNeYeCviL4XtrZ7C/wDE+irsZmjka/hC4J+797t2rp/+FheC/wDob/Dn/gzg/wDiqykmmQ7Rdjp6RulcyfiF4L/6HDw5/wCDOD/4qmH4g+C8/wDI3+Hf/BnB/wDFVDC6OnzRXMf8LB8F/wDQ3+Hf/BnB/wDFUh+IXgwDjxd4d/8ABnB/8VU6jujqQcUua5MfELwaP+Zu8O/+DOD/AOKp/wDwsLwX/wBDd4d/8GcH/wAVRqF0dSKrX1jb38XlXcYkjzu2kkc/hWB/wsLwX/0N/h3/AMGcH/xVH/CwvBf/AEN/h3/wZwf/ABVGoXXc0G0KzghP2OFVlXLRGRmdUb1wSa4bxheGbWb5GiUiIpGM8ZwAcn2yf0rqD8QvBmP+Rv8ADv8A4M4P/iq4HWPFHhW98fQvJ4n0FtPfY7OuoxbcqOjHdg9BWtJu+p0UKiUm2+hsRWGqLo9tJpwuEmvpyZCmVYKv3M+g6n8azL7XZrfVbj7SPtXmQfZp0U48zAxn2yeeK7gfEDwX28XeHQPbU4P/AIqsXX/EngS/sZ1t/E/hVLwgmOU6hBw57nDU41NdUNV4t+8b3gi/t7nTEhiRYp0GZoslju9c4GR2rpRXj3gLXPD2mX017qvi/wALxsUMccUeqwMRnHJO7Hau6X4g+C+/i/w5/wCDOD/4qs6qtLQyquPM+V6HVUVy3/Cw/Bef+Rv8Of8Agzg/+Kpf+Fh+C/8Aob/Dn/gzg/8AiqgyujqaK5b/AIWH4L/6G/w5/wCDOD/4ql/4WH4L/wChv8Of+DOD/wCKphdHUUVy/wDwsPwX/wBDf4c/8GcH/wAVTZPiL4LRGY+LvDxAGcDUoSfy3UBdDfGWlRYbVB5+4BY5UjxgjPDH6Z/KuR09EktluGAEqqRkEYOTz04/Cqmv/FLR9TDw2uv6Ta2/RQNRiDSA8fOQ3A68A/Ws+LxT4bs02f8ACSaG67eiX8HJA4HDccnrXQk1GzO/CyjFXk0dhDOjr94eZGo3hfQg4P8An0qKSdcxbY2bd8pI428Hn86wn8V+ExI00fibQ1eVEEmNQh7Dp96oZPG/hmO7jRde0ZgwyXXUYSFP/fX0pHYqkFrzHX3tgLaNDcSwtK2C0KH5gD3b07VFeBriWUHCtIRlU4IXsB7cVzr+MfDCxPK3ijRZJGILY1CEs3H+9UGkeLPC/n3F3feJdDE02Ni/2jDiMAYUfe69/wATTXcn2sFo2mzqgzqVEiqOwGeRinsyMcsrMuOccZrnm8Z+GHdSfE+hZGck6hDz/wCPVas/F3hOSd/O8WeH4ogMsx1GAkj0A3cmi43VppXbNGIl4mWJmWRSVyyAE47/AEqVI/MgRghXcuTz0/KsXUPHXg55IjbeIdEhVV2KPt8RJx/ExDdaki8ZeEwrs/irQWYj7p1GHH/oVO4lWha9zTQCQEM21xnv19/rUCvuuIZoZ1dUDI8YbhW4+971i3Hi/wAMfZZZYvE2hByCM/2nCWH0XdVG38WeGLWzVLbxFojOy7iG1CEfMfU7qaD2kJPWRt2vkzGWaKJVOTFuwMSL1OPbNW0klmRDECgBw3PXH9KxoPGHhdoE3eJNARs8r/aEOMfTdSWvinwxf3X2X/hKfD1naDBmlfUIV3DuE+br70r2KlWp/E2jsdI0mXUrtQ4Is1XMkyn7/P3F/qe3Su7iiSKNY4lVI0G1VUYAHoK5WD4geBoYlji8XeGkjQYVV1OAAD/vqpD8RfBPT/hMfDf/AINIP/iqyfdniV67rSuzqqTNcmfiJ4K7eMPDf/g0g/8AiqQfEbwX/wBDh4b/APBnB/8AFUm2ZWOtzQDmuT/4WN4L/wChw8N/+DSD/wCKpf8AhYvgr/ocPDf/AINIP/iqWoaHWUCuUX4i+Cf+hx8N/wDg0g/+Kp3/AAsXwT/0OPhv/wAGkH/xVGojq6BzXKj4i+Cf+hx8N/8Ag0g/+KpR8RvBP/Q4+G//AAaQf/FU9RHwH8V/+SpeMf8AsM3n/o96Ki+JlzBefEjxXdWk0U9tNq13JFLE4ZJEaZyGUjgggggiitSDmqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The overlying pleura (bottom right) is also thickened.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Am J Respir Crit Care Med 2004; 170:692; www.atsjournals.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43722=[""].join("\n");
var outline_f42_44_43722=null;
var title_f42_44_43723="Thromboelastography-guided transfusion parameters";
var content_f42_44_43723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Thromboelastography-guided transfusion parameters",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        r-TEG parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transfusion trigger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TEG-ACT",
"       </td>",
"       <td>",
"        78-110 seconds",
"       </td>",
"       <td>",
"        &gt;120 seconds (FFP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alpha angle",
"       </td>",
"       <td>",
"        66&deg;-82&deg;",
"       </td>",
"       <td>",
"        &lt;66&deg; (cryoprecipitate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         K",
"        </em>",
"        value",
"       </td>",
"       <td>",
"        30-120 seconds",
"       </td>",
"       <td>",
"        &gt;120 seconds (cryoprecipitate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MA (maximum amplitude)",
"       </td>",
"       <td>",
"        54-72 mm",
"       </td>",
"       <td>",
"        &lt;54 mm (platelets)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         G",
"        </em>",
"        value",
"       </td>",
"       <td>",
"        5.3-12.4 dynes/second",
"       </td>",
"       <td>",
"        &lt;5.3 dynes/second*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LY-30 (lysis at 30 min)",
"       </td>",
"       <td>",
"        0-8 percent",
"       </td>",
"       <td>",
"        &gt;8 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Values in the table are for non-citrated whole blood samples.",
"    <div class=\"footnotes\">",
"     r-TEG: rapid thromboelastography; ACT: activated clotting time; FFP: fresh frozen plasma.",
"     <br>",
"      * Reevaluate all parameters per massive transfusion algorithm-decision tree.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Consider antifibrinolytic.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stahel PF, Moore EE, Schreier SL, et al. Transfusion strategies in postinjury coagulopathy. Curr Opin Anaesthesiol 2009; 22:289. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43723=[""].join("\n");
var outline_f42_44_43723=null;
var title_f42_44_43724="Insulin receptor isoforms";
var content_f42_44_43724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Insulin receptor isoforms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 160px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Insulin receptor isoforms due to alternative splicing of the insulin receptor gene. The sequence encoded by exon 11 is either included (exon 11+) or excluded (exon 11-) from the mature mRNA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43724=[""].join("\n");
var outline_f42_44_43724=null;
var title_f42_44_43725="Adult shoulder normal AP";
var content_f42_44_43725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anteroposterior radiograph of the shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 212px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADUASADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5VNJSnrSUAFFFFABRS0lABRRRQAUUtJQAUUUUAFFFFABRRS0AJRRRQAUUtGKAEopaKAEoopaAEooooAKKKKACiiloAKKAKkjiLMAKACGMyOAK6LSrTbtqvp9gRhutb9nCVwO1AFu0QA1uWEeWBrOtUx1rcsUCgE0AeIHrSUp60lAC0UUUAFJRRQAUUUUAFFFLQAlFFKKAEopaKAEopwUk4AJ+lWI7G4kxtjbn2oAq0tbVroFxLgv8orXg8McDJHWgDkVidvuox/CpEs7hzhYW/KvQIvDjZ4YDipW0C6X7pOPpQBwK6VeMcCI1Iui3p/5Z/ma7yLSrpPvZ/Kr0WnyJjePxoA82bRL0DPl5+lVriwuYBmSJgPpXr9vbxE7XHWr/APwj0F5F8mPxoA8Hor0nxH4AnUtLaKQeuAODXDy6TdQy+XLEVcdiKAM6irpsJR95SD9KdHp8jHkYoAoUoBJrWj0wk81dg0wAHK5oAxYLZ5HAC1s2enn+4M1rWunhcHbWlBad8UAU7SzKqOOa04LVsrwKtW9ufStO1twuM9+1AFW2tmBwFzW3p9jLI4VVBzU9nbbpFVVLE9hXbaNp4twPlBdu9AHyEetBpT3ptACiigUUAJRS0UAJRRRQAtFFFABRRRQAUUU5VU9WxQBJHcSJwpAFWE1K6X7sv6VCkMbf8tBVoac2wsDkUAC6netgCZh9Kux39+OfONV4rEqRkHNXYIPmwwxQBNHrGoxkFH3Vv6b4tu4dnnxBx3rGitjn1qdbVQwwKAPRtG8WaVcEJd221u/HSuth07TdViDWsic9BXigt+QQfmFb2j6hcWTqNzAf7NAHpR8JOvzKAcHtU9to7QnO3kdqg8O+JpmRVdlcfrXYWl5b3f3l2OaAMhLNXTa6cH1rnte8GR3aGSJFDeorvhbbSWU7gfSrEcQ29PwoA8Cv/C0tq2J4gy+oFUf7DQn5Ux9K+i59LtbtPnUZ96wL/wAEIzF7Y4JoA8QGhfNhRz6VPHojxjLJmvUn8NNZkmSNi3rimDSgeSOfSgDzdNPII4x7VYWz9V/Ku8bSEz9z8ahbRGzlRkUAcnFa4xxV23tWZwqKSTW9BpErNtVCfwro9N0ZbYBtu6T3oAz9F0sW0Ss4zI3SuusLaO2j82cfMfup3pkcC2mGlG6U9F9KUyl3L5y/6CgD4ePWkpx60lACUtJS0AFFFFACUUoooAKOtFFABQaXmkoAKKKXFAAOKmiuZYyMMcCkSBmxjp61pWOkzXLhY0JB45oAnsdQSQhZRhq37S38/BjXOe9TaZ4MJMcl2yrH1rqbHTUtThceWP1oAyLfRiV3HOTVhdKVcZ5zXZWMEJiGMNn9Knl05XwVXigDiv7NCvgDFPFkQf6V1Y09DIWwcjilew+YYWgDBsUkhfKEg12WgathlWYFT61lS2YDDA+bvVi3tWLAAGgD0GzugVDIQVrThw/Q8muK0lZ7Uj7zL6GussJxLggYPpQBoJE3Vj+VWonK8dqIQWXHapPKAXrzQAp8uVSskamqc+iWs3KDY1XUU9KsxoelAHNTaDKn3SGFRrpbEhWjx6n0rsEVicAZFWUhXBBAGaAORi0xQPuDNSSQCyj3uu5z91fSuq+zRICQBurOu4W3Z2bqAOUjEk8jSOTk/pT51WGPOOfWt1zGq4MYXHUViavdWsETSzttjH60AfDVJTj1ptAC0lFLQAUUUUAFFFKoyaADBx0qWFMnkHFS2sIf71aMNspfHagBkFkjgbhyavDSYZE2smD61cs7Utgd62I7bYNrc5oA4680OaAb4f3ie1VobPJw3Udq9Ditxt9Ae1VNR0gcywpzjoKAMHSdM89wCPlruNKsUgUYQDHSsrQovLIyK9E0TTRcQ7scc0AVlthLaoxAwO1QmHBAbp2rotNhCb4ZY8x5x71dm8PecAbc7gegPagDkLKVoZ8Y+Suv09BNGCRwfSqL+HJoQvmbcd8dq3PDsDITEeccCgBE08YwF685px0vKFsdBmuws9L3kEAmrF3pMgiIjXk0Aea/Y8zMNvNbOl6aT1XmumttDjiYNNjNaMa29uMKo470AY8GlkgHbinmx8vO0Yb1q9PeknC4X6VW80nJLZoAdbyzoQGII+taNtIp+8wBrJU7m61KpzwOooA6BPK9M09SOijk1iQyOn8RrXsm+UGQcmgC/GOB60rHYCx5NIjKeM+9RXEgI2g0AVppySTuwKhF02SSc1WvW6gfnWfNc+XHhTlvWgDSvb2CGPLgFzXCeJYoryF2WbaT2qbVroncQ2T3rjtZuJivybm+hoA+YT1pKU9aKAEpaKKACiinKMmgByIWOAKsLbYdQ3APepIdqKMdaeoLD952PagC1Z2w6A5961IIfYcVV01SABjithIckFc89aAJLZSrAjNa0NvJJhsEiq1pblnXjj3rejcLEETk9OKAIraIA421fW2yv3Qc022iOcnJNbFrGSnTmgDlruxNowlUYQntXofw8kW5jaJjlhyKyLyyMtu/y9iQKX4fzG11pAM4b5SDQB1dzAba7lIABzxio5b2WFQsWfMbqR2rc1KH/SmYgZIzVH7Iqtkg+vFAFK1t5pmGSxY9cnrXV+HNNWGYSSc+gqpawqFBx0rcsGCn7vAoA6O1CqMIAOKLhuKpRT9McZFJJIecnNAFe4cBsNkH2qjPy3ByKtvk9earyRgnOKAKLkFjjrTFDluelXPLHPHNIEPcUARIhzU6RnqBSovNW0T5eO9AC2sG51z061pAbV6fQUlrDsjANWFTHzv90c0AQTN5MRZuvaucvNTlUttb5Ryasa1fb2cBwqDvXnXiHWjIDDbnbGDgt/eoA3p/FkLXS2oyW7sOlW5ryFoj5bYY9q860ePzLl5D0H6mrjmZWMzyEHsooA6F4XlLHop61j6wY7ZNsag561EuvyxjZKuVHpStd2uppu81UI/vHFAHyv3oFKTSUAFFFFABVuyRW3FqqCtDTyBHIMZOKAHOuHG2p4YzIwxUUMUkpIwdta1nGBhR19aALFopUBcc1s2mVI4zVGCLaQM5Na1unFAGnZGJmAkQ4x1FakVjgB4jlTzWdZwhcEZrf09CgUhuDzigAtofn6c962bOMgdBj3qSGJZ03ou2Wr1pblWHmDHrQA5LfdGMDr1rJ0ay8nxA20YANdTCgAAByKr21so1pnx6UAdFeIWdCemKiMRDZxmrtwB5insBSmMsaAIIlBIJ49q0oQEGc1BFb4YZq+kWMYoAkjPyg4qZhkCoghH0qZenNAEDL1xUbKx6VPglie1OSPv3oArLFyPWl8vrxV2OMD60oj+agCpFDhie9WreItKPSpBHgHAq1ZxYGSO9AEqpgVl63fCCMorY4+Y+grTvJhDEzEgCvKPFetvcTSRRPiIHDHPWgCn4i1kTuYYHIjXv6muSkUzy+WgJY/pU2x7l8IcJ61OrpbLtTr60AaFlbJZ2kan77ct9arXRZ2LdAOMVPDdRzpnB3Ac1z+vaylsTFFyx70AQaldxQZDHLdxXL3movcOV3bVXoVOKgvJ5J3ZnPNVooWk5UZbvQB5qeTRR3ooAKKKVetACouWAHetnSolWTDenNZtshMnArY09f3mTQBaACynaMLVmCMhuBSeVxu9TVuBSMA96ALdvFnBH41rWkfQkZqnbR4xWxawgRqc96AL9hEDGMjmt7T4v3ZUAZzWdYxHA/Suhs4/LUHAJ70AWLSErWlChxyMVFbID1ArUhRdoG2gBlumDjFS6dFv1J2HI4FSYESMx5wKdoHIL9y2aANaRC78D/wCtUkcbA89qeiZkBBq4kJOCO9AEVtGS2Sa0Fi5p8MAAHFWdmOQKAKpjwuP1oMYHSrOzGQaQxkDpQBU2HHFLgjirDRkikCEdqAEVeM45qRFHXFLj5amjQ5AoAaseenSrYAWMYpFUDgVS1i68m3YIecUAc34u1MrBIkbcDgmvLntpblyX4Trmuz1lTMo3nCk5PvWFdFVTYowKAMeRFij2jtxxWdMyqjGRtqrzzV/UJVt4y8jAJ2rh9Y1F7pyPup2x3oAs3WuvHP5dvwjcGsS9uDNISx+b1qGUZwU6rQYmlwVXd/SgBgZsBTwe3vVqwjlEo2ryetEdsqANI29h09q0YWZtoVcH1oA8X70UvekoAKUdRSUtAG3Db5CuehFXLSIj6ZpdOUyabE/fGKuQJgrxQBahj3J71ahiww44FLap8wwRV5Iv3gx3oAmtIt2COlbVsoO1SO9U7KLAx6VtWMRbaSB1oA1bSA7Rha2rWMLGNw5qvp6Eqo5zW3bW+8qBQAyGPGCAa04dirliBnjmoL2VLJAMBpTxis2MvM4Lk9aANO8cSRiOI5GeavaaAkYU9RVC3jA6Dmr8AIoA14Sobr1rYtU3Kp61gQkjBPJrX0642uAw47UAa6Lxz1p4FNjdWPFTKBQBHs70FM9amwDS7aAKpTnFDLt6VOV9qay56UARBCcetTquOvWljTHJ6052CIXagCOWQRAf3jWBqpLZLdK0GcvMzE8elY+rS4X17YoA5rWnOVA4Fc3rFzFZxB5DlyPlX1rU8SailigeTDSfwoa88v7h7yZpJjnPY9qAM3WLqS8l3OxCg8KO1Y0se8ED14rY8hpmZYxwO5p32ZIDz8zAUAY8NkSN0h2j371YKskeEAC1akHmsFbp2pjQENtJ49aAKhQbQcmr9kpGCwwB61EZoogAcFuwFJ5pPzOdo9KAPFz1pKD1ooAKKKUdaAOt8MkSaeVIOVJrThj+bJxWX4NOVkU10SRYJ+UUAPtowXHFa8cOQuFqrZxguOMVswR496AJbOHkADrW/Y2/CgiqmnwEYLCugs4PlXjigDR06D5Rxg1uRxLa2rSSAZqLTLbkAjtUfiCfCrAh5NAGMzG4umds4zxV63hzyBUNtEFIB7Vq2yCgCS3i5Axir8UGMUlvH04/GrsKdqACKLpV2JDkYFNSMYFWoUwO9AFu1bsetXFqkoNWoj2zQBOtPAzTBTxQAEdqQJzUmM04DigBgGeKqXTbsj+EfrVyThfrWddEbSM0AUXcCXnvXPeI7tbRC3V8cLWnd3S28uWILHgCuQ8QuZnLNkseMUAcV4gkeeYSSsSWHU9vasmG0MmTIMJ2rqrmyUwB5mJAPAxWRdjBYKh9qAKc6L5arEAD0JrPljYZAUknvWjMkrEALjPU+1Ubu4FsuwfMP71AFFwsRLPVGa9O44Hy+9FzIZiRzzVaWFlJHrQBJAY5ecY571LLE2Rj5lqjHG6n6VtaayGREm4T1NAHhxHNFKetJQAU5etNp8f3hQB1Pg8YmI7YzXZeT83PSuP8LLtueO4rvTHnaR6UAFpHzj0rZtEyBxVCyjLMfSt2zhyoFAGjp8eetdFYQ5AGO9Z2mwfLwK6XToCAowKANC2URQbzXM3UvnXrP1AOK6rUj5Fg2PTArlYI2Yg460AW7YBgOORWraxdOKq21ueMVq26YIzxQBPHHwMcVciTIximRpVyEYFAD44wAKsxr81NjUVYjUdaAHKvtUgBoAp1ADkOMZFSqfao8Zp6dqAJk9CKfjNMTk1J2oArzHGaydQl8qNicZ7VqTEAEmsLUCZ2PGRQBzVyxmuVZuDnpUd7bIvzP8zDkVoXdqsWW6t39qrXJzHluWxxQBy97KQHXaNhrBuQVQySkLGOprf1Zo7WN5ZyMdhXBa7eT3s3DbYAOFFAEOo6qpLJDnHr61iPM7nls+1PMRVvm702SNlPoaAGbQWySRUc24nGakCM3GCWqzFYSSMvmHaPQ0AU0U9jk+1XbW1ln6Kdo7mr1vBHbsNqbm7HtVrcyNucY3fwigD56pKKKACp7YfvF71CPWrliAX6c0AdF4eGLtMcV6NAhMKEivP9FXE8J7k16XaRk268UALaJhuBW7YITjis+CP96nNb9hCQAcd6ANbTosjGOa6nSLdsjI4rI0uEBlOOorr9Mi2xhuKAMfxKdtuFxisWzjPAHPrWt4iO+7VB2FQ2UXcigC1bw7QOKuxx+oogj6E9KuxR5GaABI8AYq2iY470yNeRVxEHWgBI1qdBihVAqRV/KgBVHFLigDFKBQAq+lSAcChRxz1qRRkUAOQYpZDtGe1KKrX0u1CB1oAhnbfwKqNGEGRy9TxH5fXNMl9+RQBi38YY4x1rA1G4S0hIchpB0FdDqdxHCjDIL9h6Vwt+shu2kc7g3XNAHMa48t1M0jEtz9zsK564izncK66/hGCF71ktZs4G1cdjnpQBzzKsKMduc96RLQuFeQ7U61vpZQ28MhY7pD0rKlRgMtzjtQBGNiBlhQE/3jTIxiTMhyB6VL5LSLmPk9xU9rEoceafqKALK24lVdgxjnmodVRh5a8Yq6jM8uEXAH61n6q0oyShCjpQB87mkpTSUAKKvWC5b0qiK0dNGXoA6TSMiaHjoRXrGmputF4ryvSgPNjx13V69ocZez5PagCS3tv349DXQ2UIBHsazLaPEoJ5ro9Pj9u9AGvpsXAyO9dZZxgQnjisPTIunHeumRdttk0Aclqqb75zjOOKfZpk9KdOu67lJPerdlF8vvQBNFHzg1cjQAU2JAMevrVqNRQARrk9KsgccU1VwcipAKAFUZ71IAaagxUg60AAHNKBSjrTttACqDnFSjpSIoHNO7GgA6CqV0PvE8mrVVrgZGBQBlrMVYL1pbu6CxkIcv6Vl6zfJaI6p/rDxn0rG06/O4id8hv4jQBPeHEjM3JNYWpKSH2iuluofNA8sZB5zVF7YoCzpu9qAOY+xPJh5DtHpmqmp7REEjGAvWuguoWLkbeo4PpWRe2hkcKrfMRyAKAOdkIdQP4+wqtJbkszOvygcmtie1WyG52VSOuao3N0skG6ORSo6rQBRijjMpwdtVLtJFkbbg/Q1NJdguAQB9BQZl5YcmgColxdH7pKgd6uPcTSxKkibgOvFOs5DK5XA56+1alrZGWT742+tAHy833mptFFACitLTfviiigDqdLGJIvrXsnh0f6AKKKANW2+9jArodPUYFFFAHUaV94Cuhk4tziiigDmGAMz5FW7bhRRRQBfQfKKtRgYoooAk6U8UUUAOBqRetFFAD1561KoGRRRQBJjmkaiigCPvVS9JWNiOooooA4PV2JuGZuTnvWWfmkAPA9qKKAOq045s1XA4796o3TsGcA0UUAYl5IwBwcUluo8tmx82KKKAPOfEM8hu5VLkjdWC0riThzRRQA9pGOCSasLIyx5GCfeiigB/nOq/KcZHNa9hI628eGIHpRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph of a normal shoulder demonstrates a congruent humeral head and glenoid fossa. The accromion and the acromioclavicular joint are not not well visualized in this example due to overpenetration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43725=[""].join("\n");
var outline_f42_44_43725=null;
var title_f42_44_43726="BMI Table PI";
var content_f42_44_43726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    How to find your body mass index (BMI)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Good weights",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Overweight",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        BMI, kg/m2",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Height, inches",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"14\">",
"        Weight, pounds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        58\"",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        191",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        59\"",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        173",
"       </td>",
"       <td>",
"        198",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60\"",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        204",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        61\"",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        211",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        62\"",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        218",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        63\"",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        141",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        152",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        163",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        225",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        64\"",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        163",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        204",
"       </td>",
"       <td>",
"        232",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65\"",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        240",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        66\"",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        161",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        173",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        216",
"       </td>",
"       <td>",
"        247",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        67\"",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        159",
"       </td>",
"       <td>",
"        166",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        178",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        223",
"       </td>",
"       <td>",
"        255",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        68\"",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        177",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        230",
"       </td>",
"       <td>",
"        262",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        69\"",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        149",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        182",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        196",
"       </td>",
"       <td>",
"        203",
"       </td>",
"       <td>",
"        236",
"       </td>",
"       <td>",
"        270",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70\"",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        181",
"       </td>",
"       <td>",
"        188",
"       </td>",
"       <td>",
"        195",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        209",
"       </td>",
"       <td>",
"        243",
"       </td>",
"       <td>",
"        278",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        71\"",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        165",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        193",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        208",
"       </td>",
"       <td>",
"        215",
"       </td>",
"       <td>",
"        250",
"       </td>",
"       <td>",
"        286",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        72\"",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        177",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        199",
"       </td>",
"       <td>",
"        206",
"       </td>",
"       <td>",
"        213",
"       </td>",
"       <td>",
"        221",
"       </td>",
"       <td>",
"        258",
"       </td>",
"       <td>",
"        294",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        73\"",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        159",
"       </td>",
"       <td>",
"        166",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        182",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        204",
"       </td>",
"       <td>",
"        212",
"       </td>",
"       <td>",
"        219",
"       </td>",
"       <td>",
"        227",
"       </td>",
"       <td>",
"        265",
"       </td>",
"       <td>",
"        302",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        74\"",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        163",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        194",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        218",
"       </td>",
"       <td>",
"        225",
"       </td>",
"       <td>",
"        233",
"       </td>",
"       <td>",
"        272",
"       </td>",
"       <td>",
"        311",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        75\"",
"       </td>",
"       <td>",
"        152",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        192",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        208",
"       </td>",
"       <td>",
"        216",
"       </td>",
"       <td>",
"        224",
"       </td>",
"       <td>",
"        232",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        279",
"       </td>",
"       <td>",
"        319",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        76\"",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        205",
"       </td>",
"       <td>",
"        213",
"       </td>",
"       <td>",
"        221",
"       </td>",
"       <td>",
"        230",
"       </td>",
"       <td>",
"        238",
"       </td>",
"       <td>",
"        246",
"       </td>",
"       <td>",
"        287",
"       </td>",
"       <td>",
"        328",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Body Mass Index (BMI) is a measure of weight in relation to height. It is the most practical way to estimate if a person is underweight, at a healthy weight, overweight, or obese.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43726=[""].join("\n");
var outline_f42_44_43726=null;
var title_f42_44_43727="Nail trephination";
var content_f42_44_43727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nail trephination",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A heated device is pressed against the nail in the center of the hematoma. Care should be taken to avoid the lunula and to create a hole large enough for continued drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca K Fastle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_44_43727=[""].join("\n");
var outline_f42_44_43727=null;
